id	sid	tid	token	lemma	pos
finefocus-675	1	1	fine	fine	ADJ
finefocus-675	1	2	focus	focus	NOUN
finefocus-675	1	3	,	,	PUNCT
finefocus-675	1	4	vol	vol	NOUN
finefocus-675	1	5	.	.	NOUN
finefocus-675	1	6	3	3	NUM
finefocus-675	1	7	(	(	PUNCT
finefocus-675	1	8	2	2	NUM
finefocus-675	1	9	)	)	PUNCT
finefocus-675	1	10	imatinib	imatinib	NOUN
finefocus-675	1	11	mesylate	mesylate	VERB
finefocus-675	1	12	as	as	ADP
finefocus-675	1	13	an	an	DET
finefocus-675	1	14	effective	effective	ADJ
finefocus-675	1	15	anti	anti	ADJ
finefocus-675	1	16	-	-	ADJ
finefocus-675	1	17	viral	viral	ADJ
finefocus-675	1	18	treatment	treatment	NOUN
finefocus-675	1	19	for	for	ADP
finefocus-675	1	20	alphavirus	alphavirus	NOUN
finefocus-675	1	21	infections	infections	PROPN
finefocus-675	1	22	jessica	jessica	PROPN
finefocus-675	1	23	l.	l.	PROPN
finefocus-675	1	24	costlow	costlow	PROPN
finefocus-675	1	25	,	,	PUNCT
finefocus-675	1	26	erika	erika	PROPN
finefocus-675	1	27	s.	s.	PROPN
finefocus-675	1	28	krow	krow	PROPN
finefocus-675	1	29	,	,	PUNCT
finefocus-675	1	30	&	&	CCONJ
finefocus-675	1	31	j.	j.	PROPN
finefocus-675	1	32	jordan	jordan	PROPN
finefocus-675	1	33	steel	steel	PROPN
finefocus-675	1	34	*	*	PROPN
finefocus-675	1	35	biology	biology	PROPN
finefocus-675	1	36	department	department	NOUN
finefocus-675	1	37	,	,	PUNCT
finefocus-675	1	38	colorado	colorado	PROPN
finefocus-675	1	39	state	state	PROPN
finefocus-675	1	40	university	university	PROPN
finefocus-675	1	41	-	-	PUNCT
finefocus-675	1	42	pueblo	pueblo	VERB
finefocus-675	1	43	,	,	PUNCT
finefocus-675	1	44	pueblo	pueblo	PROPN
finefocus-675	1	45	co	co	PROPN
finefocus-675	1	46	manuscript	manuscript	PROPN
finefocus-675	1	47	received	receive	VERB
finefocus-675	1	48	29	29	NUM
finefocus-675	1	49	march	march	NOUN
finefocus-675	1	50	2017	2017	NUM
finefocus-675	1	51	;	;	PUNCT
finefocus-675	1	52	accepted	accept	VERB
finefocus-675	1	53	14	14	NUM
finefocus-675	1	54	may	may	PROPN
finefocus-675	1	55	2017	2017	NUM
finefocus-675	1	56	copyright	copyright	NOUN
finefocus-675	1	57	2017	2017	NUM
finefocus-675	1	58	,	,	PUNCT
finefocus-675	1	59	fine	fine	ADJ
finefocus-675	1	60	focus	focus	NOUN
finefocus-675	1	61	.	.	PUNCT
finefocus-675	2	1	all	all	DET
finefocus-675	2	2	rights	right	NOUN
finefocus-675	2	3	reserved	reserve	VERB
finefocus-675	2	4	.	.	PUNCT
finefocus-675	3	1	imatinib	imatinib	NOUN
finefocus-675	3	2	mesylate	mesylate	VERB
finefocus-675	3	3	•	•	NUM
finefocus-675	3	4	141140	141140	NUM
finefocus-675	3	5	•	•	NUM
finefocus-675	3	6	fine	fine	ADJ
finefocus-675	3	7	focus	focus	NOUN
finefocus-675	3	8	,	,	PUNCT
finefocus-675	3	9	vol	vol	NOUN
finefocus-675	3	10	.	.	NOUN
finefocus-675	3	11	3	3	NUM
finefocus-675	3	12	(	(	PUNCT
finefocus-675	3	13	2	2	NUM
finefocus-675	3	14	)	)	PUNCT
finefocus-675	3	15	alphaviruses	alphavirus	NOUN
finefocus-675	3	16	are	be	AUX
finefocus-675	3	17	plus	plus	CCONJ
finefocus-675	3	18	-	-	PUNCT
finefocus-675	3	19	strand	strand	NOUN
finefocus-675	3	20	rna	rna	NOUN
finefocus-675	3	21	viruses	virus	NOUN
finefocus-675	3	22	that	that	PRON
finefocus-675	3	23	are	be	AUX
finefocus-675	3	24	transmitted	transmit	VERB
finefocus-675	3	25	by	by	ADP
finefocus-675	3	26	mosquitoes	mosquito	NOUN
finefocus-675	3	27	.	.	PUNCT
finefocus-675	4	1	there	there	PRON
finefocus-675	4	2	are	be	VERB
finefocus-675	4	3	very	very	ADV
finefocus-675	4	4	limited	limited	ADJ
finefocus-675	4	5	vaccines	vaccine	NOUN
finefocus-675	4	6	and	and	CCONJ
finefocus-675	4	7	treatment	treatment	NOUN
finefocus-675	4	8	options	option	NOUN
finefocus-675	4	9	available	available	ADJ
finefocus-675	4	10	to	to	ADP
finefocus-675	4	11	those	those	PRON
finefocus-675	4	12	infected	infect	VERB
finefocus-675	4	13	with	with	ADP
finefocus-675	4	14	alphaviruses	alphavirus	NOUN
finefocus-675	4	15	,	,	PUNCT
finefocus-675	4	16	resulting	result	VERB
finefocus-675	4	17	in	in	ADP
finefocus-675	4	18	significant	significant	ADJ
finefocus-675	4	19	human	human	ADJ
finefocus-675	4	20	and	and	CCONJ
finefocus-675	4	21	animal	animal	NOUN
finefocus-675	4	22	morbidity	morbidity	NOUN
finefocus-675	4	23	and	and	CCONJ
finefocus-675	4	24	mortality	mortality	NOUN
finefocus-675	4	25	each	each	DET
finefocus-675	4	26	year	year	NOUN
finefocus-675	4	27	.	.	PUNCT
finefocus-675	5	1	viruses	virus	NOUN
finefocus-675	5	2	are	be	AUX
finefocus-675	5	3	parasites	parasite	NOUN
finefocus-675	5	4	of	of	ADP
finefocus-675	5	5	host	host	NOUN
finefocus-675	5	6	cell	cell	NOUN
finefocus-675	5	7	metabolism	metabolism	NOUN
finefocus-675	5	8	and	and	CCONJ
finefocus-675	5	9	alphaviruses	alphavirus	NOUN
finefocus-675	5	10	have	have	AUX
finefocus-675	5	11	been	be	AUX
finefocus-675	5	12	shown	show	VERB
finefocus-675	5	13	to	to	PART
finefocus-675	5	14	increase	increase	VERB
finefocus-675	5	15	glycolytic	glycolytic	ADJ
finefocus-675	5	16	flux	flux	NOUN
finefocus-675	5	17	during	during	ADP
finefocus-675	5	18	infection	infection	NOUN
finefocus-675	5	19	to	to	PART
finefocus-675	5	20	aid	aid	VERB
finefocus-675	5	21	viral	viral	ADJ
finefocus-675	5	22	replication	replication	NOUN
finefocus-675	5	23	.	.	PUNCT
finefocus-675	6	1	imatinib	imatinib	NOUN
finefocus-675	6	2	mesylate	mesylate	NOUN
finefocus-675	6	3	is	be	AUX
finefocus-675	6	4	an	an	DET
finefocus-675	6	5	fda	fda	PROPN
finefocus-675	6	6	-	-	PUNCT
finefocus-675	6	7	approved	approve	VERB
finefocus-675	6	8	tyrosine	tyrosine	NOUN
finefocus-675	6	9	kinase	kinase	PROPN
finefocus-675	6	10	inhibitor	inhibitor	NOUN
finefocus-675	6	11	that	that	PRON
finefocus-675	6	12	is	be	AUX
finefocus-675	6	13	used	use	VERB
finefocus-675	6	14	to	to	PART
finefocus-675	6	15	treat	treat	VERB
finefocus-675	6	16	several	several	ADJ
finefocus-675	6	17	types	type	NOUN
finefocus-675	6	18	of	of	ADP
finefocus-675	6	19	cancers	cancer	NOUN
finefocus-675	6	20	.	.	PUNCT
finefocus-675	7	1	a	a	DET
finefocus-675	7	2	hallmark	hallmark	NOUN
finefocus-675	7	3	of	of	ADP
finefocus-675	7	4	tumorous	tumorous	ADJ
finefocus-675	7	5	cells	cell	NOUN
finefocus-675	7	6	is	be	AUX
finefocus-675	7	7	an	an	DET
finefocus-675	7	8	elevated	elevated	ADJ
finefocus-675	7	9	metabolic	metabolic	NOUN
finefocus-675	7	10	rate	rate	NOUN
finefocus-675	7	11	and	and	CCONJ
finefocus-675	7	12	imatinib	imatinib	NOUN
finefocus-675	7	13	successfully	successfully	ADV
finefocus-675	7	14	slows	slow	VERB
finefocus-675	7	15	metabolism	metabolism	NOUN
finefocus-675	7	16	by	by	ADP
finefocus-675	7	17	inhibiting	inhibit	VERB
finefocus-675	7	18	tyrosine	tyrosine	NOUN
finefocus-675	7	19	kinases	kinase	NOUN
finefocus-675	7	20	that	that	PRON
finefocus-675	7	21	are	be	AUX
finefocus-675	7	22	required	require	VERB
finefocus-675	7	23	to	to	PART
finefocus-675	7	24	activate	activate	VERB
finefocus-675	7	25	metabolic	metabolic	NOUN
finefocus-675	7	26	enzymes	enzyme	NOUN
finefocus-675	7	27	,	,	PUNCT
finefocus-675	7	28	such	such	ADJ
finefocus-675	7	29	as	as	ADP
finefocus-675	7	30	hexokinase	hexokinase	NOUN
finefocus-675	7	31	in	in	ADP
finefocus-675	7	32	the	the	DET
finefocus-675	7	33	glycolytic	glycolytic	ADJ
finefocus-675	7	34	pathway	pathway	NOUN
finefocus-675	7	35	.	.	PUNCT
finefocus-675	8	1	it	it	PRON
finefocus-675	8	2	was	be	AUX
finefocus-675	8	3	hypothesized	hypothesize	VERB
finefocus-675	8	4	that	that	SCONJ
finefocus-675	8	5	imatinib	imatinib	NOUN
finefocus-675	8	6	could	could	AUX
finefocus-675	8	7	be	be	AUX
finefocus-675	8	8	used	use	VERB
finefocus-675	8	9	to	to	PART
finefocus-675	8	10	slow	slow	VERB
finefocus-675	8	11	metabolism	metabolism	NOUN
finefocus-675	8	12	in	in	ADP
finefocus-675	8	13	virally	virally	ADV
finefocus-675	8	14	-	-	PUNCT
finefocus-675	8	15	infected	infect	VERB
finefocus-675	8	16	cells	cell	NOUN
finefocus-675	8	17	and	and	CCONJ
finefocus-675	8	18	reduce	reduce	VERB
finefocus-675	8	19	viral	viral	ADJ
finefocus-675	8	20	replication	replication	NOUN
finefocus-675	8	21	.	.	PUNCT
finefocus-675	9	1	alphavirus	alphavirus	NOUN
finefocus-675	9	2	-	-	PUNCT
finefocus-675	9	3	infected	infect	VERB
finefocus-675	9	4	cells	cell	NOUN
finefocus-675	9	5	were	be	AUX
finefocus-675	9	6	treated	treat	VERB
finefocus-675	9	7	with	with	ADP
finefocus-675	9	8	various	various	ADJ
finefocus-675	9	9	concentrations	concentration	NOUN
finefocus-675	9	10	of	of	ADP
finefocus-675	9	11	imatinib	imatinib	NOUN
finefocus-675	9	12	and	and	CCONJ
finefocus-675	9	13	at	at	ADP
finefocus-675	9	14	a	a	DET
finefocus-675	9	15	concentration	concentration	NOUN
finefocus-675	9	16	of	of	ADP
finefocus-675	9	17	6	6	NUM
finefocus-675	9	18	μm	μm	NUM
finefocus-675	9	19	,	,	PUNCT
finefocus-675	9	20	viral	viral	ADJ
finefocus-675	9	21	replication	replication	NOUN
finefocus-675	9	22	was	be	AUX
finefocus-675	9	23	reduced	reduce	VERB
finefocus-675	9	24	by	by	ADP
finefocus-675	9	25	more	more	ADJ
finefocus-675	9	26	than	than	ADP
finefocus-675	9	27	40	40	NUM
finefocus-675	9	28	%	%	NOUN
finefocus-675	9	29	while	while	SCONJ
finefocus-675	9	30	cell	cell	NOUN
finefocus-675	9	31	viability	viability	NOUN
finefocus-675	9	32	was	be	AUX
finefocus-675	9	33	still	still	ADV
finefocus-675	9	34	at	at	ADP
finefocus-675	9	35	100	100	NUM
finefocus-675	9	36	%	%	NOUN
finefocus-675	9	37	.	.	PUNCT
finefocus-675	10	1	the	the	DET
finefocus-675	10	2	efficacy	efficacy	NOUN
finefocus-675	10	3	of	of	ADP
finefocus-675	10	4	imatinib	imatinib	NOUN
finefocus-675	10	5	treatment	treatment	NOUN
finefocus-675	10	6	at	at	ADP
finefocus-675	10	7	inhibiting	inhibit	VERB
finefocus-675	10	8	alphavirus	alphavirus	NOUN
finefocus-675	10	9	replication	replication	NOUN
finefocus-675	10	10	was	be	AUX
finefocus-675	10	11	confirmed	confirm	VERB
finefocus-675	10	12	at	at	ADP
finefocus-675	10	13	different	different	ADJ
finefocus-675	10	14	times	time	NOUN
finefocus-675	10	15	post	post	NOUN
finefocus-675	10	16	infection	infection	NOUN
finefocus-675	10	17	(	(	PUNCT
finefocus-675	10	18	6	6	NUM
finefocus-675	10	19	,	,	PUNCT
finefocus-675	10	20	12	12	NUM
finefocus-675	10	21	,	,	PUNCT
finefocus-675	10	22	18	18	NUM
finefocus-675	10	23	,	,	PUNCT
finefocus-675	10	24	and	and	CCONJ
finefocus-675	10	25	24	24	NUM
finefocus-675	10	26	hours	hour	NOUN
finefocus-675	10	27	post	post	NOUN
finefocus-675	10	28	infection	infection	NOUN
finefocus-675	10	29	)	)	PUNCT
finefocus-675	10	30	,	,	PUNCT
finefocus-675	10	31	different	different	ADJ
finefocus-675	10	32	levels	level	NOUN
finefocus-675	10	33	of	of	ADP
finefocus-675	10	34	infection	infection	NOUN
finefocus-675	10	35	(	(	PUNCT
finefocus-675	10	36	multiplicities	multiplicity	NOUN
finefocus-675	10	37	of	of	ADP
finefocus-675	10	38	infection=	infection=	NUM
finefocus-675	10	39	0.1	0.1	NUM
finefocus-675	10	40	,	,	PUNCT
finefocus-675	10	41	1	1	NUM
finefocus-675	10	42	,	,	PUNCT
finefocus-675	10	43	and	and	CCONJ
finefocus-675	10	44	10	10	NUM
finefocus-675	10	45	)	)	PUNCT
finefocus-675	10	46	,	,	PUNCT
finefocus-675	10	47	and	and	CCONJ
finefocus-675	10	48	within	within	ADP
finefocus-675	10	49	different	different	ADJ
finefocus-675	10	50	cell	cell	NOUN
finefocus-675	10	51	lines	line	NOUN
finefocus-675	10	52	(	(	PUNCT
finefocus-675	10	53	bhk	bhk	PROPN
finefocus-675	10	54	,	,	PUNCT
finefocus-675	10	55	huh7	huh7	PROPN
finefocus-675	10	56	and	and	CCONJ
finefocus-675	10	57	hek	hek	PROPN
finefocus-675	10	58	)	)	PUNCT
finefocus-675	10	59	.	.	PUNCT
finefocus-675	11	1	further	further	ADJ
finefocus-675	11	2	analysis	analysis	NOUN
finefocus-675	11	3	in	in	ADP
finefocus-675	11	4	mouse	mouse	NOUN
finefocus-675	11	5	or	or	CCONJ
finefocus-675	11	6	other	other	ADJ
finefocus-675	11	7	animal	animal	NOUN
finefocus-675	11	8	models	model	NOUN
finefocus-675	11	9	is	be	AUX
finefocus-675	11	10	needed	need	VERB
finefocus-675	11	11	to	to	PART
finefocus-675	11	12	confirm	confirm	VERB
finefocus-675	11	13	the	the	DET
finefocus-675	11	14	utility	utility	NOUN
finefocus-675	11	15	of	of	ADP
finefocus-675	11	16	imatinib	imatinib	NOUN
finefocus-675	11	17	as	as	ADP
finefocus-675	11	18	a	a	DET
finefocus-675	11	19	therapeutic	therapeutic	ADJ
finefocus-675	11	20	option	option	NOUN
finefocus-675	11	21	for	for	ADP
finefocus-675	11	22	treating	treat	VERB
finefocus-675	11	23	alphavirus	alphavirus	NOUN
finefocus-675	11	24	infection	infection	NOUN
finefocus-675	11	25	,	,	PUNCT
finefocus-675	11	26	but	but	CCONJ
finefocus-675	11	27	the	the	DET
finefocus-675	11	28	data	datum	NOUN
finefocus-675	11	29	are	be	AUX
finefocus-675	11	30	promising	promise	VERB
finefocus-675	11	31	and	and	CCONJ
finefocus-675	11	32	shows	show	VERB
finefocus-675	11	33	a	a	DET
finefocus-675	11	34	significant	significant	ADJ
finefocus-675	11	35	reduction	reduction	NOUN
finefocus-675	11	36	in	in	ADP
finefocus-675	11	37	viral	viral	ADJ
finefocus-675	11	38	replication	replication	NOUN
finefocus-675	11	39	and	and	CCONJ
finefocus-675	11	40	may	may	AUX
finefocus-675	11	41	represent	represent	VERB
finefocus-675	11	42	a	a	DET
finefocus-675	11	43	novel	novel	ADJ
finefocus-675	11	44	treatment	treatment	NOUN
finefocus-675	11	45	option	option	NOUN
finefocus-675	11	46	for	for	ADP
finefocus-675	11	47	alphavirus	alphavirus	NOUN
finefocus-675	11	48	infections	infection	NOUN
finefocus-675	11	49	.	.	PUNCT
finefocus-675	12	1	abstract	abstract	ADJ
finefocus-675	12	2	corresponding	correspond	VERB
finefocus-675	12	3	author	author	PROPN
finefocus-675	12	4	j.	j.	PROPN
finefocus-675	12	5	jordan	jordan	PROPN
finefocus-675	12	6	steel	steel	PROPN
finefocus-675	12	7	*	*	PROPN
finefocus-675	12	8	jordan.steel@csupueblo.edu	jordan.steel@csupueblo.edu	PROPN
finefocus-675	12	9	keywords	keyword	NOUN
finefocus-675	12	10	•	•	ADJ
finefocus-675	12	11	alphavirus	alphavirus	NOUN
finefocus-675	12	12	•	•	ADP
finefocus-675	12	13	anti	anti	NOUN
finefocus-675	12	14	-	-	NOUN
finefocus-675	12	15	virus	virus	ADJ
finefocus-675	12	16	•	•	ADJ
finefocus-675	12	17	imatinib	imatinib	NOUN
finefocus-675	12	18	alphaviruses	alphavirus	NOUN
finefocus-675	12	19	are	be	AUX
finefocus-675	12	20	enveloped	envelop	VERB
finefocus-675	12	21	,	,	PUNCT
finefocus-675	12	22	plus	plus	CCONJ
finefocus-675	12	23	-	-	PUNCT
finefocus-675	12	24	strand	strand	NOUN
finefocus-675	12	25	rna	rna	NOUN
finefocus-675	12	26	viruses	virus	NOUN
finefocus-675	12	27	,	,	PUNCT
finefocus-675	12	28	that	that	PRON
finefocus-675	12	29	are	be	AUX
finefocus-675	12	30	transmitted	transmit	VERB
finefocus-675	12	31	via	via	ADP
finefocus-675	12	32	mosquito	mosquito	ADJ
finefocus-675	12	33	vectors	vector	NOUN
finefocus-675	12	34	.	.	PUNCT
finefocus-675	13	1	alphaviruses	alphavirus	NOUN
finefocus-675	13	2	,	,	PUNCT
finefocus-675	13	3	including	include	VERB
finefocus-675	13	4	eastern	eastern	ADJ
finefocus-675	13	5	,	,	PUNCT
finefocus-675	13	6	western	western	ADJ
finefocus-675	13	7	,	,	PUNCT
finefocus-675	13	8	and	and	CCONJ
finefocus-675	13	9	venezuelan	venezuelan	ADJ
finefocus-675	13	10	equine	equine	NOUN
finefocus-675	13	11	encephalitis	encephalitis	ADJ
finefocus-675	13	12	virus	virus	NOUN
finefocus-675	13	13	,	,	PUNCT
finefocus-675	13	14	chikungunya	chikungunya	NOUN
finefocus-675	13	15	virus	virus	NOUN
finefocus-675	13	16	,	,	PUNCT
finefocus-675	13	17	sindbis	sindbis	PROPN
finefocus-675	13	18	virus	virus	PROPN
finefocus-675	13	19	,	,	PUNCT
finefocus-675	13	20	and	and	CCONJ
finefocus-675	13	21	semliki	semliki	PROPN
finefocus-675	13	22	forest	forest	NOUN
finefocus-675	13	23	virus	virus	PROPN
finefocus-675	13	24	,	,	PUNCT
finefocus-675	13	25	are	be	AUX
finefocus-675	13	26	responsible	responsible	ADJ
finefocus-675	13	27	for	for	ADP
finefocus-675	13	28	millions	million	NOUN
finefocus-675	13	29	of	of	ADP
finefocus-675	13	30	infections	infection	NOUN
finefocus-675	13	31	each	each	DET
finefocus-675	13	32	year	year	NOUN
finefocus-675	13	33	(	(	PUNCT
finefocus-675	13	34	15	15	NUM
finefocus-675	13	35	,	,	PUNCT
finefocus-675	13	36	22	22	NUM
finefocus-675	13	37	)	)	PUNCT
finefocus-675	13	38	.	.	PUNCT
finefocus-675	14	1	chikungunya	chikungunya	PROPN
finefocus-675	14	2	virus	virus	NOUN
finefocus-675	14	3	recently	recently	ADV
finefocus-675	14	4	spread	spread	VERB
finefocus-675	14	5	to	to	ADP
finefocus-675	14	6	north	north	NOUN
finefocus-675	14	7	,	,	PUNCT
finefocus-675	14	8	south	south	ADV
finefocus-675	14	9	,	,	PUNCT
finefocus-675	14	10	and	and	CCONJ
finefocus-675	14	11	centralamerica	centralamerica	VERB
finefocus-675	14	12	and	and	CCONJ
finefocus-675	14	13	resulted	result	VERB
finefocus-675	14	14	in	in	ADP
finefocus-675	14	15	more	more	ADJ
finefocus-675	14	16	than	than	ADP
finefocus-675	14	17	2.9	2.9	NUM
finefocus-675	14	18	million	million	NUM
finefocus-675	14	19	confirmed	confirm	VERB
finefocus-675	14	20	and	and	CCONJ
finefocus-675	14	21	suspected	suspect	VERB
finefocus-675	14	22	cases	case	NOUN
finefocus-675	14	23	,	,	PUNCT
finefocus-675	14	24	with	with	ADP
finefocus-675	14	25	nearly	nearly	ADV
finefocus-675	14	26	300	300	NUM
finefocus-675	14	27	deaths	death	NOUN
finefocus-675	14	28	as	as	ADP
finefocus-675	14	29	of	of	ADP
finefocus-675	14	30	summer	summer	NOUN
finefocus-675	14	31	2016	2016	NUM
finefocus-675	14	32	(	(	PUNCT
finefocus-675	14	33	11	11	NUM
finefocus-675	14	34	,	,	PUNCT
finefocus-675	14	35	26	26	NUM
finefocus-675	14	36	)	)	PUNCT
finefocus-675	14	37	.	.	PUNCT
finefocus-675	15	1	alphavirus	alphavirus	PROPN
finefocus-675	15	2	infection	infection	NOUN
finefocus-675	15	3	results	result	VERB
finefocus-675	15	4	in	in	ADP
finefocus-675	15	5	a	a	DET
finefocus-675	15	6	wide	wide	ADJ
finefocus-675	15	7	range	range	NOUN
finefocus-675	15	8	of	of	ADP
finefocus-675	15	9	symptoms	symptom	NOUN
finefocus-675	15	10	including	include	VERB
finefocus-675	15	11	rash	rash	NOUN
finefocus-675	15	12	,	,	PUNCT
finefocus-675	15	13	malaise	malaise	NOUN
finefocus-675	15	14	,	,	PUNCT
finefocus-675	15	15	chronic	chronic	ADJ
finefocus-675	15	16	arthralgia	arthralgia	NOUN
finefocus-675	15	17	,	,	PUNCT
finefocus-675	15	18	and	and	CCONJ
finefocus-675	15	19	can	can	AUX
finefocus-675	15	20	even	even	ADV
finefocus-675	15	21	lead	lead	VERB
finefocus-675	15	22	to	to	ADP
finefocus-675	15	23	fatal	fatal	ADJ
finefocus-675	15	24	encephalitis	encephalitis	NOUN
finefocus-675	15	25	(	(	PUNCT
finefocus-675	15	26	2	2	NUM
finefocus-675	15	27	,	,	PUNCT
finefocus-675	15	28	23	23	NUM
finefocus-675	15	29	,	,	PUNCT
finefocus-675	15	30	30	30	NUM
finefocus-675	15	31	)	)	PUNCT
finefocus-675	15	32	.	.	PUNCT
finefocus-675	16	1	there	there	PRON
finefocus-675	16	2	are	be	VERB
finefocus-675	16	3	few	few	ADJ
finefocus-675	16	4	effective	effective	ADJ
finefocus-675	16	5	treatment	treatment	NOUN
finefocus-675	16	6	options	option	NOUN
finefocus-675	16	7	available	available	ADJ
finefocus-675	16	8	for	for	ADP
finefocus-675	16	9	those	those	PRON
finefocus-675	16	10	infected	infect	VERB
finefocus-675	16	11	with	with	ADP
finefocus-675	16	12	alphaviruses	alphavirus	NOUN
finefocus-675	16	13	and	and	CCONJ
finefocus-675	16	14	a	a	DET
finefocus-675	16	15	novel	novel	ADJ
finefocus-675	16	16	method	method	NOUN
finefocus-675	16	17	to	to	PART
finefocus-675	16	18	treat	treat	VERB
finefocus-675	16	19	and	and	CCONJ
finefocus-675	16	20	inhibit	inhibit	VERB
finefocus-675	16	21	alphavirus	alphavirus	NOUN
finefocus-675	16	22	infections	infection	NOUN
finefocus-675	16	23	is	be	AUX
finefocus-675	16	24	imperative	imperative	ADJ
finefocus-675	16	25	to	to	ADP
finefocus-675	16	26	public	public	ADJ
finefocus-675	16	27	health	health	NOUN
finefocus-675	16	28	.	.	PUNCT
finefocus-675	17	1	traditionally	traditionally	ADV
finefocus-675	17	2	,	,	PUNCT
finefocus-675	17	3	antiviral	antiviral	ADJ
finefocus-675	17	4	therapies	therapy	NOUN
finefocus-675	17	5	have	have	AUX
finefocus-675	17	6	been	be	AUX
finefocus-675	17	7	designed	design	VERB
finefocus-675	17	8	and	and	CCONJ
finefocus-675	17	9	engineered	engineer	VERB
finefocus-675	17	10	to	to	PART
finefocus-675	17	11	target	target	VERB
finefocus-675	17	12	viral	viral	ADJ
finefocus-675	17	13	proteins	protein	NOUN
finefocus-675	17	14	,	,	PUNCT
finefocus-675	17	15	instead	instead	ADV
finefocus-675	17	16	of	of	ADP
finefocus-675	17	17	host	host	NOUN
finefocus-675	17	18	cell	cell	NOUN
finefocus-675	17	19	proteins	protein	NOUN
finefocus-675	17	20	in	in	ADP
finefocus-675	17	21	order	order	NOUN
finefocus-675	17	22	to	to	PART
finefocus-675	17	23	prevent	prevent	VERB
finefocus-675	17	24	cytotoxicity	cytotoxicity	NOUN
finefocus-675	17	25	to	to	ADP
finefocus-675	17	26	the	the	DET
finefocus-675	17	27	host	host	NOUN
finefocus-675	17	28	cells	cell	NOUN
finefocus-675	17	29	(	(	PUNCT
finefocus-675	17	30	17	17	NUM
finefocus-675	17	31	)	)	PUNCT
finefocus-675	17	32	.	.	PUNCT
finefocus-675	18	1	however	however	ADV
finefocus-675	18	2	,	,	PUNCT
finefocus-675	18	3	due	due	ADP
finefocus-675	18	4	to	to	ADP
finefocus-675	18	5	the	the	DET
finefocus-675	18	6	rapid	rapid	ADJ
finefocus-675	18	7	rate	rate	NOUN
finefocus-675	18	8	of	of	ADP
finefocus-675	18	9	mutation	mutation	NOUN
finefocus-675	18	10	and	and	CCONJ
finefocus-675	18	11	diversity	diversity	NOUN
finefocus-675	18	12	within	within	ADP
finefocus-675	18	13	viral	viral	ADJ
finefocus-675	18	14	species	specie	NOUN
finefocus-675	18	15	,	,	PUNCT
finefocus-675	18	16	viral	viral	ADJ
finefocus-675	18	17	specific	specific	ADJ
finefocus-675	18	18	drug	drug	NOUN
finefocus-675	18	19	treatments	treatment	NOUN
finefocus-675	18	20	are	be	AUX
finefocus-675	18	21	limited	limit	VERB
finefocus-675	18	22	in	in	ADP
finefocus-675	18	23	efficacy	efficacy	NOUN
finefocus-675	18	24	and	and	CCONJ
finefocus-675	18	25	burdened	burden	VERB
finefocus-675	18	26	with	with	ADP
finefocus-675	18	27	the	the	DET
finefocus-675	18	28	rapid	rapid	ADJ
finefocus-675	18	29	development	development	NOUN
finefocus-675	18	30	of	of	ADP
finefocus-675	18	31	drug	drug	NOUN
finefocus-675	18	32	resistance	resistance	NOUN
finefocus-675	18	33	.	.	PUNCT
finefocus-675	19	1	new	new	ADJ
finefocus-675	19	2	strategies	strategy	NOUN
finefocus-675	19	3	involve	involve	VERB
finefocus-675	19	4	altering	alter	VERB
finefocus-675	19	5	or	or	CCONJ
finefocus-675	19	6	limiting	limit	VERB
finefocus-675	19	7	cellular	cellular	ADJ
finefocus-675	19	8	pathways	pathway	NOUN
finefocus-675	19	9	that	that	PRON
finefocus-675	19	10	the	the	DET
finefocus-675	19	11	virus	virus	NOUN
finefocus-675	19	12	relies	rely	VERB
finefocus-675	19	13	on	on	ADP
finefocus-675	19	14	and	and	CCONJ
finefocus-675	19	15	thereby	thereby	ADV
finefocus-675	19	16	reducing	reduce	VERB
finefocus-675	19	17	the	the	DET
finefocus-675	19	18	viral	viral	ADJ
finefocus-675	19	19	replication	replication	NOUN
finefocus-675	19	20	capacity	capacity	NOUN
finefocus-675	19	21	of	of	ADP
finefocus-675	19	22	the	the	DET
finefocus-675	19	23	host	host	NOUN
finefocus-675	19	24	cell	cell	NOUN
finefocus-675	19	25	(	(	PUNCT
finefocus-675	19	26	4	4	NUM
finefocus-675	19	27	)	)	PUNCT
finefocus-675	19	28	.	.	PUNCT
finefocus-675	20	1	all	all	DET
finefocus-675	20	2	viruses	virus	NOUN
finefocus-675	20	3	are	be	AUX
finefocus-675	20	4	parasites	parasite	NOUN
finefocus-675	20	5	of	of	ADP
finefocus-675	20	6	the	the	DET
finefocus-675	20	7	host	host	NOUN
finefocus-675	20	8	cell	cell	NOUN
finefocus-675	20	9	metabolic	metabolic	NOUN
finefocus-675	20	10	pathways	pathway	NOUN
finefocus-675	20	11	and	and	CCONJ
finefocus-675	20	12	depend	depend	VERB
finefocus-675	20	13	on	on	ADP
finefocus-675	20	14	the	the	DET
finefocus-675	20	15	host	host	NOUN
finefocus-675	20	16	cell	cell	NOUN
finefocus-675	20	17	for	for	ADP
finefocus-675	20	18	all	all	DET
finefocus-675	20	19	biomolecule	biomolecule	NOUN
finefocus-675	20	20	and	and	CCONJ
finefocus-675	20	21	energy	energy	NOUN
finefocus-675	20	22	synthesis	synthesis	NOUN
finefocus-675	20	23	requirements	requirement	NOUN
finefocus-675	20	24	.	.	PUNCT
finefocus-675	21	1	many	many	ADJ
finefocus-675	21	2	viruses	virus	NOUN
finefocus-675	21	3	,	,	PUNCT
finefocus-675	21	4	including	include	VERB
finefocus-675	21	5	alphaviruses	alphavirus	NOUN
finefocus-675	21	6	,	,	PUNCT
finefocus-675	21	7	have	have	AUX
finefocus-675	21	8	been	be	AUX
finefocus-675	21	9	shown	show	VERB
finefocus-675	21	10	to	to	PART
finefocus-675	21	11	manipulate	manipulate	VERB
finefocus-675	21	12	cellular	cellular	ADJ
finefocus-675	21	13	metabolic	metabolic	NOUN
finefocus-675	21	14	pathways	pathway	NOUN
finefocus-675	21	15	to	to	PART
finefocus-675	21	16	enhance	enhance	VERB
finefocus-675	21	17	the	the	DET
finefocus-675	21	18	cellular	cellular	ADJ
finefocus-675	21	19	environment	environment	NOUN
finefocus-675	21	20	and	and	CCONJ
finefocus-675	21	21	make	make	VERB
finefocus-675	21	22	it	it	PRON
finefocus-675	21	23	optimal	optimal	ADJ
finefocus-675	21	24	for	for	ADP
finefocus-675	21	25	viral	viral	ADJ
finefocus-675	21	26	replication	replication	NOUN
finefocus-675	21	27	(	(	PUNCT
finefocus-675	21	28	8	8	NUM
finefocus-675	21	29	,	,	PUNCT
finefocus-675	21	30	9	9	NUM
finefocus-675	21	31	,	,	PUNCT
finefocus-675	21	32	19	19	NUM
finefocus-675	21	33	,	,	PUNCT
finefocus-675	21	34	29	29	NUM
finefocus-675	21	35	)	)	PUNCT
finefocus-675	21	36	.	.	PUNCT
finefocus-675	22	1	sindbis	sindbis	PROPN
finefocus-675	22	2	virus	virus	PROPN
finefocus-675	22	3	(	(	PUNCT
finefocus-675	22	4	sinv	sinv	NOUN
finefocus-675	22	5	)	)	PUNCT
finefocus-675	22	6	is	be	AUX
finefocus-675	22	7	the	the	DET
finefocus-675	22	8	prototype	prototype	NOUN
finefocus-675	22	9	alphavirus	alphavirus	NOUN
finefocus-675	22	10	and	and	CCONJ
finefocus-675	22	11	is	be	AUX
finefocus-675	22	12	commonly	commonly	ADV
finefocus-675	22	13	used	use	VERB
finefocus-675	22	14	as	as	ADP
finefocus-675	22	15	the	the	DET
finefocus-675	22	16	model	model	NOUN
finefocus-675	22	17	virus	virus	NOUN
finefocus-675	22	18	for	for	ADP
finefocus-675	22	19	other	other	ADJ
finefocus-675	22	20	alphaviruses	alphavirus	NOUN
finefocus-675	22	21	.	.	PUNCT
finefocus-675	23	1	for	for	ADP
finefocus-675	23	2	sindbis	sindbis	PROPN
finefocus-675	23	3	virus	virus	PROPN
finefocus-675	23	4	,	,	PUNCT
finefocus-675	23	5	an	an	DET
finefocus-675	23	6	elevated	elevated	ADJ
finefocus-675	23	7	glycolytic	glycolytic	ADJ
finefocus-675	23	8	rate	rate	NOUN
finefocus-675	23	9	appears	appear	VERB
finefocus-675	23	10	to	to	PART
finefocus-675	23	11	benefit	benefit	VERB
finefocus-675	23	12	the	the	DET
finefocus-675	23	13	virus	virus	NOUN
finefocus-675	23	14	replication(6	replication(6	PROPN
finefocus-675	23	15	)	)	PUNCT
finefocus-675	23	16	.	.	PUNCT
finefocus-675	24	1	it	it	PRON
finefocus-675	24	2	was	be	AUX
finefocus-675	24	3	hypothesized	hypothesize	VERB
finefocus-675	24	4	that	that	SCONJ
finefocus-675	24	5	drugs	drug	NOUN
finefocus-675	24	6	that	that	PRON
finefocus-675	24	7	inhibit	inhibit	VERB
finefocus-675	24	8	or	or	CCONJ
finefocus-675	24	9	reduce	reduce	VERB
finefocus-675	24	10	metabolic	metabolic	NOUN
finefocus-675	24	11	rates	rate	NOUN
finefocus-675	24	12	may	may	AUX
finefocus-675	24	13	effectively	effectively	ADV
finefocus-675	24	14	be	be	AUX
finefocus-675	24	15	used	use	VERB
finefocus-675	24	16	to	to	PART
finefocus-675	24	17	slow	slow	VERB
finefocus-675	24	18	and	and	CCONJ
finefocus-675	24	19	inhibit	inhibit	VERB
finefocus-675	24	20	viral	viral	ADJ
finefocus-675	24	21	replication	replication	NOUN
finefocus-675	24	22	.	.	PUNCT
finefocus-675	25	1	metabolic	metabolic	NOUN
finefocus-675	25	2	inhibitors	inhibitor	NOUN
finefocus-675	25	3	have	have	AUX
finefocus-675	25	4	been	be	AUX
finefocus-675	25	5	studied	study	VERB
finefocus-675	25	6	extensively	extensively	ADV
finefocus-675	25	7	in	in	ADP
finefocus-675	25	8	the	the	DET
finefocus-675	25	9	cancer	cancer	NOUN
finefocus-675	25	10	research	research	NOUN
finefocus-675	25	11	fields	field	NOUN
finefocus-675	25	12	.	.	PUNCT
finefocus-675	26	1	cancer	cancer	NOUN
finefocus-675	26	2	is	be	AUX
finefocus-675	26	3	essentially	essentially	ADV
finefocus-675	26	4	a	a	DET
finefocus-675	26	5	metabolic	metabolic	NOUN
finefocus-675	26	6	/	/	SYM
finefocus-675	26	7	cell	cell	NOUN
finefocus-675	26	8	division	division	NOUN
finefocus-675	26	9	disorder	disorder	NOUN
finefocus-675	26	10	where	where	SCONJ
finefocus-675	26	11	cells	cell	NOUN
finefocus-675	26	12	grow	grow	VERB
finefocus-675	26	13	uncontrollably	uncontrollably	ADV
finefocus-675	26	14	with	with	ADP
finefocus-675	26	15	an	an	DET
finefocus-675	26	16	elevated	elevated	ADJ
finefocus-675	26	17	metabolic	metabolic	NOUN
finefocus-675	26	18	rate	rate	NOUN
finefocus-675	26	19	.	.	PUNCT
finefocus-675	27	1	many	many	ADJ
finefocus-675	27	2	cancer	cancer	NOUN
finefocus-675	27	3	drugs	drug	NOUN
finefocus-675	27	4	target	target	VERB
finefocus-675	27	5	this	this	DET
finefocus-675	27	6	elevated	elevated	ADJ
finefocus-675	27	7	metabolism	metabolism	NOUN
finefocus-675	27	8	and	and	CCONJ
finefocus-675	27	9	reduce	reduce	VERB
finefocus-675	27	10	or	or	CCONJ
finefocus-675	27	11	slow	slow	VERB
finefocus-675	27	12	down	down	ADP
finefocus-675	27	13	metabolism	metabolism	NOUN
finefocus-675	27	14	to	to	ADP
finefocus-675	27	15	normal	normal	ADJ
finefocus-675	27	16	levels	level	NOUN
finefocus-675	27	17	,	,	PUNCT
finefocus-675	27	18	thereby	thereby	ADV
finefocus-675	27	19	inhibiting	inhibit	VERB
finefocus-675	27	20	cancer	cancer	NOUN
finefocus-675	27	21	growth	growth	NOUN
finefocus-675	27	22	and	and	CCONJ
finefocus-675	27	23	metastasis	metastasis	NOUN
finefocus-675	27	24	(	(	PUNCT
finefocus-675	27	25	27	27	NUM
finefocus-675	27	26	)	)	PUNCT
finefocus-675	27	27	.	.	PUNCT
finefocus-675	28	1	due	due	ADP
finefocus-675	28	2	to	to	ADP
finefocus-675	28	3	the	the	DET
finefocus-675	28	4	widespread	widespread	ADJ
finefocus-675	28	5	burden	burden	NOUN
finefocus-675	28	6	of	of	ADP
finefocus-675	28	7	cancer	cancer	NOUN
finefocus-675	28	8	,	,	PUNCT
finefocus-675	28	9	there	there	PRON
finefocus-675	28	10	has	have	AUX
finefocus-675	28	11	been	be	AUX
finefocus-675	28	12	much	much	ADJ
finefocus-675	28	13	research	research	NOUN
finefocus-675	28	14	in	in	ADP
finefocus-675	28	15	metabolic	metabolic	NOUN
finefocus-675	28	16	inhibitor	inhibitor	NOUN
finefocus-675	28	17	drugs	drug	NOUN
finefocus-675	28	18	and	and	CCONJ
finefocus-675	28	19	there	there	PRON
finefocus-675	28	20	are	be	VERB
finefocus-675	28	21	several	several	ADJ
finefocus-675	28	22	options	option	NOUN
finefocus-675	28	23	that	that	PRON
finefocus-675	28	24	are	be	AUX
finefocus-675	28	25	fda	fda	PROPN
finefocus-675	28	26	-	-	PUNCT
finefocus-675	28	27	approved	approve	VERB
finefocus-675	28	28	and	and	CCONJ
finefocus-675	28	29	are	be	AUX
finefocus-675	28	30	used	use	VERB
finefocus-675	28	31	clinically	clinically	ADV
finefocus-675	28	32	to	to	PART
finefocus-675	28	33	treat	treat	VERB
finefocus-675	28	34	cancers	cancer	NOUN
finefocus-675	28	35	(	(	PUNCT
finefocus-675	28	36	5	5	NUM
finefocus-675	28	37	,	,	PUNCT
finefocus-675	28	38	10	10	NUM
finefocus-675	28	39	,	,	PUNCT
finefocus-675	28	40	16	16	NUM
finefocus-675	28	41	)	)	PUNCT
finefocus-675	28	42	.	.	PUNCT
finefocus-675	29	1	viral	viral	ADJ
finefocus-675	29	2	infections	infection	NOUN
finefocus-675	29	3	induce	induce	VERB
finefocus-675	29	4	a	a	DET
finefocus-675	29	5	similar	similar	ADJ
finefocus-675	29	6	elevated	elevated	ADJ
finefocus-675	29	7	metabolic	metabolic	NOUN
finefocus-675	29	8	phenotype	phenotype	NOUN
finefocus-675	29	9	in	in	ADP
finefocus-675	29	10	host	host	NOUN
finefocus-675	29	11	cells	cell	NOUN
finefocus-675	29	12	and	and	CCONJ
finefocus-675	29	13	some	some	PRON
finefocus-675	29	14	of	of	ADP
finefocus-675	29	15	these	these	DET
finefocus-675	29	16	metabolic	metabolic	ADJ
finefocus-675	29	17	inhibitor	inhibitor	NOUN
finefocus-675	29	18	cancer	cancer	NOUN
finefocus-675	29	19	drugs	drug	NOUN
finefocus-675	29	20	have	have	AUX
finefocus-675	29	21	been	be	AUX
finefocus-675	29	22	repurposed	repurpose	VERB
finefocus-675	29	23	as	as	ADP
finefocus-675	29	24	novel	novel	ADJ
finefocus-675	29	25	treatment	treatment	NOUN
finefocus-675	29	26	options	option	NOUN
finefocus-675	29	27	for	for	ADP
finefocus-675	29	28	viral	viral	ADJ
finefocus-675	29	29	infections	infection	NOUN
finefocus-675	29	30	.	.	PUNCT
finefocus-675	30	1	imatinib	imatinib	NOUN
finefocus-675	30	2	mesylate	mesylate	VERB
finefocus-675	30	3	,	,	PUNCT
finefocus-675	30	4	or	or	CCONJ
finefocus-675	30	5	gleevec	gleevec	PROPN
finefocus-675	30	6	®	®	NOUN
finefocus-675	30	7	,	,	PUNCT
finefocus-675	30	8	is	be	AUX
finefocus-675	30	9	a	a	DET
finefocus-675	30	10	tyrosine	tyrosine	NOUN
finefocus-675	30	11	kinase	kinase	NOUN
finefocus-675	30	12	inhibitor	inhibitor	NOUN
finefocus-675	30	13	that	that	PRON
finefocus-675	30	14	prevents	prevent	VERB
finefocus-675	30	15	the	the	DET
finefocus-675	30	16	phosphorylation	phosphorylation	NOUN
finefocus-675	30	17	and	and	CCONJ
finefocus-675	30	18	activation	activation	NOUN
finefocus-675	30	19	of	of	ADP
finefocus-675	30	20	key	key	ADJ
finefocus-675	30	21	enzymes	enzyme	NOUN
finefocus-675	30	22	in	in	ADP
finefocus-675	30	23	metabolic	metabolic	NOUN
finefocus-675	30	24	pathways	pathway	NOUN
finefocus-675	30	25	(	(	PUNCT
finefocus-675	30	26	1	1	NUM
finefocus-675	30	27	)	)	PUNCT
finefocus-675	30	28	.	.	PUNCT
finefocus-675	31	1	specifically	specifically	ADV
finefocus-675	31	2	,	,	PUNCT
finefocus-675	31	3	imatinib	imatinib	NOUN
finefocus-675	31	4	has	have	AUX
finefocus-675	31	5	been	be	AUX
finefocus-675	31	6	shown	show	VERB
finefocus-675	31	7	to	to	PART
finefocus-675	31	8	reduce	reduce	VERB
finefocus-675	31	9	the	the	DET
finefocus-675	31	10	activity	activity	NOUN
finefocus-675	31	11	of	of	ADP
finefocus-675	31	12	hexokinase	hexokinase	NOUN
finefocus-675	31	13	,	,	PUNCT
finefocus-675	31	14	which	which	PRON
finefocus-675	31	15	is	be	AUX
finefocus-675	31	16	a	a	DET
finefocus-675	31	17	key	key	ADJ
finefocus-675	31	18	enzyme	enzyme	NOUN
finefocus-675	31	19	in	in	ADP
finefocus-675	31	20	the	the	DET
finefocus-675	31	21	glycolysis	glycolysis	NOUN
finefocus-675	31	22	pathway	pathway	NOUN
finefocus-675	31	23	(	(	PUNCT
finefocus-675	31	24	3	3	NUM
finefocus-675	31	25	,	,	PUNCT
finefocus-675	31	26	18	18	NUM
finefocus-675	31	27	)	)	PUNCT
finefocus-675	31	28	.	.	PUNCT
finefocus-675	32	1	sindbis	sindbis	PROPN
finefocus-675	32	2	virus	virus	PROPN
finefocus-675	32	3	is	be	AUX
finefocus-675	32	4	dependent	dependent	ADJ
finefocus-675	32	5	on	on	ADP
finefocus-675	32	6	glycolysis	glycolysis	NOUN
finefocus-675	32	7	and	and	CCONJ
finefocus-675	32	8	it	it	PRON
finefocus-675	32	9	was	be	AUX
finefocus-675	32	10	predicted	predict	VERB
finefocus-675	32	11	that	that	SCONJ
finefocus-675	32	12	inhibiting	inhibit	VERB
finefocus-675	32	13	the	the	DET
finefocus-675	32	14	glycolytic	glycolytic	ADJ
finefocus-675	32	15	pathway	pathway	NOUN
finefocus-675	32	16	would	would	AUX
finefocus-675	32	17	result	result	VERB
finefocus-675	32	18	in	in	ADP
finefocus-675	32	19	less	less	ADJ
finefocus-675	32	20	viral	viral	ADJ
finefocus-675	32	21	replication	replication	NOUN
finefocus-675	32	22	.	.	PUNCT
finefocus-675	33	1	we	we	PRON
finefocus-675	33	2	hypothesized	hypothesize	VERB
finefocus-675	33	3	that	that	SCONJ
finefocus-675	33	4	imatinib	imatinib	NOUN
finefocus-675	33	5	mesylate	mesylate	NOUN
finefocus-675	33	6	,	,	PUNCT
finefocus-675	33	7	which	which	PRON
finefocus-675	33	8	is	be	AUX
finefocus-675	33	9	already	already	ADV
finefocus-675	33	10	used	use	VERB
finefocus-675	33	11	clinically	clinically	ADV
finefocus-675	33	12	,	,	PUNCT
finefocus-675	33	13	may	may	AUX
finefocus-675	33	14	be	be	AUX
finefocus-675	33	15	repurposed	repurpose	VERB
finefocus-675	33	16	and	and	CCONJ
finefocus-675	33	17	effectively	effectively	ADV
finefocus-675	33	18	used	use	VERB
finefocus-675	33	19	to	to	PART
finefocus-675	33	20	treat	treat	VERB
finefocus-675	33	21	alphavirus	alphavirus	NOUN
finefocus-675	33	22	infection	infection	NOUN
finefocus-675	33	23	.	.	PUNCT
finefocus-675	34	1	here	here	ADV
finefocus-675	34	2	we	we	PRON
finefocus-675	34	3	present	present	VERB
finefocus-675	34	4	our	our	PRON
finefocus-675	34	5	findings	finding	NOUN
finefocus-675	34	6	that	that	SCONJ
finefocus-675	34	7	imatinib	imatinib	NOUN
finefocus-675	34	8	mesylate	mesylate	NOUN
finefocus-675	34	9	successfully	successfully	ADV
finefocus-675	34	10	reduces	reduce	VERB
finefocus-675	34	11	sindbis	sindbis	PROPN
finefocus-675	34	12	virus	virus	NOUN
finefocus-675	34	13	replication	replication	NOUN
finefocus-675	34	14	in	in	ADP
finefocus-675	34	15	cell	cell	NOUN
finefocus-675	34	16	culture	culture	NOUN
finefocus-675	34	17	at	at	ADP
finefocus-675	34	18	low	low	ADJ
finefocus-675	34	19	enough	enough	ADJ
finefocus-675	34	20	concentrations	concentration	NOUN
finefocus-675	34	21	that	that	PRON
finefocus-675	34	22	do	do	AUX
finefocus-675	34	23	not	not	PART
finefocus-675	34	24	affect	affect	VERB
finefocus-675	34	25	host	host	NOUN
finefocus-675	34	26	cell	cell	NOUN
finefocus-675	34	27	viability	viability	NOUN
finefocus-675	34	28	.	.	PUNCT
finefocus-675	35	1	investigating	investigate	VERB
finefocus-675	35	2	different	different	ADJ
finefocus-675	35	3	imatinib	imatinib	NOUN
finefocus-675	35	4	concentrations	concentration	NOUN
finefocus-675	35	5	,	,	PUNCT
finefocus-675	35	6	viral	viral	ADJ
finefocus-675	35	7	titers	titer	NOUN
finefocus-675	35	8	,	,	PUNCT
finefocus-675	35	9	infection	infection	NOUN
finefocus-675	35	10	times	time	NOUN
finefocus-675	35	11	,	,	PUNCT
finefocus-675	35	12	treatment	treatment	NOUN
finefocus-675	35	13	addition	addition	NOUN
finefocus-675	35	14	times	time	NOUN
finefocus-675	35	15	,	,	PUNCT
finefocus-675	35	16	and	and	CCONJ
finefocus-675	35	17	various	various	ADJ
finefocus-675	35	18	cell	cell	NOUN
finefocus-675	35	19	lines	line	NOUN
finefocus-675	35	20	have	have	AUX
finefocus-675	35	21	all	all	PRON
finefocus-675	35	22	shown	show	VERB
finefocus-675	35	23	imatinib	imatinib	NOUN
finefocus-675	35	24	to	to	PART
finefocus-675	35	25	be	be	AUX
finefocus-675	35	26	efficacious	efficacious	ADJ
finefocus-675	35	27	at	at	ADP
finefocus-675	35	28	inhibiting	inhibit	VERB
finefocus-675	35	29	sindbis	sindbis	PROPN
finefocus-675	35	30	virus	virus	NOUN
finefocus-675	35	31	infection	infection	NOUN
finefocus-675	35	32	.	.	PUNCT
finefocus-675	36	1	methods	method	NOUN
finefocus-675	36	2	cells	cell	NOUN
finefocus-675	36	3	and	and	CCONJ
finefocus-675	36	4	cell	cell	NOUN
finefocus-675	36	5	culture	culture	NOUN
finefocus-675	36	6	baby	baby	NOUN
finefocus-675	36	7	hamster	hamster	PROPN
finefocus-675	36	8	kidney	kidney	PROPN
finefocus-675	36	9	(	(	PUNCT
finefocus-675	36	10	bhk	bhk	PROPN
finefocus-675	36	11	)	)	PUNCT
finefocus-675	36	12	cells	cell	NOUN
finefocus-675	36	13	were	be	AUX
finefocus-675	36	14	grown	grow	VERB
finefocus-675	36	15	in	in	ADP
finefocus-675	36	16	dulbecco	dulbecco	NOUN
finefocus-675	36	17	’s	’s	PART
finefocus-675	36	18	modified	modify	VERB
finefocus-675	36	19	eagle	eagle	PROPN
finefocus-675	36	20	medium	medium	ADJ
finefocus-675	36	21	(	(	PUNCT
finefocus-675	36	22	dmem	dmem	ADJ
finefocus-675	36	23	)	)	PUNCT
finefocus-675	36	24	media	medium	NOUN
finefocus-675	36	25	supplemented	supplement	VERB
finefocus-675	36	26	with	with	ADP
finefocus-675	36	27	streptomycin	streptomycin	PROPN
finefocus-675	36	28	/	/	SYM
finefocus-675	36	29	penicillin	penicillin	PROPN
finefocus-675	36	30	and	and	CCONJ
finefocus-675	36	31	10	10	NUM
finefocus-675	36	32	%	%	NOUN
finefocus-675	36	33	fbs	fbs	ADJ
finefocus-675	36	34	.	.	PUNCT
finefocus-675	37	1	cells	cell	NOUN
finefocus-675	37	2	were	be	AUX
finefocus-675	37	3	incubated	incubate	VERB
finefocus-675	37	4	in	in	ADP
finefocus-675	37	5	t75	t75	NOUN
finefocus-675	37	6	flasks	flask	NOUN
finefocus-675	37	7	or	or	CCONJ
finefocus-675	37	8	24	24	NUM
finefocus-675	37	9	-	-	PUNCT
finefocus-675	37	10	well	well	NOUN
finefocus-675	37	11	culture	culture	NOUN
finefocus-675	37	12	plates	plate	NOUN
finefocus-675	37	13	and	and	CCONJ
finefocus-675	37	14	kept	keep	VERB
finefocus-675	37	15	in	in	ADP
finefocus-675	37	16	an	an	DET
finefocus-675	37	17	incubator	incubator	NOUN
finefocus-675	37	18	at	at	ADP
finefocus-675	37	19	37ºc	37ºc	ADJ
finefocus-675	37	20	and	and	CCONJ
finefocus-675	37	21	5	5	NUM
finefocus-675	37	22	%	%	NOUN
finefocus-675	37	23	co2	co2	NOUN
finefocus-675	37	24	.	.	PUNCT
finefocus-675	38	1	cells	cell	NOUN
finefocus-675	38	2	were	be	AUX
finefocus-675	38	3	passaged	passage	VERB
finefocus-675	38	4	every	every	DET
finefocus-675	38	5	3	3	NUM
finefocus-675	38	6	days	day	NOUN
finefocus-675	38	7	once	once	SCONJ
finefocus-675	38	8	85	85	NUM
finefocus-675	38	9	%	%	NOUN
finefocus-675	38	10	confluent	confluent	NOUN
finefocus-675	38	11	using	use	VERB
finefocus-675	38	12	pbs	pbs	PROPN
finefocus-675	38	13	and	and	CCONJ
finefocus-675	38	14	0.25	0.25	NUM
finefocus-675	38	15	%	%	NOUN
finefocus-675	38	16	trypsin	trypsin	NOUN
finefocus-675	38	17	.	.	PUNCT
finefocus-675	39	1	cells	cell	NOUN
finefocus-675	39	2	were	be	AUX
finefocus-675	39	3	counted	count	VERB
finefocus-675	39	4	and	and	CCONJ
finefocus-675	39	5	seeded	seed	VERB
finefocus-675	39	6	into	into	ADP
finefocus-675	39	7	well	well	ADJ
finefocus-675	39	8	plates	plate	NOUN
finefocus-675	39	9	(	(	PUNCT
finefocus-675	39	10	24	24	NUM
finefocus-675	39	11	-	-	PUNCT
finefocus-675	39	12	well	well	NOUN
finefocus-675	39	13	)	)	PUNCT
finefocus-675	39	14	24	24	NUM
finefocus-675	39	15	hours	hour	NOUN
finefocus-675	39	16	before	before	ADP
finefocus-675	39	17	an	an	DET
finefocus-675	39	18	experiment	experiment	NOUN
finefocus-675	39	19	so	so	SCONJ
finefocus-675	39	20	introduction	introduction	NOUN
finefocus-675	39	21	imatinib	imatinib	NOUN
finefocus-675	39	22	mesylate	mesylate	VERB
finefocus-675	39	23	•	•	ADV
finefocus-675	39	24	143142	143142	NUM
finefocus-675	39	25	•	•	ADV
finefocus-675	39	26	fine	fine	ADJ
finefocus-675	39	27	focus	focus	NOUN
finefocus-675	39	28	,	,	PUNCT
finefocus-675	39	29	vol	vol	NOUN
finefocus-675	39	30	.	.	NOUN
finefocus-675	39	31	3	3	NUM
finefocus-675	39	32	(	(	PUNCT
finefocus-675	39	33	2	2	NUM
finefocus-675	39	34	)	)	PUNCT
finefocus-675	39	35	imatinib	imatinib	NOUN
finefocus-675	39	36	mesylate	mesylate	VERB
finefocus-675	39	37	•	•	ADV
finefocus-675	39	38	145	145	NUM
finefocus-675	39	39	that	that	PRON
finefocus-675	39	40	the	the	DET
finefocus-675	39	41	cells	cell	NOUN
finefocus-675	39	42	would	would	AUX
finefocus-675	39	43	be	be	AUX
finefocus-675	39	44	about	about	ADP
finefocus-675	39	45	70	70	NUM
finefocus-675	39	46	%	%	NOUN
finefocus-675	39	47	confluent	confluent	NOUN
finefocus-675	39	48	at	at	ADP
finefocus-675	39	49	the	the	DET
finefocus-675	39	50	time	time	NOUN
finefocus-675	39	51	of	of	ADP
finefocus-675	39	52	infection	infection	NOUN
finefocus-675	39	53	/	/	SYM
finefocus-675	39	54	treatment	treatment	NOUN
finefocus-675	39	55	(	(	PUNCT
finefocus-675	39	56	75,000	75,000	NUM
finefocus-675	39	57	bhk	bhk	PROPN
finefocus-675	39	58	cells	cell	NOUN
finefocus-675	39	59	/	/	SYM
finefocus-675	39	60	ml=	ml=	PROPN
finefocus-675	39	61	~37,500	~37,500	PUNCT
finefocus-675	40	1	bhk	bhk	PROPN
finefocus-675	40	2	cells	cell	NOUN
finefocus-675	40	3	/	/	SYM
finefocus-675	40	4	well	well	INTJ
finefocus-675	40	5	)	)	PUNCT
finefocus-675	40	6	.	.	PUNCT
finefocus-675	41	1	human	human	ADJ
finefocus-675	41	2	hepatoma	hepatoma	NOUN
finefocus-675	41	3	(	(	PUNCT
finefocus-675	41	4	huh7	huh7	PROPN
finefocus-675	41	5	)	)	PUNCT
finefocus-675	41	6	cells	cell	NOUN
finefocus-675	41	7	and	and	CCONJ
finefocus-675	41	8	human	human	ADJ
finefocus-675	41	9	embryonic	embryonic	ADJ
finefocus-675	41	10	kidney	kidney	NOUN
finefocus-675	41	11	(	(	PUNCT
finefocus-675	41	12	hek	hek	PROPN
finefocus-675	41	13	)	)	PUNCT
finefocus-675	41	14	cells	cell	NOUN
finefocus-675	41	15	were	be	AUX
finefocus-675	41	16	maintained	maintain	VERB
finefocus-675	41	17	in	in	ADP
finefocus-675	41	18	similar	similar	ADJ
finefocus-675	41	19	conditions	condition	NOUN
finefocus-675	41	20	but	but	CCONJ
finefocus-675	41	21	were	be	AUX
finefocus-675	41	22	passaged	passage	VERB
finefocus-675	41	23	every	every	DET
finefocus-675	41	24	4	4	NUM
finefocus-675	41	25	days	day	NOUN
finefocus-675	41	26	.	.	PUNCT
finefocus-675	42	1	virus	virus	NOUN
finefocus-675	42	2	and	and	CCONJ
finefocus-675	42	3	viral	viral	ADJ
finefocus-675	42	4	infection	infection	NOUN
finefocus-675	42	5	the	the	DET
finefocus-675	42	6	100	100	NUM
finefocus-675	42	7	+	+	NOUN
finefocus-675	42	8	/10	/10	ADJ
finefocus-675	42	9	mg	mg	X
finefocus-675	42	10	of	of	ADP
finefocus-675	42	11	fresh	fresh	ADJ
finefocus-675	42	12	rind	rind	NOUN
finefocus-675	42	13	and	and	CCONJ
finefocus-675	42	14	curd	curd	NOUN
finefocus-675	42	15	sasindbis	sasindbis	NOUN
finefocus-675	42	16	virus	virus	NOUN
finefocus-675	42	17	,	,	PUNCT
finefocus-675	42	18	which	which	PRON
finefocus-675	42	19	belongs	belong	VERB
finefocus-675	42	20	to	to	PART
finefocus-675	42	21	togaviridae	togaviridae	NOUN
finefocus-675	42	22	and	and	CCONJ
finefocus-675	42	23	is	be	AUX
finefocus-675	42	24	an	an	DET
finefocus-675	42	25	old	old	ADJ
finefocus-675	42	26	world	world	NOUN
finefocus-675	42	27	alphavirus	alphavirus	NOUN
finefocus-675	42	28	,	,	PUNCT
finefocus-675	42	29	was	be	AUX
finefocus-675	42	30	used	use	VERB
finefocus-675	42	31	as	as	ADP
finefocus-675	42	32	the	the	DET
finefocus-675	42	33	model	model	NOUN
finefocus-675	42	34	alphavirus	alphavirus	NOUN
finefocus-675	42	35	for	for	ADP
finefocus-675	42	36	all	all	DET
finefocus-675	42	37	experiments	experiment	NOUN
finefocus-675	42	38	.	.	PUNCT
finefocus-675	43	1	a	a	DET
finefocus-675	43	2	green	green	ADJ
finefocus-675	43	3	fluorescent	fluorescent	ADJ
finefocus-675	43	4	protein	protein	NOUN
finefocus-675	43	5	(	(	PUNCT
finefocus-675	43	6	gfp	gfp	PROPN
finefocus-675	43	7	)	)	PUNCT
finefocus-675	43	8	reporter	reporter	NOUN
finefocus-675	43	9	was	be	AUX
finefocus-675	43	10	previously	previously	ADV
finefocus-675	43	11	inserted	insert	VERB
finefocus-675	43	12	into	into	ADP
finefocus-675	43	13	the	the	DET
finefocus-675	43	14	viral	viral	ADJ
finefocus-675	43	15	genome	genome	NOUN
finefocus-675	43	16	via	via	ADP
finefocus-675	43	17	a	a	DET
finefocus-675	43	18	duplicated	duplicate	VERB
finefocus-675	43	19	subgenomic	subgenomic	ADJ
finefocus-675	43	20	promoter	promoter	NOUN
finefocus-675	43	21	at	at	ADP
finefocus-675	43	22	the	the	DET
finefocus-675	43	23	3	3	NUM
finefocus-675	43	24	’	'	PUNCT
finefocus-675	43	25	end	end	NOUN
finefocus-675	43	26	of	of	ADP
finefocus-675	43	27	the	the	DET
finefocus-675	43	28	viral	viral	ADJ
finefocus-675	43	29	genome	genome	NOUN
finefocus-675	43	30	.	.	PUNCT
finefocus-675	44	1	this	this	DET
finefocus-675	44	2	gfp	gfp	PROPN
finefocus-675	44	3	is	be	AUX
finefocus-675	44	4	concurrently	concurrently	ADV
finefocus-675	44	5	expressed	express	VERB
finefocus-675	44	6	with	with	ADP
finefocus-675	44	7	the	the	DET
finefocus-675	44	8	viral	viral	ADJ
finefocus-675	44	9	proteins	protein	NOUN
finefocus-675	44	10	and	and	CCONJ
finefocus-675	44	11	the	the	DET
finefocus-675	44	12	relative	relative	ADJ
finefocus-675	44	13	gfp	gfp	PROPN
finefocus-675	44	14	fluorescence	fluorescence	NOUN
finefocus-675	44	15	serves	serve	VERB
finefocus-675	44	16	as	as	ADP
finefocus-675	44	17	a	a	DET
finefocus-675	44	18	direct	direct	ADJ
finefocus-675	44	19	indicator	indicator	NOUN
finefocus-675	44	20	for	for	ADP
finefocus-675	44	21	viral	viral	ADJ
finefocus-675	44	22	replication	replication	NOUN
finefocus-675	44	23	in	in	ADP
finefocus-675	44	24	infected	infected	ADJ
finefocus-675	44	25	cells	cell	NOUN
finefocus-675	44	26	.	.	PUNCT
finefocus-675	45	1	these	these	DET
finefocus-675	45	2	double	double	ADJ
finefocus-675	45	3	subgenomic	subgenomic	ADJ
finefocus-675	45	4	alphavirus	alphavirus	NOUN
finefocus-675	45	5	reporters	reporter	NOUN
finefocus-675	45	6	are	be	AUX
finefocus-675	45	7	well	well	ADV
finefocus-675	45	8	established	establish	VERB
finefocus-675	45	9	and	and	CCONJ
finefocus-675	45	10	used	use	VERB
finefocus-675	45	11	widely	widely	ADV
finefocus-675	45	12	in	in	ADP
finefocus-675	45	13	the	the	DET
finefocus-675	45	14	alphavirology	alphavirology	NOUN
finefocus-675	45	15	field(21	field(21	NOUN
finefocus-675	45	16	,	,	PUNCT
finefocus-675	45	17	23	23	NUM
finefocus-675	45	18	,	,	PUNCT
finefocus-675	45	19	28	28	NUM
finefocus-675	45	20	)	)	PUNCT
finefocus-675	45	21	.	.	PUNCT
finefocus-675	46	1	prior	prior	ADV
finefocus-675	46	2	to	to	ADP
finefocus-675	46	3	infection	infection	NOUN
finefocus-675	46	4	,	,	PUNCT
finefocus-675	46	5	a	a	DET
finefocus-675	46	6	sample	sample	NOUN
finefocus-675	46	7	well	well	INTJ
finefocus-675	46	8	was	be	AUX
finefocus-675	46	9	used	use	VERB
finefocus-675	46	10	to	to	PART
finefocus-675	46	11	count	count	VERB
finefocus-675	46	12	cells	cell	NOUN
finefocus-675	46	13	.	.	PUNCT
finefocus-675	47	1	cells	cell	NOUN
finefocus-675	47	2	were	be	AUX
finefocus-675	47	3	trypsinized	trypsinize	VERB
finefocus-675	47	4	,	,	PUNCT
finefocus-675	47	5	resuspended	resuspend	VERB
finefocus-675	47	6	,	,	PUNCT
finefocus-675	47	7	and	and	CCONJ
finefocus-675	47	8	counted	count	VERB
finefocus-675	47	9	using	use	VERB
finefocus-675	47	10	trypan	trypan	NOUN
finefocus-675	47	11	blue	blue	ADJ
finefocus-675	47	12	staining	staining	NOUN
finefocus-675	47	13	and	and	CCONJ
finefocus-675	47	14	a	a	DET
finefocus-675	47	15	hemocytometer	hemocytometer	NOUN
finefocus-675	47	16	.	.	PUNCT
finefocus-675	48	1	once	once	ADV
finefocus-675	48	2	an	an	DET
finefocus-675	48	3	accurate	accurate	ADJ
finefocus-675	48	4	count	count	NOUN
finefocus-675	48	5	of	of	ADP
finefocus-675	48	6	cells	cell	NOUN
finefocus-675	48	7	/	/	SYM
finefocus-675	48	8	well	well	INTJ
finefocus-675	48	9	was	be	AUX
finefocus-675	48	10	available	available	ADJ
finefocus-675	48	11	,	,	PUNCT
finefocus-675	48	12	the	the	DET
finefocus-675	48	13	amount	amount	NOUN
finefocus-675	48	14	of	of	ADP
finefocus-675	48	15	virus	virus	NOUN
finefocus-675	48	16	could	could	AUX
finefocus-675	48	17	be	be	AUX
finefocus-675	48	18	calculated	calculate	VERB
finefocus-675	48	19	and	and	CCONJ
finefocus-675	48	20	added	add	VERB
finefocus-675	48	21	to	to	ADP
finefocus-675	48	22	the	the	DET
finefocus-675	48	23	specified	specified	ADJ
finefocus-675	48	24	wells	well	NOUN
finefocus-675	48	25	.	.	PUNCT
finefocus-675	49	1	cells	cell	NOUN
finefocus-675	49	2	were	be	AUX
finefocus-675	49	3	infected	infect	VERB
finefocus-675	49	4	with	with	ADP
finefocus-675	49	5	a	a	DET
finefocus-675	49	6	multiplicity	multiplicity	NOUN
finefocus-675	49	7	of	of	ADP
finefocus-675	49	8	infection	infection	NOUN
finefocus-675	49	9	(	(	PUNCT
finefocus-675	49	10	moi	moi	X
finefocus-675	49	11	)	)	PUNCT
finefocus-675	49	12	of	of	ADP
finefocus-675	49	13	1	1	NUM
finefocus-675	49	14	,	,	PUNCT
finefocus-675	49	15	unless	unless	SCONJ
finefocus-675	49	16	otherwise	otherwise	ADV
finefocus-675	49	17	noted	note	VERB
finefocus-675	49	18	.	.	PUNCT
finefocus-675	50	1	moi	moi	PROPN
finefocus-675	50	2	is	be	AUX
finefocus-675	50	3	the	the	DET
finefocus-675	50	4	ratio	ratio	NOUN
finefocus-675	50	5	of	of	ADP
finefocus-675	50	6	infectious	infectious	ADJ
finefocus-675	50	7	virus	virus	NOUN
finefocus-675	50	8	particles	particle	NOUN
finefocus-675	50	9	(	(	PUNCT
finefocus-675	50	10	plaque	plaque	NOUN
finefocus-675	50	11	forming	form	VERB
finefocus-675	50	12	units	unit	NOUN
finefocus-675	50	13	(	(	PUNCT
finefocus-675	50	14	pfu	pfu	NOUN
finefocus-675	50	15	)	)	PUNCT
finefocus-675	50	16	)	)	PUNCT
finefocus-675	50	17	to	to	ADP
finefocus-675	50	18	number	number	NOUN
finefocus-675	50	19	of	of	ADP
finefocus-675	50	20	cells	cell	NOUN
finefocus-675	50	21	and	and	CCONJ
finefocus-675	50	22	an	an	DET
finefocus-675	50	23	moi=1	moi=1	NOUN
finefocus-675	50	24	will	will	AUX
finefocus-675	50	25	infect	infect	VERB
finefocus-675	50	26	a	a	DET
finefocus-675	50	27	majority	majority	NOUN
finefocus-675	50	28	of	of	ADP
finefocus-675	50	29	cells	cell	NOUN
finefocus-675	50	30	in	in	ADP
finefocus-675	50	31	the	the	DET
finefocus-675	50	32	well	well	NOUN
finefocus-675	50	33	.	.	PUNCT
finefocus-675	51	1	the	the	DET
finefocus-675	51	2	corresponding	corresponding	ADJ
finefocus-675	51	3	amount	amount	NOUN
finefocus-675	51	4	of	of	ADP
finefocus-675	51	5	virus	virus	NOUN
finefocus-675	51	6	was	be	AUX
finefocus-675	51	7	added	add	VERB
finefocus-675	51	8	to	to	ADP
finefocus-675	51	9	the	the	DET
finefocus-675	51	10	total	total	ADJ
finefocus-675	51	11	volume	volume	NOUN
finefocus-675	51	12	needed	need	VERB
finefocus-675	51	13	and	and	CCONJ
finefocus-675	51	14	then	then	ADV
finefocus-675	51	15	was	be	AUX
finefocus-675	51	16	added	add	VERB
finefocus-675	51	17	to	to	ADP
finefocus-675	51	18	each	each	DET
finefocus-675	51	19	well	well	ADV
finefocus-675	51	20	being	be	AUX
finefocus-675	51	21	infected	infect	VERB
finefocus-675	51	22	.	.	PUNCT
finefocus-675	52	1	the	the	DET
finefocus-675	52	2	plates	plate	NOUN
finefocus-675	52	3	were	be	AUX
finefocus-675	52	4	incubated	incubate	VERB
finefocus-675	52	5	for	for	ADP
finefocus-675	52	6	1	1	NUM
finefocus-675	52	7	hour	hour	NOUN
finefocus-675	52	8	at	at	ADP
finefocus-675	52	9	37ºc	37ºc	NOUN
finefocus-675	52	10	to	to	PART
finefocus-675	52	11	allow	allow	VERB
finefocus-675	52	12	the	the	DET
finefocus-675	52	13	virus	virus	NOUN
finefocus-675	52	14	to	to	PART
finefocus-675	52	15	infect	infect	VERB
finefocus-675	52	16	and	and	CCONJ
finefocus-675	52	17	enter	enter	VERB
finefocus-675	52	18	the	the	DET
finefocus-675	52	19	host	host	NOUN
finefocus-675	52	20	cells	cell	NOUN
finefocus-675	52	21	.	.	PUNCT
finefocus-675	53	1	following	follow	VERB
finefocus-675	53	2	1	1	NUM
finefocus-675	53	3	hour	hour	NOUN
finefocus-675	53	4	of	of	ADP
finefocus-675	53	5	infection	infection	NOUN
finefocus-675	53	6	,	,	PUNCT
finefocus-675	53	7	the	the	DET
finefocus-675	53	8	media	medium	NOUN
finefocus-675	53	9	containing	contain	VERB
finefocus-675	53	10	the	the	DET
finefocus-675	53	11	virus	virus	NOUN
finefocus-675	53	12	was	be	AUX
finefocus-675	53	13	removed	remove	VERB
finefocus-675	53	14	,	,	PUNCT
finefocus-675	53	15	the	the	DET
finefocus-675	53	16	cells	cell	NOUN
finefocus-675	53	17	were	be	AUX
finefocus-675	53	18	washed	wash	VERB
finefocus-675	53	19	with	with	ADP
finefocus-675	53	20	pbs	pbs	PROPN
finefocus-675	53	21	,	,	PUNCT
finefocus-675	53	22	and	and	CCONJ
finefocus-675	53	23	fresh	fresh	ADJ
finefocus-675	53	24	media	medium	NOUN
finefocus-675	53	25	(	(	PUNCT
finefocus-675	53	26	with	with	ADP
finefocus-675	53	27	or	or	CCONJ
finefocus-675	53	28	without	without	ADP
finefocus-675	53	29	the	the	DET
finefocus-675	53	30	treatment	treatment	NOUN
finefocus-675	53	31	)	)	PUNCT
finefocus-675	53	32	was	be	AUX
finefocus-675	53	33	added	add	VERB
finefocus-675	53	34	to	to	ADP
finefocus-675	53	35	the	the	DET
finefocus-675	53	36	cells	cell	NOUN
finefocus-675	53	37	.	.	PUNCT
finefocus-675	54	1	the	the	DET
finefocus-675	54	2	infected	infected	ADJ
finefocus-675	54	3	cells	cell	NOUN
finefocus-675	54	4	were	be	AUX
finefocus-675	54	5	put	put	VERB
finefocus-675	54	6	back	back	ADV
finefocus-675	54	7	in	in	ADP
finefocus-675	54	8	the	the	DET
finefocus-675	54	9	incubator	incubator	NOUN
finefocus-675	54	10	and	and	CCONJ
finefocus-675	54	11	allowed	allow	VERB
finefocus-675	54	12	to	to	PART
finefocus-675	54	13	infect	infect	VERB
finefocus-675	54	14	for	for	ADP
finefocus-675	54	15	the	the	DET
finefocus-675	54	16	specified	specify	VERB
finefocus-675	54	17	time	time	NOUN
finefocus-675	54	18	.	.	PUNCT
finefocus-675	55	1	imatinib	imatinib	NOUN
finefocus-675	55	2	treatment	treatment	NOUN
finefocus-675	55	3	imatinib	imatinib	NOUN
finefocus-675	55	4	mesylate	mesylate	NOUN
finefocus-675	55	5	was	be	AUX
finefocus-675	55	6	purchased	purchase	VERB
finefocus-675	55	7	(	(	PUNCT
finefocus-675	55	8	sigma	sigma	PROPN
finefocus-675	55	9	)	)	PUNCT
finefocus-675	55	10	and	and	CCONJ
finefocus-675	55	11	resuspended	resuspend	VERB
finefocus-675	55	12	in	in	ADP
finefocus-675	55	13	h2o	h2o	NOUN
finefocus-675	55	14	to	to	PART
finefocus-675	55	15	make	make	VERB
finefocus-675	55	16	a	a	DET
finefocus-675	55	17	100	100	NUM
finefocus-675	55	18	mm	mm	NOUN
finefocus-675	55	19	stock	stock	NOUN
finefocus-675	55	20	.	.	PUNCT
finefocus-675	56	1	this	this	DET
finefocus-675	56	2	100	100	NUM
finefocus-675	56	3	mm	mm	NOUN
finefocus-675	56	4	stock	stock	NOUN
finefocus-675	56	5	was	be	AUX
finefocus-675	56	6	then	then	ADV
finefocus-675	56	7	serially	serially	ADV
finefocus-675	56	8	diluted	dilute	VERB
finefocus-675	56	9	with	with	ADP
finefocus-675	56	10	two	two	NUM
finefocus-675	56	11	-	-	PUNCT
finefocus-675	56	12	fold	fold	ADJ
finefocus-675	56	13	dilutions	dilution	NOUN
finefocus-675	56	14	to	to	PART
finefocus-675	56	15	acquire	acquire	VERB
finefocus-675	56	16	stock	stock	NOUN
finefocus-675	56	17	concentrations	concentration	NOUN
finefocus-675	56	18	at	at	ADP
finefocus-675	56	19	50	50	NUM
finefocus-675	56	20	mm	mm	NOUN
finefocus-675	56	21	,	,	PUNCT
finefocus-675	56	22	25	25	NUM
finefocus-675	56	23	mm	mm	NOUN
finefocus-675	56	24	,	,	PUNCT
finefocus-675	56	25	12.5	12.5	NUM
finefocus-675	56	26	mm	mm	NOUN
finefocus-675	56	27	,	,	PUNCT
finefocus-675	56	28	6.25	6.25	NUM
finefocus-675	56	29	mm	mm	NOUN
finefocus-675	56	30	,	,	PUNCT
finefocus-675	56	31	3.125	3.125	NUM
finefocus-675	56	32	mm	mm	NOUN
finefocus-675	56	33	,	,	PUNCT
finefocus-675	56	34	and	and	CCONJ
finefocus-675	56	35	1.56	1.56	NUM
finefocus-675	56	36	mm	mm	NOUN
finefocus-675	56	37	.	.	PUNCT
finefocus-675	57	1	to	to	PART
finefocus-675	57	2	treat	treat	VERB
finefocus-675	57	3	the	the	DET
finefocus-675	57	4	cells	cell	NOUN
finefocus-675	57	5	,	,	PUNCT
finefocus-675	57	6	the	the	DET
finefocus-675	57	7	mm	mm	PROPN
finefocus-675	57	8	stocks	stock	NOUN
finefocus-675	57	9	were	be	AUX
finefocus-675	57	10	diluted	dilute	VERB
finefocus-675	57	11	1:1000	1:1000	NUM
finefocus-675	57	12	in	in	ADP
finefocus-675	57	13	cell	cell	NOUN
finefocus-675	57	14	culture	culture	NOUN
finefocus-675	57	15	media	medium	NOUN
finefocus-675	57	16	to	to	PART
finefocus-675	57	17	provide	provide	VERB
finefocus-675	57	18	media	medium	NOUN
finefocus-675	57	19	with	with	ADP
finefocus-675	57	20	100μm	100μm	NOUN
finefocus-675	57	21	,	,	PUNCT
finefocus-675	57	22	50μm	50μm	NOUN
finefocus-675	57	23	,	,	PUNCT
finefocus-675	57	24	25μm	25μm	ADJ
finefocus-675	57	25	,	,	PUNCT
finefocus-675	57	26	12.5μm	12.5μm	NUM
finefocus-675	57	27	,	,	PUNCT
finefocus-675	57	28	6.25μm	6.25μm	NUM
finefocus-675	57	29	,	,	PUNCT
finefocus-675	57	30	3.125μm	3.125μm	NUM
finefocus-675	57	31	,	,	PUNCT
finefocus-675	57	32	and	and	CCONJ
finefocus-675	57	33	1.56μm	1.56μm	NUM
finefocus-675	57	34	concentrations	concentration	NOUN
finefocus-675	57	35	of	of	ADP
finefocus-675	57	36	imatinib	imatinib	NOUN
finefocus-675	57	37	in	in	ADP
finefocus-675	57	38	cell	cell	NOUN
finefocus-675	57	39	culture	culture	NOUN
finefocus-675	57	40	media	medium	NOUN
finefocus-675	57	41	that	that	PRON
finefocus-675	57	42	could	could	AUX
finefocus-675	57	43	be	be	AUX
finefocus-675	57	44	added	add	VERB
finefocus-675	57	45	directly	directly	ADV
finefocus-675	57	46	to	to	ADP
finefocus-675	57	47	infected	infected	ADJ
finefocus-675	57	48	cells	cell	NOUN
finefocus-675	57	49	.	.	PUNCT
finefocus-675	58	1	a	a	DET
finefocus-675	58	2	control	control	NOUN
finefocus-675	58	3	treatment	treatment	NOUN
finefocus-675	58	4	was	be	AUX
finefocus-675	58	5	prepared	prepare	VERB
finefocus-675	58	6	by	by	ADP
finefocus-675	58	7	diluting	dilute	VERB
finefocus-675	58	8	h2o	h2o	PROPN
finefocus-675	58	9	solvent	solvent	NOUN
finefocus-675	58	10	1:1000	1:1000	NUM
finefocus-675	58	11	in	in	ADP
finefocus-675	58	12	media	medium	NOUN
finefocus-675	58	13	following	follow	VERB
finefocus-675	58	14	the	the	DET
finefocus-675	58	15	protocol	protocol	NOUN
finefocus-675	58	16	as	as	ADP
finefocus-675	58	17	the	the	DET
finefocus-675	58	18	drug	drug	NOUN
finefocus-675	58	19	dilutions	dilution	NOUN
finefocus-675	58	20	.	.	PUNCT
finefocus-675	59	1	the	the	DET
finefocus-675	59	2	dilutions	dilution	NOUN
finefocus-675	59	3	of	of	ADP
finefocus-675	59	4	imatinib	imatinib	NOUN
finefocus-675	59	5	in	in	ADP
finefocus-675	59	6	cell	cell	NOUN
finefocus-675	59	7	culture	culture	NOUN
finefocus-675	59	8	media	medium	NOUN
finefocus-675	59	9	were	be	AUX
finefocus-675	59	10	always	always	ADV
finefocus-675	59	11	prepared	prepare	VERB
finefocus-675	59	12	fresh	fresh	ADJ
finefocus-675	59	13	for	for	ADP
finefocus-675	59	14	experiments	experiment	NOUN
finefocus-675	59	15	.	.	PUNCT
finefocus-675	60	1	for	for	ADP
finefocus-675	60	2	the	the	DET
finefocus-675	60	3	experiments	experiment	NOUN
finefocus-675	60	4	with	with	ADP
finefocus-675	60	5	different	different	ADJ
finefocus-675	60	6	times	time	NOUN
finefocus-675	60	7	of	of	ADP
finefocus-675	60	8	imatinib	imatinib	NOUN
finefocus-675	60	9	addition	addition	NOUN
finefocus-675	60	10	,	,	PUNCT
finefocus-675	60	11	the	the	DET
finefocus-675	60	12	media	medium	NOUN
finefocus-675	60	13	was	be	AUX
finefocus-675	60	14	removed	remove	VERB
finefocus-675	60	15	at	at	ADP
finefocus-675	60	16	the	the	DET
finefocus-675	60	17	specified	specified	ADJ
finefocus-675	60	18	time	time	NOUN
finefocus-675	60	19	and	and	CCONJ
finefocus-675	60	20	replaced	replace	VERB
finefocus-675	60	21	with	with	ADP
finefocus-675	60	22	fresh	fresh	ADJ
finefocus-675	60	23	dmem	dmem	NOUN
finefocus-675	60	24	containing	contain	VERB
finefocus-675	60	25	the	the	DET
finefocus-675	60	26	corresponding	corresponding	ADJ
finefocus-675	60	27	dilution	dilution	NOUN
finefocus-675	60	28	of	of	ADP
finefocus-675	60	29	imatinib	imatinib	NOUN
finefocus-675	60	30	or	or	CCONJ
finefocus-675	60	31	the	the	DET
finefocus-675	60	32	solvent	solvent	NOUN
finefocus-675	60	33	control	control	NOUN
finefocus-675	60	34	.	.	PUNCT
finefocus-675	61	1	cytotoxicity	cytotoxicity	NOUN
finefocus-675	61	2	of	of	ADP
finefocus-675	61	3	imatinib	imatinib	NOUN
finefocus-675	61	4	and	and	CCONJ
finefocus-675	61	5	plate	plate	NOUN
finefocus-675	61	6	reader	reader	NOUN
finefocus-675	61	7	cell	cell	NOUN
finefocus-675	61	8	viability	viability	NOUN
finefocus-675	61	9	was	be	AUX
finefocus-675	61	10	assessed	assess	VERB
finefocus-675	61	11	using	use	VERB
finefocus-675	61	12	the	the	DET
finefocus-675	61	13	alamarblue	alamarblue	ADJ
finefocus-675	61	14	cell	cell	NOUN
finefocus-675	61	15	viability	viability	NOUN
finefocus-675	61	16	assay	assay	VERB
finefocus-675	61	17	®	®	NOUN
finefocus-675	61	18	from	from	ADP
finefocus-675	61	19	thermofisher	thermofisher	PROPN
finefocus-675	61	20	according	accord	VERB
finefocus-675	61	21	to	to	ADP
finefocus-675	61	22	manufacturer	manufacturer	NOUN
finefocus-675	61	23	’s	’s	PART
finefocus-675	61	24	protocols	protocol	NOUN
finefocus-675	61	25	.	.	PUNCT
finefocus-675	62	1	briefly	briefly	ADV
finefocus-675	62	2	,	,	PUNCT
finefocus-675	62	3	imatinib	imatinib	NOUN
finefocus-675	62	4	treated	treat	VERB
finefocus-675	62	5	cells	cell	NOUN
finefocus-675	62	6	were	be	AUX
finefocus-675	62	7	stained	stain	VERB
finefocus-675	62	8	with	with	ADP
finefocus-675	62	9	a	a	DET
finefocus-675	62	10	concentration	concentration	NOUN
finefocus-675	62	11	of	of	ADP
finefocus-675	62	12	100μm	100μm	PROPN
finefocus-675	62	13	resazurin	resazurin	NOUN
finefocus-675	62	14	/	/	SYM
finefocus-675	62	15	alamarblue	alamarblue	NOUN
finefocus-675	62	16	and	and	CCONJ
finefocus-675	62	17	allowed	allow	VERB
finefocus-675	62	18	to	to	PART
finefocus-675	62	19	incubate	incubate	VERB
finefocus-675	62	20	for	for	ADP
finefocus-675	62	21	1	1	NUM
finefocus-675	62	22	hour	hour	NOUN
finefocus-675	62	23	at	at	ADP
finefocus-675	62	24	37ºc	37ºc	NOUN
finefocus-675	62	25	.	.	PUNCT
finefocus-675	63	1	following	follow	VERB
finefocus-675	63	2	the	the	DET
finefocus-675	63	3	one	one	NUM
finefocus-675	63	4	hour	hour	NOUN
finefocus-675	63	5	incubation	incubation	NOUN
finefocus-675	63	6	,	,	PUNCT
finefocus-675	63	7	the	the	DET
finefocus-675	63	8	plates	plate	NOUN
finefocus-675	63	9	were	be	AUX
finefocus-675	63	10	analyzed	analyze	VERB
finefocus-675	63	11	on	on	ADP
finefocus-675	63	12	an	an	DET
finefocus-675	63	13	enspire	enspire	NOUN
finefocus-675	63	14	multimode	multimode	NOUN
finefocus-675	63	15	plate	plate	NOUN
finefocus-675	63	16	reader	reader	NOUN
finefocus-675	63	17	®	®	NOUN
finefocus-675	63	18	from	from	ADP
finefocus-675	63	19	perkinelmer	perkinelmer	NOUN
finefocus-675	63	20	for	for	ADP
finefocus-675	63	21	fluorescence	fluorescence	NOUN
finefocus-675	63	22	at	at	ADP
finefocus-675	63	23	an	an	DET
finefocus-675	63	24	excitation	excitation	NOUN
finefocus-675	63	25	of	of	ADP
finefocus-675	63	26	540	540	NUM
finefocus-675	63	27	-	-	SYM
finefocus-675	63	28	570	570	NUM
finefocus-675	63	29	nm	nm	NOUN
finefocus-675	63	30	and	and	CCONJ
finefocus-675	63	31	an	an	DET
finefocus-675	63	32	emission	emission	NOUN
finefocus-675	63	33	of	of	ADP
finefocus-675	63	34	580	580	NUM
finefocus-675	63	35	-	-	SYM
finefocus-675	63	36	610	610	NUM
finefocus-675	63	37	nm	nm	NOUN
finefocus-675	63	38	to	to	PART
finefocus-675	63	39	measure	measure	VERB
finefocus-675	63	40	the	the	DET
finefocus-675	63	41	viable	viable	ADJ
finefocus-675	63	42	cells	cell	NOUN
finefocus-675	63	43	.	.	PUNCT
finefocus-675	64	1	the	the	DET
finefocus-675	64	2	mock	mock	ADJ
finefocus-675	64	3	/	/	SYM
finefocus-675	64	4	control	control	NOUN
finefocus-675	64	5	treated	treat	VERB
finefocus-675	64	6	cells	cell	NOUN
finefocus-675	64	7	were	be	AUX
finefocus-675	64	8	set	set	VERB
finefocus-675	64	9	to	to	ADP
finefocus-675	64	10	100	100	NUM
finefocus-675	64	11	%	%	NOUN
finefocus-675	64	12	and	and	CCONJ
finefocus-675	64	13	then	then	ADV
finefocus-675	64	14	the	the	DET
finefocus-675	64	15	viability	viability	NOUN
finefocus-675	64	16	readings	reading	VERB
finefocus-675	64	17	from	from	ADP
finefocus-675	64	18	the	the	DET
finefocus-675	64	19	treated	treat	VERB
finefocus-675	64	20	wells	well	NOUN
finefocus-675	64	21	were	be	AUX
finefocus-675	64	22	calculated	calculate	VERB
finefocus-675	64	23	as	as	ADP
finefocus-675	64	24	a	a	DET
finefocus-675	64	25	percentage	percentage	NOUN
finefocus-675	64	26	of	of	ADP
finefocus-675	64	27	the	the	DET
finefocus-675	64	28	control	control	NOUN
finefocus-675	64	29	.	.	PUNCT
finefocus-675	65	1	all	all	DET
finefocus-675	65	2	experiments	experiment	NOUN
finefocus-675	65	3	were	be	AUX
finefocus-675	65	4	performed	perform	VERB
finefocus-675	65	5	and	and	CCONJ
finefocus-675	65	6	analyzed	analyze	VERB
finefocus-675	65	7	multiple	multiple	ADJ
finefocus-675	65	8	times	time	NOUN
finefocus-675	65	9	in	in	ADP
finefocus-675	65	10	triplicate	triplicate	NOUN
finefocus-675	65	11	.	.	PUNCT
finefocus-675	66	1	quantifying	quantify	VERB
finefocus-675	66	2	virus	virus	NOUN
finefocus-675	66	3	replication	replication	NOUN
finefocus-675	66	4	and	and	CCONJ
finefocus-675	66	5	flow	flow	VERB
finefocus-675	66	6	cytometry	cytometry	NOUN
finefocus-675	66	7	virus	virus	NOUN
finefocus-675	66	8	replication	replication	NOUN
finefocus-675	66	9	was	be	AUX
finefocus-675	66	10	quantified	quantify	VERB
finefocus-675	66	11	based	base	VERB
finefocus-675	66	12	on	on	ADP
finefocus-675	66	13	the	the	DET
finefocus-675	66	14	gfp	gfp	PROPN
finefocus-675	66	15	reporter	reporter	NOUN
finefocus-675	66	16	inserted	insert	VERB
finefocus-675	66	17	into	into	ADP
finefocus-675	66	18	the	the	DET
finefocus-675	66	19	viral	viral	ADJ
finefocus-675	66	20	genome	genome	NOUN
finefocus-675	66	21	.	.	PUNCT
finefocus-675	67	1	gfp	gfp	PROPN
finefocus-675	67	2	was	be	AUX
finefocus-675	67	3	measured	measure	VERB
finefocus-675	67	4	in	in	ADP
finefocus-675	67	5	infected	infect	VERB
finefocus-675	67	6	/	/	SYM
finefocus-675	67	7	treated	treat	VERB
finefocus-675	67	8	cells	cell	NOUN
finefocus-675	67	9	using	use	VERB
finefocus-675	67	10	the	the	DET
finefocus-675	67	11	plate	plate	NOUN
finefocus-675	67	12	reader	reader	NOUN
finefocus-675	67	13	(	(	PUNCT
finefocus-675	67	14	see	see	VERB
finefocus-675	67	15	above	above	ADV
finefocus-675	67	16	)	)	PUNCT
finefocus-675	67	17	and	and	CCONJ
finefocus-675	67	18	an	an	DET
finefocus-675	67	19	excitation	excitation	NOUN
finefocus-675	67	20	of	of	ADP
finefocus-675	67	21	488	488	NUM
finefocus-675	67	22	nm	nm	NOUN
finefocus-675	67	23	and	and	CCONJ
finefocus-675	67	24	an	an	DET
finefocus-675	67	25	emission	emission	NOUN
finefocus-675	67	26	filter	filter	NOUN
finefocus-675	67	27	of	of	ADP
finefocus-675	67	28	509	509	NUM
finefocus-675	67	29	nm	nm	NOUN
finefocus-675	67	30	.	.	PUNCT
finefocus-675	68	1	additionally	additionally	ADV
finefocus-675	68	2	,	,	PUNCT
finefocus-675	68	3	cells	cell	NOUN
finefocus-675	68	4	were	be	AUX
finefocus-675	68	5	trypsinized	trypsinize	VERB
finefocus-675	68	6	,	,	PUNCT
finefocus-675	68	7	resuspended	resuspend	VERB
finefocus-675	68	8	,	,	PUNCT
finefocus-675	68	9	and	and	CCONJ
finefocus-675	68	10	run	run	VERB
finefocus-675	68	11	over	over	ADP
finefocus-675	68	12	a	a	DET
finefocus-675	68	13	guava	guava	NOUN
finefocus-675	68	14	easycyte	easycyte	NOUN
finefocus-675	68	15	®	®	NOUN
finefocus-675	68	16	flow	flow	NOUN
finefocus-675	68	17	cytometer	cytometer	NOUN
finefocus-675	68	18	from	from	ADP
finefocus-675	68	19	millipore	millipore	PROPN
finefocus-675	68	20	to	to	PART
finefocus-675	68	21	assess	assess	VERB
finefocus-675	68	22	the	the	DET
finefocus-675	68	23	percent	percent	NOUN
finefocus-675	68	24	of	of	ADP
finefocus-675	68	25	cells	cell	NOUN
finefocus-675	68	26	infected	infect	VERB
finefocus-675	68	27	(	(	PUNCT
finefocus-675	68	28	expressing	express	VERB
finefocus-675	68	29	gfp	gfp	PROPN
finefocus-675	68	30	)	)	PUNCT
finefocus-675	68	31	and	and	CCONJ
finefocus-675	68	32	the	the	DET
finefocus-675	68	33	relative	relative	ADJ
finefocus-675	68	34	levels	level	NOUN
finefocus-675	68	35	of	of	ADP
finefocus-675	68	36	gfp	gfp	PROPN
finefocus-675	68	37	fluorescence	fluorescence	NOUN
finefocus-675	68	38	per	per	ADP
finefocus-675	68	39	cell	cell	NOUN
finefocus-675	68	40	.	.	PUNCT
finefocus-675	69	1	5,000	5,000	NUM
finefocus-675	69	2	cells	cell	NOUN
finefocus-675	69	3	were	be	AUX
finefocus-675	69	4	analyzed	analyze	VERB
finefocus-675	69	5	for	for	ADP
finefocus-675	69	6	each	each	DET
finefocus-675	69	7	sample	sample	NOUN
finefocus-675	69	8	and	and	CCONJ
finefocus-675	69	9	each	each	DET
finefocus-675	69	10	condition	condition	NOUN
finefocus-675	69	11	was	be	AUX
finefocus-675	69	12	run	run	VERB
finefocus-675	69	13	in	in	ADP
finefocus-675	69	14	triplicate	triplicate	NOUN
finefocus-675	69	15	.	.	PUNCT
finefocus-675	70	1	the	the	DET
finefocus-675	70	2	same	same	ADJ
finefocus-675	70	3	parameters	parameter	NOUN
finefocus-675	70	4	,	,	PUNCT
finefocus-675	70	5	regions	region	NOUN
finefocus-675	70	6	,	,	PUNCT
finefocus-675	70	7	thresholds	threshold	NOUN
finefocus-675	70	8	,	,	PUNCT
finefocus-675	70	9	and	and	CCONJ
finefocus-675	70	10	gating	gating	NOUN
finefocus-675	70	11	was	be	AUX
finefocus-675	70	12	used	use	VERB
finefocus-675	70	13	for	for	ADP
finefocus-675	70	14	all	all	DET
finefocus-675	70	15	analysis	analysis	NOUN
finefocus-675	70	16	to	to	PART
finefocus-675	70	17	successfully	successfully	ADV
finefocus-675	70	18	measure	measure	VERB
finefocus-675	70	19	gfp	gfp	PROPN
finefocus-675	70	20	positive	positive	ADJ
finefocus-675	70	21	cells	cell	NOUN
finefocus-675	70	22	.	.	PUNCT
finefocus-675	71	1	statistical	statistical	ADJ
finefocus-675	71	2	analysis	analysis	NOUN
finefocus-675	71	3	all	all	DET
finefocus-675	71	4	data	datum	NOUN
finefocus-675	71	5	graphs	graph	NOUN
finefocus-675	71	6	were	be	AUX
finefocus-675	71	7	generated	generate	VERB
finefocus-675	71	8	with	with	ADP
finefocus-675	71	9	microsoft	microsoft	PROPN
finefocus-675	71	10	excel	excel	PROPN
finefocus-675	71	11	.	.	PUNCT
finefocus-675	72	1	data	datum	NOUN
finefocus-675	72	2	and	and	CCONJ
finefocus-675	72	3	statistical	statistical	ADJ
finefocus-675	72	4	analysis	analysis	NOUN
finefocus-675	72	5	was	be	AUX
finefocus-675	72	6	performed	perform	VERB
finefocus-675	72	7	using	use	VERB
finefocus-675	72	8	r	r	NOUN
finefocus-675	72	9	software	software	NOUN
finefocus-675	72	10	.	.	PUNCT
finefocus-675	73	1	student	student	NOUN
finefocus-675	73	2	’s	’s	PART
finefocus-675	73	3	t	t	PROPN
finefocus-675	73	4	-	-	PUNCT
finefocus-675	73	5	tests	test	NOUN
finefocus-675	73	6	were	be	AUX
finefocus-675	73	7	performed	perform	VERB
finefocus-675	73	8	and	and	CCONJ
finefocus-675	73	9	a	a	DET
finefocus-675	73	10	p	p	NOUN
finefocus-675	73	11	-	-	PUNCT
finefocus-675	73	12	value	value	NOUN
finefocus-675	73	13	<	<	NOUN
finefocus-675	73	14	0.05	0.05	NUM
finefocus-675	73	15	indicated	indicate	VERB
finefocus-675	73	16	statistically	statistically	ADV
finefocus-675	73	17	significant	significant	ADJ
finefocus-675	73	18	differences	difference	NOUN
finefocus-675	73	19	.	.	PUNCT
finefocus-675	74	1	error	error	NOUN
finefocus-675	74	2	bars	bar	NOUN
finefocus-675	74	3	indicate	indicate	VERB
finefocus-675	74	4	the	the	DET
finefocus-675	74	5	standard	standard	ADJ
finefocus-675	74	6	error	error	NOUN
finefocus-675	74	7	of	of	ADP
finefocus-675	74	8	the	the	DET
finefocus-675	74	9	mean	mean	NOUN
finefocus-675	74	10	unless	unless	SCONJ
finefocus-675	74	11	noted	note	VERB
finefocus-675	74	12	otherwise	otherwise	ADV
finefocus-675	74	13	.	.	PUNCT
finefocus-675	75	1	quantifying	quantify	VERB
finefocus-675	75	2	virus	virus	NOUN
finefocus-675	75	3	replication	replication	NOUN
finefocus-675	75	4	and	and	CCONJ
finefocus-675	75	5	flow	flow	NOUN
finefocus-675	75	6	cytometry	cytometry	ADJ
finefocus-675	75	7	baby	baby	NOUN
finefocus-675	75	8	hamster	hamster	PROPN
finefocus-675	75	9	kidney	kidney	PROPN
finefocus-675	75	10	(	(	PUNCT
finefocus-675	75	11	bhk	bhk	PROPN
finefocus-675	75	12	)	)	PUNCT
finefocus-675	75	13	cells	cell	NOUN
finefocus-675	75	14	were	be	AUX
finefocus-675	75	15	infected	infect	VERB
finefocus-675	75	16	with	with	ADP
finefocus-675	75	17	a	a	DET
finefocus-675	75	18	double	double	ADJ
finefocus-675	75	19	subgenomic	subgenomic	PROPN
finefocus-675	75	20	sindbis	sindbis	PROPN
finefocus-675	75	21	virus	virus	PROPN
finefocus-675	75	22	(	(	PUNCT
finefocus-675	75	23	sinv	sinv	NOUN
finefocus-675	75	24	)	)	PUNCT
finefocus-675	75	25	containing	contain	VERB
finefocus-675	75	26	a	a	DET
finefocus-675	75	27	fluorescent	fluorescent	ADJ
finefocus-675	75	28	reporter	reporter	NOUN
finefocus-675	75	29	(	(	PUNCT
finefocus-675	75	30	gfp	gfp	PROPN
finefocus-675	75	31	)	)	PUNCT
finefocus-675	75	32	protein	protein	NOUN
finefocus-675	75	33	inserted	insert	VERB
finefocus-675	75	34	in	in	ADP
finefocus-675	75	35	the	the	DET
finefocus-675	75	36	viral	viral	ADJ
finefocus-675	75	37	genome(21	genome(21	NOUN
finefocus-675	75	38	)	)	PUNCT
finefocus-675	75	39	.	.	PUNCT
finefocus-675	76	1	virus	virus	NOUN
finefocus-675	76	2	was	be	AUX
finefocus-675	76	3	added	add	VERB
finefocus-675	76	4	to	to	ADP
finefocus-675	76	5	the	the	DET
finefocus-675	76	6	cells	cell	NOUN
finefocus-675	76	7	to	to	PART
finefocus-675	76	8	achieve	achieve	VERB
finefocus-675	76	9	a	a	DET
finefocus-675	76	10	multiplicity	multiplicity	NOUN
finefocus-675	76	11	of	of	ADP
finefocus-675	76	12	infection	infection	NOUN
finefocus-675	76	13	(	(	PUNCT
finefocus-675	76	14	moi	moi	X
finefocus-675	76	15	)	)	PUNCT
finefocus-675	76	16	of	of	ADP
finefocus-675	76	17	one	one	NUM
finefocus-675	76	18	and	and	CCONJ
finefocus-675	76	19	after	after	ADP
finefocus-675	76	20	one	one	NUM
finefocus-675	76	21	hour	hour	NOUN
finefocus-675	76	22	of	of	ADP
finefocus-675	76	23	infection	infection	NOUN
finefocus-675	76	24	,	,	PUNCT
finefocus-675	76	25	imatinib	imatinib	NOUN
finefocus-675	76	26	was	be	AUX
finefocus-675	76	27	added	add	VERB
finefocus-675	76	28	to	to	PART
finefocus-675	76	29	specified	specified	VERB
finefocus-675	76	30	wells	well	NOUN
finefocus-675	76	31	at	at	ADP
finefocus-675	76	32	various	various	ADJ
finefocus-675	76	33	low	low	ADJ
finefocus-675	76	34	concentrations	concentration	NOUN
finefocus-675	76	35	of	of	ADP
finefocus-675	76	36	imatinib	imatinib	NOUN
finefocus-675	76	37	(	(	PUNCT
finefocus-675	76	38	0	0	NUM
finefocus-675	76	39	-	-	PUNCT
finefocus-675	76	40	100μm	100μm	NOUN
finefocus-675	76	41	)	)	PUNCT
finefocus-675	76	42	.	.	PUNCT
finefocus-675	77	1	after	after	ADP
finefocus-675	77	2	24	24	NUM
finefocus-675	77	3	hours	hour	NOUN
finefocus-675	77	4	of	of	ADP
finefocus-675	77	5	infection	infection	NOUN
finefocus-675	77	6	,	,	PUNCT
finefocus-675	77	7	the	the	DET
finefocus-675	77	8	cells	cell	NOUN
finefocus-675	77	9	were	be	AUX
finefocus-675	77	10	analyzed	analyze	VERB
finefocus-675	77	11	for	for	ADP
finefocus-675	77	12	gfp	gfp	PROPN
finefocus-675	77	13	fluorescence	fluorescence	NOUN
finefocus-675	77	14	as	as	ADP
finefocus-675	77	15	an	an	DET
finefocus-675	77	16	indicator	indicator	NOUN
finefocus-675	77	17	for	for	ADP
finefocus-675	77	18	sinv	sinv	NOUN
finefocus-675	77	19	replication	replication	NOUN
finefocus-675	77	20	either	either	CCONJ
finefocus-675	77	21	with	with	ADP
finefocus-675	77	22	a	a	DET
finefocus-675	77	23	plate	plate	NOUN
finefocus-675	77	24	reader	reader	NOUN
finefocus-675	77	25	or	or	CCONJ
finefocus-675	77	26	with	with	ADP
finefocus-675	77	27	the	the	DET
finefocus-675	77	28	flow	flow	NOUN
finefocus-675	77	29	cytometer	cytometer	NOUN
finefocus-675	77	30	.	.	PUNCT
finefocus-675	78	1	data	datum	NOUN
finefocus-675	78	2	from	from	ADP
finefocus-675	78	3	the	the	DET
finefocus-675	78	4	flow	flow	NOUN
finefocus-675	78	5	cytometer	cytometer	NOUN
finefocus-675	78	6	accurately	accurately	ADV
finefocus-675	78	7	matched	match	VERB
finefocus-675	78	8	the	the	DET
finefocus-675	78	9	data	datum	NOUN
finefocus-675	78	10	from	from	ADP
finefocus-675	78	11	the	the	DET
finefocus-675	78	12	plate	plate	NOUN
finefocus-675	78	13	reader	reader	NOUN
finefocus-675	78	14	,	,	PUNCT
finefocus-675	78	15	but	but	CCONJ
finefocus-675	78	16	the	the	DET
finefocus-675	78	17	flow	flow	NOUN
finefocus-675	78	18	cytometer	cytometer	NOUN
finefocus-675	78	19	allowed	allow	VERB
finefocus-675	78	20	more	more	ADJ
finefocus-675	78	21	specifics	specific	NOUN
finefocus-675	78	22	to	to	PART
finefocus-675	78	23	be	be	AUX
finefocus-675	78	24	analyzed	analyze	VERB
finefocus-675	78	25	(	(	PUNCT
finefocus-675	78	26	fluorescence	fluorescence	NOUN
finefocus-675	78	27	per	per	ADP
finefocus-675	78	28	cell	cell	NOUN
finefocus-675	78	29	and	and	CCONJ
finefocus-675	78	30	percent	percent	NOUN
finefocus-675	78	31	infected	infect	VERB
finefocus-675	78	32	)	)	PUNCT
finefocus-675	78	33	.	.	PUNCT
finefocus-675	79	1	treatment	treatment	NOUN
finefocus-675	79	2	of	of	ADP
finefocus-675	79	3	sinv	sinv	NOUN
finefocus-675	79	4	-	-	PUNCT
finefocus-675	79	5	infected	infect	VERB
finefocus-675	79	6	bhk	bhk	PROPN
finefocus-675	79	7	cells	cell	NOUN
finefocus-675	79	8	with	with	ADP
finefocus-675	79	9	imatinib	imatinib	NOUN
finefocus-675	79	10	showed	show	VERB
finefocus-675	79	11	a	a	DET
finefocus-675	79	12	dose	dose	NOUN
finefocus-675	79	13	-	-	PUNCT
finefocus-675	79	14	dependent	dependent	ADJ
finefocus-675	79	15	decrease	decrease	NOUN
finefocus-675	79	16	in	in	ADP
finefocus-675	79	17	viral	viral	ADJ
finefocus-675	79	18	replication	replication	NOUN
finefocus-675	79	19	(	(	PUNCT
finefocus-675	79	20	figure	figure	NOUN
finefocus-675	79	21	1	1	NUM
finefocus-675	79	22	)	)	PUNCT
finefocus-675	79	23	.	.	PUNCT
finefocus-675	80	1	cytotoxicity	cytotoxicity	NOUN
finefocus-675	80	2	of	of	ADP
finefocus-675	80	3	the	the	DET
finefocus-675	80	4	imatinib	imatinib	NOUN
finefocus-675	80	5	concentrations	concentration	NOUN
finefocus-675	80	6	was	be	AUX
finefocus-675	80	7	also	also	ADV
finefocus-675	80	8	measured	measure	VERB
finefocus-675	80	9	on	on	ADP
finefocus-675	80	10	the	the	DET
finefocus-675	80	11	bhk	bhk	PROPN
finefocus-675	80	12	cells	cell	NOUN
finefocus-675	80	13	using	use	VERB
finefocus-675	80	14	alamarblue	alamarblue	ADJ
finefocus-675	80	15	cell	cell	NOUN
finefocus-675	80	16	viability	viability	NOUN
finefocus-675	80	17	assay	assay	VERB
finefocus-675	80	18	.	.	PUNCT
finefocus-675	81	1	imatinib	imatinib	NOUN
finefocus-675	81	2	started	start	VERB
finefocus-675	81	3	reducing	reduce	VERB
finefocus-675	81	4	cell	cell	NOUN
finefocus-675	81	5	viability	viability	NOUN
finefocus-675	81	6	at	at	ADP
finefocus-675	81	7	concentrations	concentration	NOUN
finefocus-675	81	8	above	above	ADP
finefocus-675	81	9	12μm	12μm	NOUN
finefocus-675	81	10	,	,	PUNCT
finefocus-675	81	11	with	with	ADP
finefocus-675	81	12	a	a	DET
finefocus-675	81	13	dosedependent	dosedependent	NOUN
finefocus-675	81	14	curve	curve	NOUN
finefocus-675	81	15	of	of	ADP
finefocus-675	81	16	cytotoxicity	cytotoxicity	NOUN
finefocus-675	81	17	at	at	ADP
finefocus-675	81	18	higher	high	ADJ
finefocus-675	81	19	concentrations	concentration	NOUN
finefocus-675	81	20	of	of	ADP
finefocus-675	81	21	imatinib	imatinib	NOUN
finefocus-675	81	22	.	.	PUNCT
finefocus-675	82	1	treatment	treatment	NOUN
finefocus-675	82	2	with	with	ADP
finefocus-675	82	3	concentrations	concentration	NOUN
finefocus-675	82	4	less	less	ADJ
finefocus-675	82	5	than	than	ADP
finefocus-675	82	6	12μm	12μm	NOUN
finefocus-675	82	7	resulted	result	VERB
finefocus-675	82	8	in	in	ADP
finefocus-675	82	9	greater	great	ADJ
finefocus-675	82	10	than	than	ADP
finefocus-675	82	11	80	80	NUM
finefocus-675	82	12	%	%	NOUN
finefocus-675	82	13	cell	cell	NOUN
finefocus-675	82	14	viability	viability	NOUN
finefocus-675	82	15	.	.	PUNCT
finefocus-675	83	1	however	however	ADV
finefocus-675	83	2	,	,	PUNCT
finefocus-675	83	3	at	at	ADP
finefocus-675	83	4	6μm	6μm	ADJ
finefocus-675	83	5	imatinib	imatinib	NOUN
finefocus-675	83	6	treatment	treatment	NOUN
finefocus-675	83	7	,	,	PUNCT
finefocus-675	83	8	viral	viral	ADJ
finefocus-675	83	9	replication	replication	NOUN
finefocus-675	83	10	was	be	AUX
finefocus-675	83	11	significantly	significantly	ADV
finefocus-675	83	12	reduced	reduce	VERB
finefocus-675	83	13	by	by	ADP
finefocus-675	83	14	more	more	ADJ
finefocus-675	83	15	than	than	ADP
finefocus-675	83	16	50	50	NUM
finefocus-675	83	17	%	%	NOUN
finefocus-675	83	18	.	.	PUNCT
finefocus-675	84	1	the	the	DET
finefocus-675	84	2	ic50	ic50	PROPN
finefocus-675	84	3	and	and	CCONJ
finefocus-675	84	4	cc50	cc50	PROPN
finefocus-675	84	5	were	be	AUX
finefocus-675	84	6	calculated	calculate	VERB
finefocus-675	84	7	to	to	PART
finefocus-675	84	8	be	be	AUX
finefocus-675	84	9	4.8μm	4.8μm	PROPN
finefocus-675	84	10	and	and	CCONJ
finefocus-675	84	11	28.1μm	28.1μm	NUM
finefocus-675	84	12	,	,	PUNCT
finefocus-675	84	13	respectively	respectively	ADV
finefocus-675	84	14	,	,	PUNCT
finefocus-675	84	15	giving	give	VERB
finefocus-675	84	16	a	a	DET
finefocus-675	84	17	therapeutic	therapeutic	ADJ
finefocus-675	84	18	index	index	NOUN
finefocus-675	84	19	of	of	ADP
finefocus-675	84	20	5.85	5.85	NUM
finefocus-675	84	21	for	for	ADP
finefocus-675	84	22	using	use	VERB
finefocus-675	84	23	imatinib	imatinib	NOUN
finefocus-675	84	24	as	as	ADP
finefocus-675	84	25	an	an	DET
finefocus-675	84	26	antiviral	antiviral	NOUN
finefocus-675	84	27	for	for	ADP
finefocus-675	84	28	alphaviruses	alphavirus	NOUN
finefocus-675	84	29	.	.	PUNCT
finefocus-675	85	1	ribavirin	ribavirin	NOUN
finefocus-675	85	2	,	,	PUNCT
finefocus-675	85	3	which	which	PRON
finefocus-675	85	4	is	be	AUX
finefocus-675	85	5	a	a	DET
finefocus-675	85	6	wellestablished	wellestablished	ADJ
finefocus-675	85	7	antiviral	antiviral	ADJ
finefocus-675	85	8	therapy	therapy	NOUN
finefocus-675	85	9	that	that	PRON
finefocus-675	85	10	is	be	AUX
finefocus-675	85	11	used	use	VERB
finefocus-675	85	12	in	in	ADP
finefocus-675	85	13	severe	severe	ADJ
finefocus-675	85	14	viral	viral	ADJ
finefocus-675	85	15	infections	infection	NOUN
finefocus-675	85	16	,	,	PUNCT
finefocus-675	85	17	has	have	VERB
finefocus-675	85	18	a	a	DET
finefocus-675	85	19	therapeutic	therapeutic	ADJ
finefocus-675	85	20	index	index	NOUN
finefocus-675	85	21	of	of	ADP
finefocus-675	85	22	around	around	ADV
finefocus-675	85	23	5	5	NUM
finefocus-675	85	24	-	-	SYM
finefocus-675	85	25	8	8	NUM
finefocus-675	85	26	for	for	ADP
finefocus-675	85	27	sindbis	sindbis	PROPN
finefocus-675	85	28	virus	virus	NOUN
finefocus-675	85	29	,	,	PUNCT
finefocus-675	85	30	indicating	indicate	VERB
finefocus-675	85	31	that	that	SCONJ
finefocus-675	85	32	imatinib	imatinib	NOUN
finefocus-675	85	33	treatment	treatment	NOUN
finefocus-675	85	34	is	be	AUX
finefocus-675	85	35	equally	equally	ADV
finefocus-675	85	36	effective	effective	ADJ
finefocus-675	85	37	at	at	ADP
finefocus-675	85	38	treating	treat	VERB
finefocus-675	85	39	alphavirus	alphavirus	NOUN
finefocus-675	85	40	infection(13	infection(13	NOUN
finefocus-675	85	41	,	,	PUNCT
finefocus-675	85	42	20	20	NUM
finefocus-675	85	43	,	,	PUNCT
finefocus-675	85	44	24	24	NUM
finefocus-675	85	45	)	)	PUNCT
finefocus-675	85	46	.	.	PUNCT
finefocus-675	86	1	imatinib	imatinib	NOUN
finefocus-675	86	2	’s	’s	PART
finefocus-675	86	3	effect	effect	NOUN
finefocus-675	86	4	over	over	ADP
finefocus-675	86	5	time	time	NOUN
finefocus-675	86	6	and	and	CCONJ
finefocus-675	86	7	different	different	ADJ
finefocus-675	86	8	levels	level	NOUN
finefocus-675	86	9	of	of	ADP
finefocus-675	86	10	sinv	sinv	ADJ
finefocus-675	86	11	infection	infection	NOUN
finefocus-675	86	12	imatinib	imatinib	NOUN
finefocus-675	86	13	’s	’s	PART
finefocus-675	86	14	effects	effect	NOUN
finefocus-675	86	15	on	on	ADP
finefocus-675	86	16	sinv	sinv	NOUN
finefocus-675	86	17	virus	virus	NOUN
finefocus-675	86	18	replication	replication	NOUN
finefocus-675	86	19	over	over	ADP
finefocus-675	86	20	time	time	NOUN
finefocus-675	86	21	was	be	AUX
finefocus-675	86	22	investigated	investigate	VERB
finefocus-675	86	23	next	next	ADV
finefocus-675	86	24	.	.	PUNCT
finefocus-675	87	1	cells	cell	NOUN
finefocus-675	87	2	were	be	AUX
finefocus-675	87	3	infected	infect	VERB
finefocus-675	87	4	with	with	ADP
finefocus-675	87	5	dssinv	dssinv	ADJ
finefocus-675	87	6	-	-	PUNCT
finefocus-675	87	7	gfp	gfp	NOUN
finefocus-675	87	8	at	at	ADP
finefocus-675	87	9	an	an	DET
finefocus-675	87	10	moi=1	moi=1	NOUN
finefocus-675	87	11	and	and	CCONJ
finefocus-675	87	12	then	then	ADV
finefocus-675	87	13	half	half	NOUN
finefocus-675	87	14	of	of	ADP
finefocus-675	87	15	the	the	DET
finefocus-675	87	16	cells	cell	NOUN
finefocus-675	87	17	were	be	AUX
finefocus-675	87	18	left	leave	VERB
finefocus-675	87	19	untreated	untreated	ADJ
finefocus-675	87	20	and	and	CCONJ
finefocus-675	87	21	half	half	NOUN
finefocus-675	87	22	of	of	ADP
finefocus-675	87	23	the	the	DET
finefocus-675	87	24	cells	cell	NOUN
finefocus-675	87	25	were	be	AUX
finefocus-675	87	26	treated	treat	VERB
finefocus-675	87	27	with	with	ADP
finefocus-675	87	28	10μm	10μm	ADJ
finefocus-675	87	29	imatinib	imatinib	NOUN
finefocus-675	87	30	.	.	PUNCT
finefocus-675	88	1	cells	cell	NOUN
finefocus-675	88	2	were	be	AUX
finefocus-675	88	3	analyzed	analyze	VERB
finefocus-675	88	4	every	every	DET
finefocus-675	88	5	6	6	NUM
finefocus-675	88	6	hours	hour	NOUN
finefocus-675	88	7	for	for	ADP
finefocus-675	88	8	a	a	DET
finefocus-675	88	9	24	24	NUM
finefocus-675	88	10	hour	hour	NOUN
finefocus-675	88	11	period	period	NOUN
finefocus-675	88	12	to	to	PART
finefocus-675	88	13	detect	detect	VERB
finefocus-675	88	14	gfp	gfp	PROPN
finefocus-675	88	15	fluorescence	fluorescence	NOUN
finefocus-675	88	16	results	result	VERB
finefocus-675	88	17	144	144	NUM
finefocus-675	88	18	•	•	NUM
finefocus-675	88	19	fine	fine	ADJ
finefocus-675	88	20	focus	focus	NOUN
finefocus-675	88	21	,	,	PUNCT
finefocus-675	88	22	vol	vol	NOUN
finefocus-675	88	23	.	.	NOUN
finefocus-675	88	24	3	3	NUM
finefocus-675	88	25	(	(	PUNCT
finefocus-675	88	26	2	2	NUM
finefocus-675	88	27	)	)	PUNCT
finefocus-675	88	28	discussion	discussion	NOUN
finefocus-675	88	29	imatinib	imatinib	NOUN
finefocus-675	88	30	mesylate	mesylate	VERB
finefocus-675	88	31	•	•	NUM
finefocus-675	88	32	147	147	NUM
finefocus-675	88	33	figure	figure	NOUN
finefocus-675	88	34	1	1	NUM
finefocus-675	88	35	:	:	PUNCT
finefocus-675	88	36	imatinib	imatinib	NOUN
finefocus-675	88	37	inhibition	inhibition	NOUN
finefocus-675	88	38	of	of	ADP
finefocus-675	88	39	sindbis	sindbis	PROPN
finefocus-675	88	40	virus	virus	NOUN
finefocus-675	88	41	and	and	CCONJ
finefocus-675	88	42	cell	cell	NOUN
finefocus-675	88	43	viability	viability	NOUN
finefocus-675	88	44	flow	flow	NOUN
finefocus-675	88	45	cytometry	cytometry	NOUN
finefocus-675	88	46	analysis	analysis	NOUN
finefocus-675	88	47	of	of	ADP
finefocus-675	88	48	bhk	bhk	PROPN
finefocus-675	88	49	cells	cell	NOUN
finefocus-675	88	50	infected	infect	VERB
finefocus-675	88	51	with	with	ADP
finefocus-675	88	52	dssinv	dssinv	ADJ
finefocus-675	88	53	-	-	PUNCT
finefocus-675	88	54	gfp	gfp	NOUN
finefocus-675	88	55	at	at	ADP
finefocus-675	88	56	an	an	DET
finefocus-675	88	57	moi=1	moi=1	NOUN
finefocus-675	88	58	and	and	CCONJ
finefocus-675	88	59	treated	treat	VERB
finefocus-675	88	60	with	with	ADP
finefocus-675	88	61	dilutions	dilution	NOUN
finefocus-675	88	62	of	of	ADP
finefocus-675	88	63	imatinib	imatinib	NOUN
finefocus-675	88	64	sinv	sinv	NOUN
finefocus-675	88	65	replication	replication	NOUN
finefocus-675	88	66	(	(	PUNCT
finefocus-675	88	67	gray	gray	ADJ
finefocus-675	88	68	bars	bar	NOUN
finefocus-675	88	69	)	)	PUNCT
finefocus-675	88	70	and	and	CCONJ
finefocus-675	88	71	cell	cell	NOUN
finefocus-675	88	72	viability	viability	NOUN
finefocus-675	88	73	(	(	PUNCT
finefocus-675	88	74	black	black	ADJ
finefocus-675	88	75	line	line	NOUN
finefocus-675	88	76	)	)	PUNCT
finefocus-675	88	77	are	be	AUX
finefocus-675	88	78	shown	show	VERB
finefocus-675	88	79	with	with	ADP
finefocus-675	88	80	increasing	increase	VERB
finefocus-675	88	81	concentrations	concentration	NOUN
finefocus-675	88	82	of	of	ADP
finefocus-675	88	83	imatinib	imatinib	NOUN
finefocus-675	88	84	.	.	PUNCT
finefocus-675	89	1	both	both	CCONJ
finefocus-675	89	2	the	the	DET
finefocus-675	89	3	mock	mock	ADJ
finefocus-675	89	4	/	/	SYM
finefocus-675	89	5	untreated	untreated	ADJ
finefocus-675	89	6	samples	sample	NOUN
finefocus-675	89	7	were	be	AUX
finefocus-675	89	8	set	set	VERB
finefocus-675	89	9	to	to	ADP
finefocus-675	89	10	100	100	NUM
finefocus-675	89	11	%	%	NOUN
finefocus-675	89	12	and	and	CCONJ
finefocus-675	89	13	the	the	DET
finefocus-675	89	14	different	different	ADJ
finefocus-675	89	15	treatment	treatment	NOUN
finefocus-675	89	16	conditions	condition	NOUN
finefocus-675	89	17	were	be	AUX
finefocus-675	89	18	calculated	calculate	VERB
finefocus-675	89	19	as	as	ADP
finefocus-675	89	20	a	a	DET
finefocus-675	89	21	percentage	percentage	NOUN
finefocus-675	89	22	of	of	ADP
finefocus-675	89	23	the	the	DET
finefocus-675	89	24	mock	mock	NOUN
finefocus-675	89	25	.	.	PUNCT
finefocus-675	90	1	sinv	sinv	PROPN
finefocus-675	90	2	was	be	AUX
finefocus-675	90	3	significantly	significantly	ADV
finefocus-675	90	4	inhibited	inhibit	VERB
finefocus-675	90	5	at	at	ADP
finefocus-675	90	6	6	6	NUM
finefocus-675	90	7	μm	μm	NOUN
finefocus-675	90	8	of	of	ADP
finefocus-675	90	9	imatinib	imatinib	NOUN
finefocus-675	90	10	compared	compare	VERB
finefocus-675	90	11	to	to	PART
finefocus-675	90	12	mock	mock	ADV
finefocus-675	90	13	treated	treat	VERB
finefocus-675	90	14	(	(	PUNCT
finefocus-675	90	15	p<0.05	p<0.05	PROPN
finefocus-675	90	16	)	)	PUNCT
finefocus-675	90	17	.	.	PUNCT
finefocus-675	91	1	error	error	NOUN
finefocus-675	91	2	bars	bar	NOUN
finefocus-675	91	3	represent	represent	VERB
finefocus-675	91	4	standard	standard	ADJ
finefocus-675	91	5	deviation	deviation	NOUN
finefocus-675	91	6	n=3	n=3	NOUN
finefocus-675	91	7	.	.	PUNCT
finefocus-675	92	1	and	and	CCONJ
finefocus-675	92	2	calculate	calculate	VERB
finefocus-675	92	3	the	the	DET
finefocus-675	92	4	percentage	percentage	NOUN
finefocus-675	92	5	of	of	ADP
finefocus-675	92	6	cells	cell	NOUN
finefocus-675	92	7	infected	infect	VERB
finefocus-675	92	8	using	use	VERB
finefocus-675	92	9	flow	flow	NOUN
finefocus-675	92	10	cytometry	cytometry	NOUN
finefocus-675	92	11	.	.	PUNCT
finefocus-675	93	1	significant	significant	ADJ
finefocus-675	93	2	inhibition	inhibition	NOUN
finefocus-675	93	3	of	of	ADP
finefocus-675	93	4	virus	virus	NOUN
finefocus-675	93	5	replication	replication	NOUN
finefocus-675	93	6	(	(	PUNCT
finefocus-675	93	7	student	student	NOUN
finefocus-675	93	8	’s	’s	PART
finefocus-675	93	9	t	t	PROPN
finefocus-675	93	10	-	-	PUNCT
finefocus-675	93	11	test	test	NOUN
finefocus-675	93	12	p<0.05	p<0.05	NOUN
finefocus-675	93	13	)	)	PUNCT
finefocus-675	93	14	was	be	AUX
finefocus-675	93	15	seen	see	VERB
finefocus-675	93	16	in	in	ADP
finefocus-675	93	17	all	all	DET
finefocus-675	93	18	time	time	NOUN
finefocus-675	93	19	points	point	NOUN
finefocus-675	93	20	past	past	ADJ
finefocus-675	93	21	12	12	NUM
finefocus-675	93	22	hours	hour	NOUN
finefocus-675	93	23	that	that	PRON
finefocus-675	93	24	were	be	AUX
finefocus-675	93	25	treated	treat	VERB
finefocus-675	93	26	with	with	ADP
finefocus-675	93	27	imatinib	imatinib	NOUN
finefocus-675	93	28	(	(	PUNCT
finefocus-675	93	29	figure	figure	NOUN
finefocus-675	93	30	2a	2a	NUM
finefocus-675	93	31	)	)	PUNCT
finefocus-675	93	32	.	.	PUNCT
finefocus-675	94	1	additionally	additionally	ADV
finefocus-675	94	2	,	,	PUNCT
finefocus-675	94	3	bhk	bhk	PROPN
finefocus-675	94	4	cells	cell	NOUN
finefocus-675	94	5	were	be	AUX
finefocus-675	94	6	infected	infect	VERB
finefocus-675	94	7	with	with	ADP
finefocus-675	94	8	an	an	DET
finefocus-675	94	9	increasing	increase	VERB
finefocus-675	94	10	amount	amount	NOUN
finefocus-675	94	11	of	of	ADP
finefocus-675	94	12	virus	virus	NOUN
finefocus-675	94	13	and	and	CCONJ
finefocus-675	94	14	then	then	ADV
finefocus-675	94	15	treated	treat	VERB
finefocus-675	94	16	with	with	ADP
finefocus-675	94	17	mock	mock	ADJ
finefocus-675	94	18	solvent	solvent	NOUN
finefocus-675	94	19	or	or	CCONJ
finefocus-675	94	20	10um	10um	ADJ
finefocus-675	94	21	imatinib	imatinib	NOUN
finefocus-675	94	22	and	and	CCONJ
finefocus-675	94	23	allowed	allow	VERB
finefocus-675	94	24	to	to	PART
finefocus-675	94	25	infect	infect	VERB
finefocus-675	94	26	for	for	ADP
finefocus-675	94	27	24	24	NUM
finefocus-675	94	28	hours	hour	NOUN
finefocus-675	94	29	.	.	PUNCT
finefocus-675	95	1	cells	cell	NOUN
finefocus-675	95	2	were	be	AUX
finefocus-675	95	3	analyzed	analyze	VERB
finefocus-675	95	4	on	on	ADP
finefocus-675	95	5	flow	flow	NOUN
finefocus-675	95	6	cytometry	cytometry	NOUN
finefocus-675	95	7	to	to	PART
finefocus-675	95	8	determine	determine	VERB
finefocus-675	95	9	the	the	DET
finefocus-675	95	10	percentage	percentage	NOUN
finefocus-675	95	11	of	of	ADP
finefocus-675	95	12	cells	cell	NOUN
finefocus-675	95	13	infected	infect	VERB
finefocus-675	95	14	(	(	PUNCT
finefocus-675	95	15	figure	figure	NOUN
finefocus-675	95	16	2b	2b	NOUN
finefocus-675	95	17	)	)	PUNCT
finefocus-675	95	18	.	.	PUNCT
finefocus-675	96	1	increasing	increase	VERB
finefocus-675	96	2	the	the	DET
finefocus-675	96	3	level	level	NOUN
finefocus-675	96	4	of	of	ADP
finefocus-675	96	5	infection	infection	NOUN
finefocus-675	96	6	(	(	PUNCT
finefocus-675	96	7	multiplicity	multiplicity	NOUN
finefocus-675	96	8	of	of	ADP
finefocus-675	96	9	infection=	infection=	NUM
finefocus-675	96	10	moi	moi	NOUN
finefocus-675	96	11	)	)	PUNCT
finefocus-675	96	12	by	by	ADP
finefocus-675	96	13	up	up	ADP
finefocus-675	96	14	to	to	PART
finefocus-675	96	15	10	10	NUM
finefocus-675	96	16	fold	fold	NOUN
finefocus-675	96	17	still	still	ADV
finefocus-675	96	18	showed	show	VERB
finefocus-675	96	19	a	a	DET
finefocus-675	96	20	reduction	reduction	NOUN
finefocus-675	96	21	in	in	ADP
finefocus-675	96	22	virus	virus	NOUN
finefocus-675	96	23	infection	infection	NOUN
finefocus-675	96	24	in	in	ADP
finefocus-675	96	25	cells	cell	NOUN
finefocus-675	96	26	treated	treat	VERB
finefocus-675	96	27	with	with	ADP
finefocus-675	96	28	10μm	10μm	ADJ
finefocus-675	96	29	imatinib	imatinib	NOUN
finefocus-675	96	30	(	(	PUNCT
finefocus-675	96	31	figure	figure	NOUN
finefocus-675	96	32	2b	2b	NOUN
finefocus-675	96	33	)	)	PUNCT
finefocus-675	96	34	.	.	PUNCT
finefocus-675	97	1	time	time	NOUN
finefocus-675	97	2	of	of	ADP
finefocus-675	97	3	treatment	treatment	NOUN
finefocus-675	97	4	affects	affect	VERB
finefocus-675	97	5	imatinib	imatinib	NOUN
finefocus-675	97	6	inhibition	inhibition	NOUN
finefocus-675	97	7	of	of	ADP
finefocus-675	97	8	sinv	sinv	NOUN
finefocus-675	97	9	we	we	PRON
finefocus-675	97	10	sought	seek	VERB
finefocus-675	97	11	to	to	PART
finefocus-675	97	12	validate	validate	VERB
finefocus-675	97	13	imatinib	imatinib	NOUN
finefocus-675	97	14	as	as	ADP
finefocus-675	97	15	a	a	DET
finefocus-675	97	16	treatment	treatment	NOUN
finefocus-675	97	17	option	option	NOUN
finefocus-675	97	18	by	by	ADP
finefocus-675	97	19	investigating	investigate	VERB
finefocus-675	97	20	different	different	ADJ
finefocus-675	97	21	times	time	NOUN
finefocus-675	97	22	of	of	ADP
finefocus-675	97	23	treatment	treatment	NOUN
finefocus-675	97	24	and	and	CCONJ
finefocus-675	97	25	at	at	ADP
finefocus-675	97	26	a	a	DET
finefocus-675	97	27	higher	high	ADJ
finefocus-675	97	28	infection	infection	NOUN
finefocus-675	97	29	level	level	NOUN
finefocus-675	97	30	(	(	PUNCT
finefocus-675	97	31	moi=10	moi=10	PROPN
finefocus-675	97	32	)	)	PUNCT
finefocus-675	97	33	.	.	PUNCT
finefocus-675	98	1	bhk	bhk	PROPN
finefocus-675	98	2	cells	cell	NOUN
finefocus-675	98	3	were	be	AUX
finefocus-675	98	4	treated	treat	VERB
finefocus-675	98	5	with	with	ADP
finefocus-675	98	6	10μm	10μm	ADJ
finefocus-675	98	7	imatinib	imatinib	NOUN
finefocus-675	98	8	at	at	ADP
finefocus-675	98	9	6	6	NUM
finefocus-675	98	10	or	or	CCONJ
finefocus-675	98	11	3	3	NUM
finefocus-675	98	12	hours	hour	NOUN
finefocus-675	98	13	pre	pre	X
finefocus-675	98	14	infection	infection	NOUN
finefocus-675	98	15	,	,	PUNCT
finefocus-675	98	16	at	at	ADP
finefocus-675	98	17	the	the	DET
finefocus-675	98	18	same	same	ADJ
finefocus-675	98	19	time	time	NOUN
finefocus-675	98	20	as	as	ADP
finefocus-675	98	21	infection	infection	NOUN
finefocus-675	98	22	(	(	PUNCT
finefocus-675	98	23	0hrs	0hrs	ADJ
finefocus-675	98	24	)	)	PUNCT
finefocus-675	98	25	,	,	PUNCT
finefocus-675	98	26	or	or	CCONJ
finefocus-675	98	27	3	3	NUM
finefocus-675	98	28	,	,	PUNCT
finefocus-675	98	29	6	6	NUM
finefocus-675	98	30	,	,	PUNCT
finefocus-675	98	31	or	or	CCONJ
finefocus-675	98	32	12	12	NUM
finefocus-675	98	33	hours	hour	NOUN
finefocus-675	98	34	post	post	NOUN
finefocus-675	98	35	infection	infection	NOUN
finefocus-675	98	36	.	.	PUNCT
finefocus-675	99	1	the	the	DET
finefocus-675	99	2	virus	virus	NOUN
finefocus-675	99	3	was	be	AUX
finefocus-675	99	4	added	add	VERB
finefocus-675	99	5	at	at	ADP
finefocus-675	99	6	time	time	NOUN
finefocus-675	99	7	0	0	NUM
finefocus-675	99	8	at	at	ADP
finefocus-675	99	9	an	an	DET
finefocus-675	99	10	moi=10	moi=10	PROPN
finefocus-675	99	11	and	and	CCONJ
finefocus-675	99	12	then	then	ADV
finefocus-675	99	13	the	the	DET
finefocus-675	99	14	cells	cell	NOUN
finefocus-675	99	15	were	be	AUX
finefocus-675	99	16	allowed	allow	VERB
finefocus-675	99	17	to	to	PART
finefocus-675	99	18	infect	infect	VERB
finefocus-675	99	19	for	for	ADP
finefocus-675	99	20	24	24	NUM
finefocus-675	99	21	hours	hour	NOUN
finefocus-675	99	22	before	before	ADP
finefocus-675	99	23	being	be	AUX
finefocus-675	99	24	analyzed	analyze	VERB
finefocus-675	99	25	on	on	ADP
finefocus-675	99	26	flow	flow	NOUN
finefocus-675	99	27	cytometry	cytometry	NOUN
finefocus-675	99	28	.	.	PUNCT
finefocus-675	100	1	each	each	DET
finefocus-675	100	2	time	time	NOUN
finefocus-675	100	3	point	point	NOUN
finefocus-675	100	4	was	be	AUX
finefocus-675	100	5	analyzed	analyze	VERB
finefocus-675	100	6	and	and	CCONJ
finefocus-675	100	7	the	the	DET
finefocus-675	100	8	treatment	treatment	NOUN
finefocus-675	100	9	was	be	AUX
finefocus-675	100	10	set	set	VERB
finefocus-675	100	11	as	as	ADP
finefocus-675	100	12	a	a	DET
finefocus-675	100	13	percentage	percentage	NOUN
finefocus-675	100	14	of	of	ADP
finefocus-675	100	15	the	the	DET
finefocus-675	100	16	untreated	untreated	ADJ
finefocus-675	100	17	control	control	NOUN
finefocus-675	100	18	(	(	PUNCT
finefocus-675	100	19	figure	figure	NOUN
finefocus-675	100	20	3	3	NUM
finefocus-675	100	21	)	)	PUNCT
finefocus-675	100	22	.	.	PUNCT
finefocus-675	101	1	imatinib	imatinib	NOUN
finefocus-675	101	2	inhibition	inhibition	NOUN
finefocus-675	101	3	of	of	ADP
finefocus-675	101	4	sinv	sinv	NOUN
finefocus-675	101	5	works	work	NOUN
finefocus-675	101	6	in	in	ADP
finefocus-675	101	7	multiple	multiple	ADJ
finefocus-675	101	8	cell	cell	NOUN
finefocus-675	101	9	types	type	NOUN
finefocus-675	101	10	to	to	PART
finefocus-675	101	11	confirm	confirm	VERB
finefocus-675	101	12	the	the	DET
finefocus-675	101	13	anti	anti	ADJ
finefocus-675	101	14	-	-	ADJ
finefocus-675	101	15	viral	viral	ADJ
finefocus-675	101	16	effect	effect	NOUN
finefocus-675	101	17	of	of	ADP
finefocus-675	101	18	imatinib	imatinib	NOUN
finefocus-675	101	19	on	on	ADP
finefocus-675	101	20	infected	infected	ADJ
finefocus-675	101	21	cells	cell	NOUN
finefocus-675	101	22	,	,	PUNCT
finefocus-675	101	23	the	the	DET
finefocus-675	101	24	study	study	NOUN
finefocus-675	101	25	was	be	AUX
finefocus-675	101	26	expanded	expand	VERB
finefocus-675	101	27	to	to	PART
finefocus-675	101	28	include	include	VERB
finefocus-675	101	29	human	human	ADJ
finefocus-675	101	30	cultured	cultured	ADJ
finefocus-675	101	31	cells	cell	NOUN
finefocus-675	101	32	.	.	PUNCT
finefocus-675	102	1	human	human	ADJ
finefocus-675	102	2	hepatoma	hepatoma	ADJ
finefocus-675	102	3	cells	cell	NOUN
finefocus-675	102	4	(	(	PUNCT
finefocus-675	102	5	huh7	huh7	PROPN
finefocus-675	102	6	)	)	PUNCT
finefocus-675	102	7	and	and	CCONJ
finefocus-675	102	8	human	human	ADJ
finefocus-675	102	9	embryonic	embryonic	ADJ
finefocus-675	102	10	kidney	kidney	NOUN
finefocus-675	102	11	cells	cell	NOUN
finefocus-675	102	12	(	(	PUNCT
finefocus-675	102	13	hek	hek	PROPN
finefocus-675	102	14	)	)	PUNCT
finefocus-675	102	15	were	be	AUX
finefocus-675	102	16	utilized	utilize	VERB
finefocus-675	102	17	by	by	ADP
finefocus-675	102	18	being	be	AUX
finefocus-675	102	19	plated	plate	VERB
finefocus-675	102	20	and	and	CCONJ
finefocus-675	102	21	infected	infect	VERB
finefocus-675	102	22	with	with	ADP
finefocus-675	102	23	dssinv	dssinv	ADJ
finefocus-675	102	24	-	-	PUNCT
finefocus-675	102	25	gfp	gfp	NOUN
finefocus-675	102	26	at	at	ADP
finefocus-675	102	27	an	an	DET
finefocus-675	102	28	moi=10	moi=10	PROPN
finefocus-675	102	29	similar	similar	ADJ
finefocus-675	102	30	to	to	ADP
finefocus-675	102	31	the	the	DET
finefocus-675	102	32	bhk	bhk	PROPN
finefocus-675	102	33	cells	cell	NOUN
finefocus-675	102	34	.	.	PUNCT
finefocus-675	103	1	10μm	10μm	NUM
finefocus-675	103	2	of	of	ADP
finefocus-675	103	3	imatinib	imatinib	NOUN
finefocus-675	103	4	treatment	treatment	NOUN
finefocus-675	103	5	successfully	successfully	ADV
finefocus-675	103	6	reduced	reduce	VERB
finefocus-675	103	7	sinv	sinv	NOUN
finefocus-675	103	8	replication	replication	NOUN
finefocus-675	103	9	in	in	ADP
finefocus-675	103	10	both	both	CCONJ
finefocus-675	103	11	the	the	DET
finefocus-675	103	12	huh7	huh7	NOUN
finefocus-675	103	13	and	and	CCONJ
finefocus-675	103	14	the	the	DET
finefocus-675	103	15	hek	hek	PROPN
finefocus-675	103	16	cells	cell	NOUN
finefocus-675	103	17	at	at	ADP
finefocus-675	103	18	24	24	NUM
finefocus-675	103	19	hours	hour	NOUN
finefocus-675	103	20	post	post	NOUN
finefocus-675	103	21	infection	infection	NOUN
finefocus-675	103	22	with	with	ADP
finefocus-675	103	23	an	an	DET
finefocus-675	103	24	moi=1(figure	moi=1(figure	NOUN
finefocus-675	103	25	4	4	NUM
finefocus-675	103	26	)	)	PUNCT
finefocus-675	103	27	.	.	PUNCT
finefocus-675	104	1	imatinib	imatinib	NOUN
finefocus-675	104	2	mesylate	mesylate	VERB
finefocus-675	104	3	,	,	PUNCT
finefocus-675	104	4	or	or	CCONJ
finefocus-675	104	5	gleevec	gleevec	PROPN
finefocus-675	104	6	®	®	NOUN
finefocus-675	104	7	,	,	PUNCT
finefocus-675	104	8	is	be	AUX
finefocus-675	104	9	already	already	ADV
finefocus-675	104	10	fda	fda	PROPN
finefocus-675	104	11	-	-	PUNCT
finefocus-675	104	12	approved	approve	VERB
finefocus-675	104	13	and	and	CCONJ
finefocus-675	104	14	is	be	AUX
finefocus-675	104	15	used	use	VERB
finefocus-675	104	16	regularly	regularly	ADV
finefocus-675	104	17	in	in	ADP
finefocus-675	104	18	cancer	cancer	NOUN
finefocus-675	104	19	treatments	treatment	NOUN
finefocus-675	104	20	.	.	PUNCT
finefocus-675	105	1	clinically	clinically	ADV
finefocus-675	105	2	,	,	PUNCT
finefocus-675	105	3	imatinib	imatinib	NOUN
finefocus-675	105	4	is	be	AUX
finefocus-675	105	5	administered	administer	VERB
finefocus-675	105	6	orally	orally	ADV
finefocus-675	105	7	at	at	ADP
finefocus-675	105	8	low	low	ADJ
finefocus-675	105	9	dosages	dosage	NOUN
finefocus-675	105	10	(	(	PUNCT
finefocus-675	105	11	400	400	NUM
finefocus-675	105	12	mg	mg	PROPN
finefocus-675	105	13	p.o	p.o	PROPN
finefocus-675	105	14	.	.	PROPN
finefocus-675	105	15	b.i.d=.800mg/	b.i.d=.800mg/	NOUN
finefocus-675	105	16	day)(5	day)(5	VERB
finefocus-675	105	17	)	)	PUNCT
finefocus-675	105	18	.	.	PUNCT
finefocus-675	106	1	we	we	PRON
finefocus-675	106	2	report	report	VERB
finefocus-675	106	3	that	that	SCONJ
finefocus-675	106	4	at	at	ADP
finefocus-675	106	5	similarly	similarly	ADV
finefocus-675	106	6	low	low	ADJ
finefocus-675	106	7	concentrations	concentration	NOUN
finefocus-675	106	8	(	(	PUNCT
finefocus-675	106	9	10	10	NUM
finefocus-675	106	10	μm	μm	NUM
finefocus-675	106	11	)	)	PUNCT
finefocus-675	106	12	,	,	PUNCT
finefocus-675	106	13	imatinib	imatinib	NOUN
finefocus-675	106	14	reduced	reduce	VERB
finefocus-675	106	15	sinv	sinv	NOUN
finefocus-675	106	16	replication	replication	NOUN
finefocus-675	106	17	in	in	ADP
finefocus-675	106	18	cultured	cultured	ADJ
finefocus-675	106	19	cells	cell	NOUN
finefocus-675	106	20	.	.	PUNCT
finefocus-675	107	1	this	this	DET
finefocus-675	107	2	novel	novel	NOUN
finefocus-675	107	3	finding	finding	NOUN
finefocus-675	107	4	suggests	suggest	VERB
finefocus-675	107	5	that	that	SCONJ
finefocus-675	107	6	metabolic	metabolic	NOUN
finefocus-675	107	7	inhibitors	inhibitor	NOUN
finefocus-675	107	8	used	use	VERB
finefocus-675	107	9	in	in	ADP
finefocus-675	107	10	cancer	cancer	NOUN
finefocus-675	107	11	chemotherapy	chemotherapy	NOUN
finefocus-675	107	12	may	may	AUX
finefocus-675	107	13	be	be	AUX
finefocus-675	107	14	repurposed	repurpose	VERB
finefocus-675	107	15	and	and	CCONJ
finefocus-675	107	16	used	use	VERB
finefocus-675	107	17	for	for	ADP
finefocus-675	107	18	treating	treat	VERB
finefocus-675	107	19	viral	viral	ADJ
finefocus-675	107	20	infections	infection	NOUN
finefocus-675	107	21	.	.	PUNCT
finefocus-675	108	1	imatinib	imatinib	NOUN
finefocus-675	108	2	mesylate	mesylate	NOUN
finefocus-675	108	3	works	work	NOUN
finefocus-675	108	4	by	by	ADP
finefocus-675	108	5	inhibiting	inhibit	VERB
finefocus-675	108	6	tyrosine	tyrosine	NOUN
finefocus-675	108	7	kinases	kinase	NOUN
finefocus-675	108	8	within	within	ADP
finefocus-675	108	9	the	the	DET
finefocus-675	108	10	host	host	NOUN
finefocus-675	108	11	cell(5	cell(5	PROPN
finefocus-675	108	12	,	,	PUNCT
finefocus-675	108	13	18	18	NUM
finefocus-675	108	14	)	)	PUNCT
finefocus-675	108	15	.	.	PUNCT
finefocus-675	109	1	many	many	ADJ
finefocus-675	109	2	metabolic	metabolic	NOUN
finefocus-675	109	3	enzymes	enzyme	NOUN
finefocus-675	109	4	require	require	VERB
finefocus-675	109	5	phosphorylation	phosphorylation	NOUN
finefocus-675	109	6	from	from	ADP
finefocus-675	109	7	tyrosine	tyrosine	NOUN
finefocus-675	109	8	kinases	kinase	NOUN
finefocus-675	109	9	in	in	ADP
finefocus-675	109	10	order	order	NOUN
finefocus-675	109	11	to	to	PART
finefocus-675	109	12	be	be	AUX
finefocus-675	109	13	activated	activate	VERB
finefocus-675	109	14	.	.	PUNCT
finefocus-675	110	1	the	the	DET
finefocus-675	110	2	general	general	ADJ
finefocus-675	110	3	inhibition	inhibition	NOUN
finefocus-675	110	4	of	of	ADP
finefocus-675	110	5	tyrosine	tyrosine	NOUN
finefocus-675	110	6	kinases	kinase	NOUN
finefocus-675	110	7	reduces	reduce	VERB
finefocus-675	110	8	the	the	DET
finefocus-675	110	9	ability	ability	NOUN
finefocus-675	110	10	of	of	ADP
finefocus-675	110	11	the	the	DET
finefocus-675	110	12	cell	cell	NOUN
finefocus-675	110	13	to	to	PART
finefocus-675	110	14	have	have	AUX
finefocus-675	110	15	elevated	elevate	VERB
finefocus-675	110	16	metabolic	metabolic	NOUN
finefocus-675	110	17	rates	rate	NOUN
finefocus-675	110	18	.	.	PUNCT
finefocus-675	111	1	this	this	DET
finefocus-675	111	2	limitation	limitation	NOUN
finefocus-675	111	3	on	on	ADP
finefocus-675	111	4	cellular	cellular	ADJ
finefocus-675	111	5	pathways	pathway	NOUN
finefocus-675	111	6	prevents	prevent	VERB
finefocus-675	111	7	the	the	DET
finefocus-675	111	8	virus	virus	NOUN
finefocus-675	111	9	from	from	ADP
finefocus-675	111	10	manipulating	manipulate	VERB
finefocus-675	111	11	host	host	NOUN
finefocus-675	111	12	cell	cell	NOUN
finefocus-675	111	13	metabolism	metabolism	NOUN
finefocus-675	111	14	and	and	CCONJ
finefocus-675	111	15	hijacking	hijack	VERB
finefocus-675	111	16	certain	certain	ADJ
finefocus-675	111	17	pathways	pathway	NOUN
finefocus-675	111	18	for	for	ADP
finefocus-675	111	19	optimal	optimal	ADJ
finefocus-675	111	20	viral	viral	ADJ
finefocus-675	111	21	replication	replication	NOUN
finefocus-675	111	22	.	.	PUNCT
finefocus-675	112	1	during	during	ADP
finefocus-675	112	2	imatinib	imatinib	ADJ
finefocus-675	112	3	treatment	treatment	NOUN
finefocus-675	112	4	,	,	PUNCT
finefocus-675	112	5	the	the	DET
finefocus-675	112	6	cell	cell	NOUN
finefocus-675	112	7	is	be	AUX
finefocus-675	112	8	maintained	maintain	VERB
finefocus-675	112	9	at	at	ADP
finefocus-675	112	10	lower	low	ADJ
finefocus-675	112	11	metabolic	metabolic	NOUN
finefocus-675	112	12	rates	rate	NOUN
finefocus-675	112	13	and	and	CCONJ
finefocus-675	112	14	therefore	therefore	ADV
finefocus-675	112	15	limits	limit	VERB
finefocus-675	112	16	the	the	DET
finefocus-675	112	17	ability	ability	NOUN
finefocus-675	112	18	of	of	ADP
finefocus-675	112	19	the	the	DET
finefocus-675	112	20	virus	virus	NOUN
finefocus-675	112	21	to	to	PART
finefocus-675	112	22	replicate	replicate	VERB
finefocus-675	112	23	.	.	PUNCT
finefocus-675	113	1	this	this	DET
finefocus-675	113	2	hypothesis	hypothesis	NOUN
finefocus-675	113	3	has	have	AUX
finefocus-675	113	4	been	be	AUX
finefocus-675	113	5	validated	validate	VERB
finefocus-675	113	6	and	and	CCONJ
finefocus-675	113	7	it	it	PRON
finefocus-675	113	8	has	have	AUX
finefocus-675	113	9	been	be	AUX
finefocus-675	113	10	shown	show	VERB
finefocus-675	113	11	that	that	SCONJ
finefocus-675	113	12	sindbis	sindbis	PROPN
finefocus-675	113	13	virus	virus	NOUN
finefocus-675	113	14	is	be	AUX
finefocus-675	113	15	significantly	significantly	ADV
finefocus-675	113	16	inhibited	inhibit	VERB
finefocus-675	113	17	in	in	ADP
finefocus-675	113	18	cells	cell	NOUN
finefocus-675	113	19	treated	treat	VERB
finefocus-675	113	20	with	with	ADP
finefocus-675	113	21	10μm	10μm	ADJ
finefocus-675	113	22	imatinib	imatinib	NOUN
finefocus-675	113	23	.	.	PUNCT
finefocus-675	114	1	this	this	DET
finefocus-675	114	2	concentration	concentration	NOUN
finefocus-675	114	3	of	of	ADP
finefocus-675	114	4	imatinib	imatinib	NOUN
finefocus-675	114	5	was	be	AUX
finefocus-675	114	6	not	not	PART
finefocus-675	114	7	toxic	toxic	ADJ
finefocus-675	114	8	to	to	ADP
finefocus-675	114	9	the	the	DET
finefocus-675	114	10	cells	cell	NOUN
finefocus-675	114	11	and	and	CCONJ
finefocus-675	114	12	presents	present	VERB
finefocus-675	114	13	a	a	DET
finefocus-675	114	14	therapeutic	therapeutic	ADJ
finefocus-675	114	15	window	window	NOUN
finefocus-675	114	16	where	where	SCONJ
finefocus-675	114	17	imatinib	imatinib	NOUN
finefocus-675	114	18	may	may	AUX
finefocus-675	114	19	be	be	AUX
finefocus-675	114	20	used	use	VERB
finefocus-675	114	21	effectively	effectively	ADV
finefocus-675	114	22	to	to	PART
finefocus-675	114	23	limit	limit	VERB
finefocus-675	114	24	virus	virus	NOUN
finefocus-675	114	25	replication	replication	NOUN
finefocus-675	114	26	,	,	PUNCT
finefocus-675	114	27	while	while	SCONJ
finefocus-675	114	28	maintaining	maintain	VERB
finefocus-675	114	29	host	host	NOUN
finefocus-675	114	30	cell	cell	NOUN
finefocus-675	114	31	viability	viability	NOUN
finefocus-675	114	32	(	(	PUNCT
finefocus-675	114	33	figure	figure	NOUN
finefocus-675	114	34	1	1	NUM
finefocus-675	114	35	)	)	PUNCT
finefocus-675	114	36	.	.	PUNCT
finefocus-675	115	1	imatinib	imatinib	NOUN
finefocus-675	115	2	’s	’s	PART
finefocus-675	115	3	therapeutic	therapeutic	ADJ
finefocus-675	115	4	index	index	NOUN
finefocus-675	115	5	was	be	AUX
finefocus-675	115	6	similar	similar	ADJ
finefocus-675	115	7	to	to	ADP
finefocus-675	115	8	ribavirin	ribavirin	NOUN
finefocus-675	115	9	,	,	PUNCT
finefocus-675	115	10	which	which	PRON
finefocus-675	115	11	is	be	AUX
finefocus-675	115	12	a	a	DET
finefocus-675	115	13	clinical	clinical	ADJ
finefocus-675	115	14	antiviral	antiviral	NOUN
finefocus-675	115	15	used	use	VERB
finefocus-675	115	16	to	to	PART
finefocus-675	115	17	treat	treat	VERB
finefocus-675	115	18	severe	severe	ADJ
finefocus-675	115	19	cases	case	NOUN
finefocus-675	115	20	of	of	ADP
finefocus-675	115	21	respiratory	respiratory	ADJ
finefocus-675	115	22	syncytia	syncytia	ADJ
finefocus-675	115	23	virus	virus	NOUN
finefocus-675	115	24	(	(	PUNCT
finefocus-675	115	25	rsv)(12	rsv)(12	PROPN
finefocus-675	115	26	)	)	PUNCT
finefocus-675	115	27	.	.	PUNCT
finefocus-675	116	1	although	although	SCONJ
finefocus-675	116	2	it	it	PRON
finefocus-675	116	3	would	would	AUX
finefocus-675	116	4	be	be	AUX
finefocus-675	116	5	more	more	ADV
finefocus-675	116	6	advantageous	advantageous	ADJ
finefocus-675	116	7	if	if	SCONJ
finefocus-675	116	8	imatinib	imatinib	NOUN
finefocus-675	116	9	had	have	VERB
finefocus-675	116	10	a	a	DET
finefocus-675	116	11	higher	high	ADJ
finefocus-675	116	12	therapeutic	therapeutic	ADJ
finefocus-675	116	13	index	index	NOUN
finefocus-675	116	14	,	,	PUNCT
finefocus-675	116	15	the	the	DET
finefocus-675	116	16	proof	proof	NOUN
finefocus-675	116	17	-	-	PUNCT
finefocus-675	116	18	of	of	ADP
finefocus-675	116	19	-	-	PUNCT
finefocus-675	116	20	principle	principle	NOUN
finefocus-675	116	21	is	be	AUX
finefocus-675	116	22	still	still	ADV
finefocus-675	116	23	validated	validate	VERB
finefocus-675	116	24	that	that	SCONJ
finefocus-675	116	25	anti	anti	ADJ
finefocus-675	116	26	-	-	ADJ
finefocus-675	116	27	cancer	cancer	ADJ
finefocus-675	116	28	and	and	CCONJ
finefocus-675	116	29	antimetabolism	antimetabolism	NOUN
finefocus-675	116	30	compounds	compound	NOUN
finefocus-675	116	31	may	may	AUX
finefocus-675	116	32	be	be	AUX
finefocus-675	116	33	repurposed	repurpose	VERB
finefocus-675	116	34	and	and	CCONJ
finefocus-675	116	35	used	use	VERB
finefocus-675	116	36	for	for	ADP
finefocus-675	116	37	antivirals	antiviral	NOUN
finefocus-675	116	38	.	.	PUNCT
finefocus-675	117	1	imatinib	imatinib	NOUN
finefocus-675	117	2	is	be	AUX
finefocus-675	117	3	effective	effective	ADJ
finefocus-675	117	4	against	against	ADP
finefocus-675	117	5	sindbis	sindbis	PROPN
finefocus-675	117	6	virus	virus	NOUN
finefocus-675	117	7	and	and	CCONJ
finefocus-675	117	8	investigation	investigation	NOUN
finefocus-675	117	9	of	of	ADP
finefocus-675	117	10	other	other	ADJ
finefocus-675	117	11	anti	anti	ADJ
finefocus-675	117	12	-	-	ADJ
finefocus-675	117	13	metabolism	metabolism	ADJ
finefocus-675	117	14	compounds	compound	NOUN
finefocus-675	117	15	may	may	AUX
finefocus-675	117	16	lead	lead	VERB
finefocus-675	117	17	to	to	ADP
finefocus-675	117	18	the	the	DET
finefocus-675	117	19	discovery	discovery	NOUN
finefocus-675	117	20	of	of	ADP
finefocus-675	117	21	an	an	DET
finefocus-675	117	22	even	even	ADV
finefocus-675	117	23	more	more	ADV
finefocus-675	117	24	effective	effective	ADJ
finefocus-675	117	25	drug	drug	NOUN
finefocus-675	117	26	that	that	PRON
finefocus-675	117	27	can	can	AUX
finefocus-675	117	28	be	be	AUX
finefocus-675	117	29	used	use	VERB
finefocus-675	117	30	to	to	PART
finefocus-675	117	31	treat	treat	VERB
finefocus-675	117	32	viral	viral	ADJ
finefocus-675	117	33	infections	infection	NOUN
finefocus-675	117	34	.	.	PUNCT
finefocus-675	118	1	this	this	DET
finefocus-675	118	2	imatinib	imatinib	ADJ
finefocus-675	118	3	anti	anti	ADJ
finefocus-675	118	4	-	-	ADJ
finefocus-675	118	5	viral	viral	ADJ
finefocus-675	118	6	effect	effect	NOUN
finefocus-675	118	7	was	be	AUX
finefocus-675	118	8	confirmed	confirm	VERB
finefocus-675	118	9	at	at	ADP
finefocus-675	118	10	different	different	ADJ
finefocus-675	118	11	times	time	NOUN
finefocus-675	118	12	during	during	ADP
finefocus-675	118	13	the	the	DET
finefocus-675	118	14	virus	virus	NOUN
finefocus-675	118	15	replication	replication	NOUN
finefocus-675	118	16	cycle	cycle	NOUN
finefocus-675	118	17	and	and	CCONJ
finefocus-675	118	18	indicates	indicate	VERB
finefocus-675	118	19	a	a	DET
finefocus-675	118	20	general	general	ADJ
finefocus-675	118	21	overall	overall	ADJ
finefocus-675	118	22	reduction	reduction	NOUN
finefocus-675	118	23	in	in	ADP
finefocus-675	118	24	virus	virus	NOUN
finefocus-675	118	25	infection	infection	NOUN
finefocus-675	118	26	as	as	SCONJ
finefocus-675	118	27	compared	compare	VERB
finefocus-675	118	28	to	to	ADP
finefocus-675	118	29	a	a	DET
finefocus-675	118	30	step	step	NOUN
finefocus-675	118	31	/	/	SYM
finefocus-675	118	32	cycle	cycle	NOUN
finefocus-675	118	33	specific	specific	ADJ
finefocus-675	118	34	inhibition	inhibition	NOUN
finefocus-675	118	35	effect	effect	NOUN
finefocus-675	118	36	.	.	PUNCT
finefocus-675	119	1	over	over	ADP
finefocus-675	119	2	the	the	DET
finefocus-675	119	3	course	course	NOUN
finefocus-675	119	4	of	of	ADP
finefocus-675	119	5	24	24	NUM
finefocus-675	119	6	hours	hour	NOUN
finefocus-675	119	7	,	,	PUNCT
finefocus-675	119	8	untreated	untreated	ADJ
finefocus-675	119	9	cells	cell	NOUN
finefocus-675	119	10	showed	show	VERB
finefocus-675	119	11	a	a	DET
finefocus-675	119	12	gradual	gradual	ADJ
finefocus-675	119	13	increase	increase	NOUN
finefocus-675	119	14	in	in	ADP
finefocus-675	119	15	percent	percent	NOUN
finefocus-675	119	16	of	of	ADP
finefocus-675	119	17	sinvinfected	sinvinfecte	VERB
finefocus-675	119	18	cells	cell	NOUN
finefocus-675	119	19	eventually	eventually	ADV
finefocus-675	119	20	reaching	reach	VERB
finefocus-675	119	21	about	about	ADP
finefocus-675	119	22	25	25	NUM
finefocus-675	119	23	%	%	NOUN
finefocus-675	119	24	infected	infect	VERB
finefocus-675	119	25	,	,	PUNCT
finefocus-675	119	26	which	which	PRON
finefocus-675	119	27	is	be	AUX
finefocus-675	119	28	statistically	statistically	ADV
finefocus-675	119	29	significant	significant	ADJ
finefocus-675	119	30	when	when	SCONJ
finefocus-675	119	31	compared	compare	VERB
finefocus-675	119	32	to	to	ADP
finefocus-675	119	33	the	the	DET
finefocus-675	119	34	imatinib	imatinib	NOUN
finefocus-675	119	35	treated	treat	VERB
finefocus-675	119	36	cells	cell	NOUN
finefocus-675	119	37	that	that	PRON
finefocus-675	119	38	only	only	ADV
finefocus-675	119	39	reached	reach	VERB
finefocus-675	119	40	about	about	ADV
finefocus-675	119	41	5	5	NUM
finefocus-675	119	42	%	%	NOUN
finefocus-675	119	43	of	of	ADP
finefocus-675	119	44	cells	cell	NOUN
finefocus-675	119	45	infected	infect	VERB
finefocus-675	119	46	at	at	ADP
finefocus-675	119	47	24	24	NUM
finefocus-675	119	48	hours	hour	NOUN
finefocus-675	119	49	.	.	PUNCT
finefocus-675	120	1	significant	significant	ADJ
finefocus-675	120	2	reduction	reduction	NOUN
finefocus-675	120	3	in	in	ADP
finefocus-675	120	4	virus	virus	NOUN
finefocus-675	120	5	replication	replication	NOUN
finefocus-675	120	6	was	be	AUX
finefocus-675	120	7	seen	see	VERB
finefocus-675	120	8	in	in	ADP
finefocus-675	120	9	a	a	DET
finefocus-675	120	10	wide	wide	ADJ
finefocus-675	120	11	variety	variety	NOUN
finefocus-675	120	12	of	of	ADP
finefocus-675	120	13	infection	infection	NOUN
finefocus-675	120	14	levels	level	NOUN
finefocus-675	120	15	,	,	PUNCT
finefocus-675	120	16	as	as	SCONJ
finefocus-675	120	17	indicated	indicate	VERB
finefocus-675	120	18	by	by	ADP
finefocus-675	120	19	different	different	ADJ
finefocus-675	120	20	infection	infection	NOUN
finefocus-675	120	21	moi	moi	X
finefocus-675	120	22	’s	’s	PART
finefocus-675	120	23	(	(	PUNCT
finefocus-675	120	24	figure	figure	NOUN
finefocus-675	120	25	2	2	NUM
finefocus-675	120	26	)	)	PUNCT
finefocus-675	120	27	.	.	PUNCT
finefocus-675	121	1	interestingly	interestingly	ADV
finefocus-675	121	2	,	,	PUNCT
finefocus-675	121	3	the	the	DET
finefocus-675	121	4	plates	plate	NOUN
finefocus-675	121	5	that	that	PRON
finefocus-675	121	6	were	be	AUX
finefocus-675	121	7	examined	examine	VERB
finefocus-675	121	8	at	at	ADP
finefocus-675	121	9	different	different	ADJ
finefocus-675	121	10	time	time	NOUN
finefocus-675	121	11	points	point	NOUN
finefocus-675	121	12	showed	show	VERB
finefocus-675	121	13	higher	high	ADJ
finefocus-675	121	14	infection	infection	NOUN
finefocus-675	121	15	levels	level	NOUN
finefocus-675	121	16	(	(	PUNCT
finefocus-675	121	17	up	up	ADP
finefocus-675	121	18	to	to	PART
finefocus-675	121	19	25	25	NUM
finefocus-675	121	20	%	%	NOUN
finefocus-675	121	21	)	)	PUNCT
finefocus-675	121	22	compared	compare	VERB
finefocus-675	121	23	to	to	ADP
finefocus-675	121	24	the	the	DET
finefocus-675	121	25	moi	moi	X
finefocus-675	121	26	plates	plate	NOUN
finefocus-675	121	27	(	(	PUNCT
finefocus-675	121	28	only	only	ADV
finefocus-675	121	29	up	up	ADP
finefocus-675	121	30	to	to	ADP
finefocus-675	121	31	about	about	ADP
finefocus-675	121	32	17	17	NUM
finefocus-675	121	33	%	%	NOUN
finefocus-675	121	34	)	)	PUNCT
finefocus-675	121	35	.	.	PUNCT
finefocus-675	122	1	this	this	PRON
finefocus-675	122	2	may	may	AUX
finefocus-675	122	3	be	be	AUX
finefocus-675	122	4	due	due	ADJ
finefocus-675	122	5	to	to	ADP
finefocus-675	122	6	the	the	DET
finefocus-675	122	7	fact	fact	NOUN
finefocus-675	122	8	that	that	SCONJ
finefocus-675	122	9	the	the	DET
finefocus-675	122	10	time	time	NOUN
finefocus-675	122	11	course	course	NOUN
finefocus-675	122	12	plates	plate	NOUN
finefocus-675	122	13	were	be	AUX
finefocus-675	122	14	physically	physically	ADV
finefocus-675	122	15	moved	move	VERB
finefocus-675	122	16	every	every	DET
finefocus-675	122	17	6	6	NUM
finefocus-675	122	18	hours	hour	NOUN
finefocus-675	122	19	,	,	PUNCT
finefocus-675	122	20	which	which	PRON
finefocus-675	122	21	would	would	AUX
finefocus-675	122	22	result	result	VERB
finefocus-675	122	23	in	in	ADP
finefocus-675	122	24	a	a	DET
finefocus-675	122	25	disruption	disruption	NOUN
finefocus-675	122	26	of	of	ADP
finefocus-675	122	27	the	the	DET
finefocus-675	122	28	media	medium	NOUN
finefocus-675	122	29	and	and	CCONJ
finefocus-675	122	30	may	may	AUX
finefocus-675	122	31	have	have	AUX
finefocus-675	122	32	redistributed	redistribute	VERB
finefocus-675	122	33	the	the	DET
finefocus-675	122	34	virus	virus	NOUN
finefocus-675	122	35	supernatant	supernatant	NOUN
finefocus-675	122	36	throughout	throughout	ADP
finefocus-675	122	37	the	the	DET
finefocus-675	122	38	culture	culture	NOUN
finefocus-675	122	39	.	.	PUNCT
finefocus-675	123	1	these	these	DET
finefocus-675	123	2	results	result	NOUN
finefocus-675	123	3	imply	imply	VERB
finefocus-675	123	4	that	that	SCONJ
finefocus-675	123	5	imatinib	imatinib	NOUN
finefocus-675	123	6	may	may	AUX
finefocus-675	123	7	be	be	AUX
finefocus-675	123	8	successfully	successfully	ADV
finefocus-675	123	9	used	use	VERB
finefocus-675	123	10	to	to	PART
finefocus-675	123	11	reduce	reduce	VERB
finefocus-675	123	12	viral	viral	ADJ
finefocus-675	123	13	loads	load	NOUN
finefocus-675	123	14	at	at	ADP
finefocus-675	123	15	different	different	ADJ
finefocus-675	123	16	times	time	NOUN
finefocus-675	123	17	and	and	CCONJ
finefocus-675	123	18	levels	level	NOUN
finefocus-675	123	19	of	of	ADP
finefocus-675	123	20	infection	infection	NOUN
finefocus-675	123	21	.	.	PUNCT
finefocus-675	124	1	to	to	PART
finefocus-675	124	2	further	far	ADV
finefocus-675	124	3	assess	assess	VERB
finefocus-675	124	4	the	the	DET
finefocus-675	124	5	efficacy	efficacy	NOUN
finefocus-675	124	6	of	of	ADP
finefocus-675	124	7	imatinib	imatinib	NOUN
finefocus-675	124	8	to	to	PART
finefocus-675	124	9	lower	lower	VERB
finefocus-675	124	10	viral	viral	ADJ
finefocus-675	124	11	replication	replication	NOUN
finefocus-675	124	12	,	,	PUNCT
finefocus-675	124	13	the	the	DET
finefocus-675	124	14	impact	impact	NOUN
finefocus-675	124	15	of	of	ADP
finefocus-675	124	16	treatment	treatment	NOUN
finefocus-675	124	17	timing	timing	NOUN
finefocus-675	124	18	on	on	ADP
finefocus-675	124	19	viral	viral	ADJ
finefocus-675	124	20	infection	infection	NOUN
finefocus-675	124	21	was	be	AUX
finefocus-675	124	22	investigated	investigate	VERB
finefocus-675	124	23	.	.	PUNCT
finefocus-675	125	1	understanding	understand	VERB
finefocus-675	125	2	the	the	DET
finefocus-675	125	3	opportune	opportune	ADJ
finefocus-675	125	4	timing	timing	NOUN
finefocus-675	125	5	for	for	ADP
finefocus-675	125	6	treatment	treatment	NOUN
finefocus-675	125	7	is	be	AUX
finefocus-675	125	8	a	a	DET
finefocus-675	125	9	critical	critical	ADJ
finefocus-675	125	10	component	component	NOUN
finefocus-675	125	11	for	for	ADP
finefocus-675	125	12	antivirals	antiviral	NOUN
finefocus-675	125	13	to	to	PART
finefocus-675	125	14	discover	discover	VERB
finefocus-675	125	15	if	if	SCONJ
finefocus-675	125	16	the	the	DET
finefocus-675	125	17	compound	compound	NOUN
finefocus-675	125	18	is	be	AUX
finefocus-675	125	19	more	more	ADV
finefocus-675	125	20	effective	effective	ADJ
finefocus-675	125	21	if	if	SCONJ
finefocus-675	125	22	given	give	VERB
finefocus-675	125	23	prophylactically	prophylactically	ADV
finefocus-675	125	24	prior	prior	ADV
finefocus-675	125	25	to	to	ADP
finefocus-675	125	26	exposure	exposure	NOUN
finefocus-675	125	27	or	or	CCONJ
finefocus-675	125	28	if	if	SCONJ
finefocus-675	125	29	post	post	ADJ
finefocus-675	125	30	-	-	ADJ
finefocus-675	125	31	infection	infection	ADJ
finefocus-675	125	32	treatment	treatment	NOUN
finefocus-675	125	33	is	be	AUX
finefocus-675	125	34	more	more	ADV
finefocus-675	125	35	effective	effective	ADJ
finefocus-675	125	36	.	.	PUNCT
finefocus-675	126	1	the	the	DET
finefocus-675	126	2	greatest	great	ADJ
finefocus-675	126	3	inhibition	inhibition	NOUN
finefocus-675	126	4	of	of	ADP
finefocus-675	126	5	virus	virus	NOUN
finefocus-675	126	6	replication	replication	NOUN
finefocus-675	126	7	was	be	AUX
finefocus-675	126	8	seen	see	VERB
finefocus-675	126	9	in	in	ADP
finefocus-675	126	10	cells	cell	NOUN
finefocus-675	126	11	that	that	PRON
finefocus-675	126	12	received	receive	VERB
finefocus-675	126	13	the	the	DET
finefocus-675	126	14	imatinib	imatinib	NOUN
finefocus-675	126	15	treatment	treatment	NOUN
finefocus-675	126	16	3	3	NUM
finefocus-675	126	17	or	or	CCONJ
finefocus-675	126	18	6	6	NUM
finefocus-675	126	19	hours	hour	NOUN
finefocus-675	126	20	prior	prior	ADV
finefocus-675	126	21	to	to	ADP
finefocus-675	126	22	infection	infection	NOUN
finefocus-675	126	23	.	.	PUNCT
finefocus-675	127	1	adding	add	VERB
finefocus-675	127	2	the	the	DET
finefocus-675	127	3	imatinib	imatinib	NOUN
finefocus-675	127	4	at	at	ADP
finefocus-675	127	5	the	the	DET
finefocus-675	127	6	same	same	ADJ
finefocus-675	127	7	time	time	NOUN
finefocus-675	127	8	as	as	ADP
finefocus-675	127	9	infection	infection	NOUN
finefocus-675	127	10	or	or	CCONJ
finefocus-675	127	11	up	up	ADP
finefocus-675	127	12	to	to	PART
finefocus-675	127	13	3	3	NUM
finefocus-675	127	14	hours	hour	NOUN
finefocus-675	127	15	post	post	NOUN
finefocus-675	127	16	infection	infection	NOUN
finefocus-675	127	17	still	still	ADV
finefocus-675	127	18	achieved	achieve	VERB
finefocus-675	127	19	about	about	ADV
finefocus-675	127	20	a	a	DET
finefocus-675	127	21	20	20	NUM
finefocus-675	127	22	%	%	NOUN
finefocus-675	127	23	reduction	reduction	NOUN
finefocus-675	127	24	in	in	ADP
finefocus-675	127	25	virus	virus	NOUN
finefocus-675	127	26	replication	replication	NOUN
finefocus-675	127	27	,	,	PUNCT
finefocus-675	127	28	but	but	CCONJ
finefocus-675	127	29	adding	add	VERB
finefocus-675	127	30	146	146	NUM
finefocus-675	127	31	•	•	NUM
finefocus-675	127	32	fine	fine	ADJ
finefocus-675	127	33	focus	focus	NOUN
finefocus-675	127	34	,	,	PUNCT
finefocus-675	127	35	vol	vol	NOUN
finefocus-675	127	36	.	.	NOUN
finefocus-675	127	37	3	3	NUM
finefocus-675	127	38	(	(	PUNCT
finefocus-675	127	39	2	2	NUM
finefocus-675	127	40	)	)	PUNCT
finefocus-675	127	41	imatinib	imatinib	NOUN
finefocus-675	127	42	mesylate	mesylate	VERB
finefocus-675	127	43	•	•	NUM
finefocus-675	127	44	149	149	NUM
finefocus-675	127	45	figure	figure	NOUN
finefocus-675	127	46	2	2	NUM
finefocus-675	127	47	:	:	PUNCT
finefocus-675	127	48	imatinib	imatinib	NOUN
finefocus-675	127	49	treatment	treatment	NOUN
finefocus-675	127	50	at	at	ADP
finefocus-675	127	51	different	different	ADJ
finefocus-675	127	52	times	time	NOUN
finefocus-675	127	53	post	post	ADJ
finefocus-675	127	54	-	-	ADJ
finefocus-675	127	55	infection	infection	NOUN
finefocus-675	127	56	and	and	CCONJ
finefocus-675	127	57	sinv	sinv	NOUN
finefocus-675	127	58	concentrations	concentration	NOUN
finefocus-675	127	59	a	a	DET
finefocus-675	127	60	)	)	PUNCT
finefocus-675	127	61	sinv	sinv	NOUN
finefocus-675	127	62	-	-	PUNCT
finefocus-675	127	63	infected	infect	VERB
finefocus-675	127	64	bhk	bhk	PROPN
finefocus-675	127	65	cells	cell	NOUN
finefocus-675	127	66	(	(	PUNCT
finefocus-675	127	67	moi=1	moi=1	ADV
finefocus-675	127	68	)	)	PUNCT
finefocus-675	127	69	were	be	AUX
finefocus-675	127	70	treated	treat	VERB
finefocus-675	127	71	with	with	ADP
finefocus-675	127	72	10μm	10μm	ADJ
finefocus-675	127	73	imatinib	imatinib	NOUN
finefocus-675	127	74	(	(	PUNCT
finefocus-675	127	75	dotted	dotted	ADJ
finefocus-675	127	76	line	line	NOUN
finefocus-675	127	77	)	)	PUNCT
finefocus-675	127	78	or	or	CCONJ
finefocus-675	127	79	left	leave	VERB
finefocus-675	127	80	untreated	untreated	ADJ
finefocus-675	127	81	(	(	PUNCT
finefocus-675	127	82	black	black	ADJ
finefocus-675	127	83	line	line	NOUN
finefocus-675	127	84	)	)	PUNCT
finefocus-675	127	85	and	and	CCONJ
finefocus-675	127	86	analyzed	analyze	VERB
finefocus-675	127	87	every	every	DET
finefocus-675	127	88	6	6	NUM
finefocus-675	127	89	hours	hour	NOUN
finefocus-675	127	90	for	for	ADP
finefocus-675	127	91	the	the	DET
finefocus-675	127	92	percentage	percentage	NOUN
finefocus-675	127	93	of	of	ADP
finefocus-675	127	94	cells	cell	NOUN
finefocus-675	127	95	infected	infect	VERB
finefocus-675	127	96	using	use	VERB
finefocus-675	127	97	flow	flow	NOUN
finefocus-675	127	98	cytometry	cytometry	NOUN
finefocus-675	127	99	.	.	PUNCT
finefocus-675	128	1	b	b	X
finefocus-675	128	2	)	)	PUNCT
finefocus-675	128	3	bhk	bhk	PROPN
finefocus-675	128	4	cells	cell	NOUN
finefocus-675	128	5	infected	infect	VERB
finefocus-675	128	6	with	with	ADP
finefocus-675	128	7	increasing	increase	VERB
finefocus-675	128	8	amounts	amount	NOUN
finefocus-675	128	9	of	of	ADP
finefocus-675	128	10	virus	virus	NOUN
finefocus-675	128	11	and	and	CCONJ
finefocus-675	128	12	treated	treat	VERB
finefocus-675	128	13	with	with	ADP
finefocus-675	128	14	10	10	NUM
finefocus-675	128	15	μm	μm	ADJ
finefocus-675	128	16	imatinib	imatinib	NOUN
finefocus-675	128	17	(	(	PUNCT
finefocus-675	128	18	gray	gray	ADJ
finefocus-675	128	19	)	)	PUNCT
finefocus-675	128	20	or	or	CCONJ
finefocus-675	128	21	left	leave	VERB
finefocus-675	128	22	untreated	untreated	ADJ
finefocus-675	128	23	(	(	PUNCT
finefocus-675	128	24	black	black	NOUN
finefocus-675	128	25	)	)	PUNCT
finefocus-675	128	26	.	.	PUNCT
finefocus-675	129	1	the	the	DET
finefocus-675	129	2	percentage	percentage	NOUN
finefocus-675	129	3	of	of	ADP
finefocus-675	129	4	cells	cell	NOUN
finefocus-675	129	5	infected	infect	VERB
finefocus-675	129	6	was	be	AUX
finefocus-675	129	7	determined	determine	VERB
finefocus-675	129	8	with	with	ADP
finefocus-675	129	9	flow	flow	NOUN
finefocus-675	129	10	cytometry	cytometry	NOUN
finefocus-675	129	11	at	at	ADP
finefocus-675	129	12	24	24	NUM
finefocus-675	129	13	hours	hour	NOUN
finefocus-675	129	14	.	.	PUNCT
finefocus-675	130	1	significant	significant	ADJ
finefocus-675	130	2	reductions	reduction	NOUN
finefocus-675	130	3	(	(	PUNCT
finefocus-675	130	4	students	student	NOUN
finefocus-675	130	5	t	t	NOUN
finefocus-675	130	6	-	-	PUNCT
finefocus-675	130	7	test	test	NOUN
finefocus-675	130	8	p<0.05	p<0.05	NOUN
finefocus-675	130	9	)	)	PUNCT
finefocus-675	130	10	in	in	ADP
finefocus-675	130	11	dssinv	dssinv	ADJ
finefocus-675	130	12	-	-	PUNCT
finefocus-675	130	13	gfp	gfp	NOUN
finefocus-675	130	14	replication	replication	NOUN
finefocus-675	130	15	are	be	AUX
finefocus-675	130	16	indicated	indicate	VERB
finefocus-675	130	17	with	with	ADP
finefocus-675	130	18	an	an	DET
finefocus-675	130	19	asterisk	asterisk	NOUN
finefocus-675	130	20	(	(	PUNCT
finefocus-675	130	21	*	*	NOUN
finefocus-675	130	22	)	)	PUNCT
finefocus-675	130	23	.	.	PUNCT
finefocus-675	131	1	figure	figure	VERB
finefocus-675	131	2	3	3	NUM
finefocus-675	131	3	:	:	PUNCT
finefocus-675	131	4	treatment	treatment	NOUN
finefocus-675	131	5	with	with	ADP
finefocus-675	131	6	imatinib	imatinib	NOUN
finefocus-675	131	7	at	at	ADP
finefocus-675	131	8	different	different	ADJ
finefocus-675	131	9	treatment	treatment	NOUN
finefocus-675	131	10	times	time	NOUN
finefocus-675	131	11	bhk	bhk	PROPN
finefocus-675	131	12	cells	cell	NOUN
finefocus-675	131	13	were	be	AUX
finefocus-675	131	14	treated	treat	VERB
finefocus-675	131	15	with	with	ADP
finefocus-675	131	16	10	10	NUM
finefocus-675	131	17	μm	μm	NOUN
finefocus-675	131	18	imatinib	imatinib	NOUN
finefocus-675	131	19	or	or	CCONJ
finefocus-675	131	20	solvent	solvent	ADJ
finefocus-675	131	21	control	control	NOUN
finefocus-675	131	22	at	at	ADP
finefocus-675	131	23	the	the	DET
finefocus-675	131	24	times	time	NOUN
finefocus-675	131	25	indicated	indicate	VERB
finefocus-675	131	26	and	and	CCONJ
finefocus-675	131	27	dssinv	dssinv	ADJ
finefocus-675	131	28	-	-	PUNCT
finefocus-675	131	29	gfp	gfp	NOUN
finefocus-675	131	30	(	(	PUNCT
finefocus-675	131	31	moi=10	moi=10	PROPN
finefocus-675	131	32	)	)	PUNCT
finefocus-675	131	33	was	be	AUX
finefocus-675	131	34	added	add	VERB
finefocus-675	131	35	at	at	ADP
finefocus-675	131	36	time	time	NOUN
finefocus-675	131	37	0	0	NUM
finefocus-675	131	38	.	.	PUNCT
finefocus-675	132	1	at	at	ADP
finefocus-675	132	2	24	24	NUM
finefocus-675	132	3	hours	hour	NOUN
finefocus-675	132	4	post	post	NOUN
finefocus-675	132	5	infection	infection	NOUN
finefocus-675	132	6	,	,	PUNCT
finefocus-675	132	7	the	the	DET
finefocus-675	132	8	cells	cell	NOUN
finefocus-675	132	9	were	be	AUX
finefocus-675	132	10	analyzed	analyze	VERB
finefocus-675	132	11	for	for	ADP
finefocus-675	132	12	dssinv	dssinv	ADJ
finefocus-675	132	13	-	-	PUNCT
finefocus-675	132	14	gfp	gfp	NOUN
finefocus-675	132	15	via	via	ADP
finefocus-675	132	16	flow	flow	NOUN
finefocus-675	132	17	cytometry	cytometry	NOUN
finefocus-675	132	18	.	.	PUNCT
finefocus-675	133	1	the	the	DET
finefocus-675	133	2	untreated	untreated	ADJ
finefocus-675	133	3	sample	sample	NOUN
finefocus-675	133	4	for	for	ADP
finefocus-675	133	5	each	each	DET
finefocus-675	133	6	condition	condition	NOUN
finefocus-675	133	7	was	be	AUX
finefocus-675	133	8	set	set	VERB
finefocus-675	133	9	to	to	ADP
finefocus-675	133	10	100	100	NUM
finefocus-675	133	11	%	%	NOUN
finefocus-675	133	12	.	.	PUNCT
finefocus-675	134	1	the	the	DET
finefocus-675	134	2	greatest	great	ADJ
finefocus-675	134	3	difference	difference	NOUN
finefocus-675	134	4	was	be	AUX
finefocus-675	134	5	seen	see	VERB
finefocus-675	134	6	with	with	ADP
finefocus-675	134	7	a	a	DET
finefocus-675	134	8	single	single	ADJ
finefocus-675	134	9	treatment	treatment	NOUN
finefocus-675	134	10	.	.	PUNCT
finefocus-675	135	1	figure	figure	VERB
finefocus-675	135	2	4	4	NUM
finefocus-675	135	3	:	:	PUNCT
finefocus-675	135	4	a	a	X
finefocus-675	135	5	)	)	PUNCT
finefocus-675	135	6	human	human	ADJ
finefocus-675	135	7	hepatoma	hepatoma	NOUN
finefocus-675	135	8	(	(	PUNCT
finefocus-675	135	9	huh7	huh7	PROPN
finefocus-675	135	10	)	)	PUNCT
finefocus-675	135	11	and	and	CCONJ
finefocus-675	135	12	b	b	X
finefocus-675	135	13	)	)	PUNCT
finefocus-675	135	14	human	human	ADJ
finefocus-675	135	15	embryonic	embryonic	ADJ
finefocus-675	135	16	kidney	kidney	NOUN
finefocus-675	135	17	(	(	PUNCT
finefocus-675	135	18	hek	hek	PROPN
finefocus-675	135	19	)	)	PUNCT
finefocus-675	135	20	cells	cell	NOUN
finefocus-675	135	21	were	be	AUX
finefocus-675	135	22	infected	infect	VERB
finefocus-675	135	23	with	with	ADP
finefocus-675	135	24	dssinv	dssinv	ADJ
finefocus-675	135	25	-	-	PUNCT
finefocus-675	135	26	gfp	gfp	NOUN
finefocus-675	135	27	at	at	ADP
finefocus-675	135	28	an	an	DET
finefocus-675	135	29	moi=10	moi=10	PROPN
finefocus-675	135	30	and	and	CCONJ
finefocus-675	135	31	then	then	ADV
finefocus-675	135	32	treated	treat	VERB
finefocus-675	135	33	with	with	ADP
finefocus-675	135	34	10	10	NUM
finefocus-675	135	35	μm	μm	ADJ
finefocus-675	135	36	imatinib	imatinib	NOUN
finefocus-675	135	37	or	or	CCONJ
finefocus-675	135	38	solvent	solvent	ADJ
finefocus-675	135	39	control	control	NOUN
finefocus-675	135	40	(	(	PUNCT
finefocus-675	135	41	untreated	untreated	ADJ
finefocus-675	135	42	)	)	PUNCT
finefocus-675	135	43	.	.	PUNCT
finefocus-675	136	1	at	at	ADP
finefocus-675	136	2	24	24	NUM
finefocus-675	136	3	hours	hour	NOUN
finefocus-675	136	4	post	post	NOUN
finefocus-675	136	5	infection	infection	NOUN
finefocus-675	136	6	,	,	PUNCT
finefocus-675	136	7	the	the	DET
finefocus-675	136	8	cells	cell	NOUN
finefocus-675	136	9	were	be	AUX
finefocus-675	136	10	analyzed	analyze	VERB
finefocus-675	136	11	for	for	ADP
finefocus-675	136	12	dssinv	dssinv	ADJ
finefocus-675	136	13	-	-	PUNCT
finefocus-675	136	14	gfp	gfp	NOUN
finefocus-675	136	15	via	via	ADP
finefocus-675	136	16	flow	flow	NOUN
finefocus-675	136	17	cytometry	cytometry	NOUN
finefocus-675	136	18	.	.	PUNCT
finefocus-675	137	1	all	all	DET
finefocus-675	137	2	data	datum	NOUN
finefocus-675	137	3	is	be	AUX
finefocus-675	137	4	displayed	display	VERB
finefocus-675	137	5	as	as	ADP
finefocus-675	137	6	a	a	DET
finefocus-675	137	7	percentage	percentage	NOUN
finefocus-675	137	8	of	of	ADP
finefocus-675	137	9	the	the	DET
finefocus-675	137	10	untreated	untreated	ADJ
finefocus-675	137	11	samples	sample	NOUN
finefocus-675	137	12	.	.	PUNCT
finefocus-675	138	1	(	(	PUNCT
finefocus-675	138	2	n=6	n=6	NOUN
finefocus-675	138	3	)	)	PUNCT
finefocus-675	138	4	.	.	PUNCT
finefocus-675	139	1	the	the	DET
finefocus-675	139	2	imatinib	imatinib	NOUN
finefocus-675	139	3	6	6	NUM
finefocus-675	139	4	hours	hour	NOUN
finefocus-675	139	5	or	or	CCONJ
finefocus-675	139	6	later	later	ADV
finefocus-675	139	7	after	after	ADP
finefocus-675	139	8	infection	infection	NOUN
finefocus-675	139	9	did	do	AUX
finefocus-675	139	10	not	not	PART
finefocus-675	139	11	result	result	VERB
finefocus-675	139	12	in	in	ADP
finefocus-675	139	13	a	a	DET
finefocus-675	139	14	significant	significant	ADJ
finefocus-675	139	15	inhibition	inhibition	NOUN
finefocus-675	139	16	of	of	ADP
finefocus-675	139	17	virus	virus	NOUN
finefocus-675	139	18	infection	infection	NOUN
finefocus-675	139	19	(	(	PUNCT
finefocus-675	139	20	figure	figure	NOUN
finefocus-675	139	21	3	3	NUM
finefocus-675	139	22	)	)	PUNCT
finefocus-675	139	23	.	.	PUNCT
finefocus-675	140	1	the	the	DET
finefocus-675	140	2	20	20	NUM
finefocus-675	140	3	%	%	NOUN
finefocus-675	140	4	reduction	reduction	NOUN
finefocus-675	140	5	is	be	AUX
finefocus-675	140	6	not	not	PART
finefocus-675	140	7	as	as	ADV
finefocus-675	140	8	significant	significant	ADJ
finefocus-675	140	9	as	as	ADP
finefocus-675	140	10	what	what	PRON
finefocus-675	140	11	was	be	AUX
finefocus-675	140	12	seen	see	VERB
finefocus-675	140	13	in	in	ADP
finefocus-675	140	14	previous	previous	ADJ
finefocus-675	140	15	experiments	experiment	NOUN
finefocus-675	140	16	,	,	PUNCT
finefocus-675	140	17	but	but	CCONJ
finefocus-675	140	18	that	that	PRON
finefocus-675	140	19	is	be	AUX
finefocus-675	140	20	likely	likely	ADJ
finefocus-675	140	21	due	due	ADP
finefocus-675	140	22	to	to	ADP
finefocus-675	140	23	the	the	DET
finefocus-675	140	24	higher	high	ADJ
finefocus-675	140	25	moi	moi	NOUN
finefocus-675	140	26	and	and	CCONJ
finefocus-675	140	27	also	also	ADV
finefocus-675	140	28	greater	great	ADJ
finefocus-675	140	29	movement	movement	NOUN
finefocus-675	140	30	of	of	ADP
finefocus-675	140	31	the	the	DET
finefocus-675	140	32	plate	plate	NOUN
finefocus-675	140	33	during	during	ADP
finefocus-675	140	34	the	the	DET
finefocus-675	140	35	infection	infection	NOUN
finefocus-675	140	36	incubation	incubation	NOUN
finefocus-675	140	37	.	.	PUNCT
finefocus-675	141	1	pre	pre	ADJ
finefocus-675	141	2	-	-	ADJ
finefocus-675	141	3	infection	infection	ADJ
finefocus-675	141	4	treatment	treatment	NOUN
finefocus-675	141	5	with	with	ADP
finefocus-675	141	6	imatinib	imatinib	NOUN
finefocus-675	141	7	reduced	reduce	VERB
finefocus-675	141	8	the	the	DET
finefocus-675	141	9	virus	virus	NOUN
finefocus-675	141	10	replication	replication	NOUN
finefocus-675	141	11	more	more	ADV
finefocus-675	141	12	effectively	effectively	ADV
finefocus-675	141	13	than	than	ADP
finefocus-675	141	14	treatments	treatment	NOUN
finefocus-675	141	15	that	that	PRON
finefocus-675	141	16	were	be	AUX
finefocus-675	141	17	added	add	VERB
finefocus-675	141	18	concurrently	concurrently	ADV
finefocus-675	141	19	or	or	CCONJ
finefocus-675	141	20	post	post	VERB
finefocus-675	141	21	infection	infection	NOUN
finefocus-675	141	22	.	.	PUNCT
finefocus-675	142	1	this	this	PRON
finefocus-675	142	2	indicates	indicate	VERB
finefocus-675	142	3	that	that	SCONJ
finefocus-675	142	4	imatinib	imatinib	NOUN
finefocus-675	142	5	may	may	AUX
finefocus-675	142	6	be	be	AUX
finefocus-675	142	7	most	most	ADV
finefocus-675	142	8	effective	effective	ADJ
finefocus-675	142	9	as	as	ADP
finefocus-675	142	10	a	a	DET
finefocus-675	142	11	prophylactic	prophylactic	ADJ
finefocus-675	142	12	drug	drug	NOUN
finefocus-675	142	13	,	,	PUNCT
finefocus-675	142	14	given	give	VERB
finefocus-675	142	15	prior	prior	ADV
finefocus-675	142	16	to	to	ADP
finefocus-675	142	17	high	high	ADJ
finefocus-675	142	18	risk	risk	NOUN
finefocus-675	142	19	exposure	exposure	NOUN
finefocus-675	142	20	situations	situation	NOUN
finefocus-675	142	21	.	.	PUNCT
finefocus-675	143	1	however	however	ADV
finefocus-675	143	2	,	,	PUNCT
finefocus-675	143	3	due	due	ADP
finefocus-675	143	4	to	to	ADP
finefocus-675	143	5	the	the	DET
finefocus-675	143	6	inherent	inherent	ADJ
finefocus-675	143	7	side	side	NOUN
finefocus-675	143	8	effects	effect	NOUN
finefocus-675	143	9	of	of	ADP
finefocus-675	143	10	anti	anti	ADJ
finefocus-675	143	11	-	-	ADJ
finefocus-675	143	12	cancer	cancer	ADJ
finefocus-675	143	13	and	and	CCONJ
finefocus-675	143	14	antimetabolic	antimetabolic	ADJ
finefocus-675	143	15	drugs	drug	NOUN
finefocus-675	143	16	,	,	PUNCT
finefocus-675	143	17	prophylactic	prophylactic	ADJ
finefocus-675	143	18	treatment	treatment	NOUN
finefocus-675	143	19	might	might	AUX
finefocus-675	143	20	not	not	PART
finefocus-675	143	21	be	be	AUX
finefocus-675	143	22	feasible	feasible	ADJ
finefocus-675	143	23	in	in	ADP
finefocus-675	143	24	a	a	DET
finefocus-675	143	25	clinical	clinical	ADJ
finefocus-675	143	26	setting	setting	NOUN
finefocus-675	143	27	,	,	PUNCT
finefocus-675	143	28	but	but	CCONJ
finefocus-675	143	29	postinfection	postinfection	NOUN
finefocus-675	143	30	treatment	treatment	NOUN
finefocus-675	143	31	may	may	AUX
finefocus-675	143	32	be	be	AUX
finefocus-675	143	33	effective	effective	ADJ
finefocus-675	143	34	.	.	PUNCT
finefocus-675	144	1	although	although	SCONJ
finefocus-675	144	2	not	not	PART
finefocus-675	144	3	as	as	ADV
finefocus-675	144	4	significant	significant	ADJ
finefocus-675	144	5	as	as	ADP
finefocus-675	144	6	a	a	DET
finefocus-675	144	7	pre	pre	ADJ
finefocus-675	144	8	-	-	ADJ
finefocus-675	144	9	infection	infection	ADJ
finefocus-675	144	10	treatment	treatment	NOUN
finefocus-675	144	11	,	,	PUNCT
finefocus-675	144	12	even	even	ADV
finefocus-675	144	13	treating	treat	VERB
finefocus-675	144	14	with	with	ADP
finefocus-675	144	15	imatinib	imatinib	NOUN
finefocus-675	144	16	at	at	ADP
finefocus-675	144	17	3	3	NUM
finefocus-675	144	18	hours	hour	NOUN
finefocus-675	144	19	postinfection	postinfection	NOUN
finefocus-675	144	20	successfully	successfully	ADV
finefocus-675	144	21	reduced	reduce	VERB
finefocus-675	144	22	virus	virus	NOUN
finefocus-675	144	23	infection	infection	NOUN
finefocus-675	144	24	and	and	CCONJ
finefocus-675	144	25	confirms	confirm	VERB
finefocus-675	144	26	the	the	DET
finefocus-675	144	27	potential	potential	ADJ
finefocus-675	144	28	utility	utility	NOUN
finefocus-675	144	29	of	of	ADP
finefocus-675	144	30	using	use	VERB
finefocus-675	144	31	imatinib	imatinib	NOUN
finefocus-675	144	32	as	as	ADP
finefocus-675	144	33	a	a	DET
finefocus-675	144	34	post	post	ADJ
finefocus-675	144	35	-	-	ADJ
finefocus-675	144	36	exposure	exposure	ADJ
finefocus-675	144	37	/	/	SYM
finefocus-675	144	38	infection	infection	NOUN
finefocus-675	144	39	treatment	treatment	NOUN
finefocus-675	144	40	option	option	NOUN
finefocus-675	144	41	(	(	PUNCT
finefocus-675	144	42	figure	figure	NOUN
finefocus-675	144	43	3	3	NUM
finefocus-675	144	44	)	)	PUNCT
finefocus-675	144	45	.	.	PUNCT
finefocus-675	145	1	the	the	DET
finefocus-675	145	2	imatinib	imatinib	NOUN
finefocus-675	145	3	inhibition	inhibition	NOUN
finefocus-675	145	4	of	of	ADP
finefocus-675	145	5	sinv	sinv	ADJ
finefocus-675	145	6	infection	infection	NOUN
finefocus-675	145	7	was	be	AUX
finefocus-675	145	8	further	far	ADV
finefocus-675	145	9	confirmed	confirm	VERB
finefocus-675	145	10	in	in	ADP
finefocus-675	145	11	human	human	ADJ
finefocus-675	145	12	cultured	cultured	ADJ
finefocus-675	145	13	cells	cell	NOUN
finefocus-675	145	14	,	,	PUNCT
finefocus-675	145	15	both	both	DET
finefocus-675	145	16	liver	liver	NOUN
finefocus-675	145	17	(	(	PUNCT
finefocus-675	145	18	huh7	huh7	PROPN
finefocus-675	145	19	)	)	PUNCT
finefocus-675	145	20	and	and	CCONJ
finefocus-675	145	21	kidney	kidney	NOUN
finefocus-675	145	22	cells	cell	NOUN
finefocus-675	145	23	(	(	PUNCT
finefocus-675	145	24	hek	hek	PROPN
finefocus-675	145	25	)	)	PUNCT
finefocus-675	145	26	,	,	PUNCT
finefocus-675	145	27	which	which	PRON
finefocus-675	145	28	both	both	PRON
finefocus-675	145	29	showed	show	VERB
finefocus-675	145	30	a	a	DET
finefocus-675	145	31	similar	similar	ADJ
finefocus-675	145	32	reduction	reduction	NOUN
finefocus-675	145	33	in	in	ADP
finefocus-675	145	34	virus	virus	NOUN
finefocus-675	145	35	replication	replication	NOUN
finefocus-675	145	36	as	as	SCONJ
finefocus-675	145	37	was	be	AUX
finefocus-675	145	38	observed	observe	VERB
finefocus-675	145	39	in	in	ADP
finefocus-675	145	40	the	the	DET
finefocus-675	145	41	bhk	bhk	PROPN
finefocus-675	145	42	cells	cell	NOUN
finefocus-675	145	43	(	(	PUNCT
finefocus-675	145	44	figure	figure	NOUN
finefocus-675	145	45	4	4	NUM
finefocus-675	145	46	)	)	PUNCT
finefocus-675	145	47	.	.	PUNCT
finefocus-675	146	1	huh7	huh7	PROPN
finefocus-675	146	2	and	and	CCONJ
finefocus-675	146	3	hek	hek	PROPN
finefocus-675	146	4	cells	cell	NOUN
finefocus-675	146	5	are	be	AUX
finefocus-675	146	6	common	common	ADJ
finefocus-675	146	7	cell	cell	NOUN
finefocus-675	146	8	lines	line	NOUN
finefocus-675	146	9	used	use	VERB
finefocus-675	146	10	in	in	ADP
finefocus-675	146	11	virology	virology	NOUN
finefocus-675	146	12	to	to	PART
finefocus-675	146	13	assess	assess	VERB
finefocus-675	146	14	virus	virus	NOUN
finefocus-675	146	15	replication	replication	NOUN
finefocus-675	146	16	in	in	ADP
finefocus-675	146	17	human	human	ADJ
finefocus-675	146	18	tissue	tissue	NOUN
finefocus-675	146	19	and	and	CCONJ
finefocus-675	146	20	it	it	PRON
finefocus-675	146	21	is	be	AUX
finefocus-675	146	22	promising	promise	VERB
finefocus-675	146	23	that	that	SCONJ
finefocus-675	146	24	both	both	DET
finefocus-675	146	25	cell	cell	NOUN
finefocus-675	146	26	lines	line	NOUN
finefocus-675	146	27	show	show	VERB
finefocus-675	146	28	an	an	DET
finefocus-675	146	29	effective	effective	ADJ
finefocus-675	146	30	reduction	reduction	NOUN
finefocus-675	146	31	in	in	ADP
finefocus-675	146	32	sinv	sinv	ADJ
finefocus-675	146	33	replication	replication	NOUN
finefocus-675	146	34	when	when	SCONJ
finefocus-675	146	35	treated	treat	VERB
finefocus-675	146	36	with	with	ADP
finefocus-675	146	37	10μm	10μm	ADJ
finefocus-675	146	38	imatinib	imatinib	NOUN
finefocus-675	146	39	.	.	PUNCT
finefocus-675	147	1	variation	variation	NOUN
finefocus-675	147	2	in	in	ADP
finefocus-675	147	3	viral	viral	ADJ
finefocus-675	147	4	reduction	reduction	NOUN
finefocus-675	147	5	is	be	AUX
finefocus-675	147	6	likely	likely	ADJ
finefocus-675	147	7	due	due	ADJ
finefocus-675	147	8	to	to	ADP
finefocus-675	147	9	specific	specific	ADJ
finefocus-675	147	10	differences	difference	NOUN
finefocus-675	147	11	in	in	ADP
finefocus-675	147	12	the	the	DET
finefocus-675	147	13	cell	cell	NOUN
finefocus-675	147	14	type	type	NOUN
finefocus-675	147	15	,	,	PUNCT
finefocus-675	147	16	but	but	CCONJ
finefocus-675	147	17	the	the	DET
finefocus-675	147	18	overall	overall	ADJ
finefocus-675	147	19	trend	trend	NOUN
finefocus-675	147	20	of	of	ADP
finefocus-675	147	21	viral	viral	ADJ
finefocus-675	147	22	inhibition	inhibition	NOUN
finefocus-675	147	23	with	with	ADP
finefocus-675	147	24	imatinib	imatinib	NOUN
finefocus-675	147	25	treatment	treatment	NOUN
finefocus-675	147	26	is	be	AUX
finefocus-675	147	27	maintained	maintain	VERB
finefocus-675	147	28	in	in	ADP
finefocus-675	147	29	the	the	DET
finefocus-675	147	30	different	different	ADJ
finefocus-675	147	31	human	human	ADJ
finefocus-675	147	32	cell	cell	NOUN
finefocus-675	147	33	lines	line	NOUN
finefocus-675	147	34	.	.	PUNCT
finefocus-675	148	1	this	this	PRON
finefocus-675	148	2	validates	validate	VERB
finefocus-675	148	3	the	the	DET
finefocus-675	148	4	potential	potential	ADJ
finefocus-675	148	5	efficacy	efficacy	NOUN
finefocus-675	148	6	of	of	ADP
finefocus-675	148	7	using	use	VERB
finefocus-675	148	8	imatinib	imatinib	NOUN
finefocus-675	148	9	as	as	ADP
finefocus-675	148	10	a	a	DET
finefocus-675	148	11	therapeutic	therapeutic	ADJ
finefocus-675	148	12	anti	anti	ADJ
finefocus-675	148	13	-	-	ADJ
finefocus-675	148	14	viral	viral	ADJ
finefocus-675	148	15	treatment	treatment	NOUN
finefocus-675	148	16	option	option	NOUN
finefocus-675	148	17	in	in	ADP
finefocus-675	148	18	human	human	ADJ
finefocus-675	148	19	alphavirus	alphavirus	NOUN
finefocus-675	148	20	infections	infection	NOUN
finefocus-675	148	21	.	.	PUNCT
finefocus-675	149	1	in	in	ADP
finefocus-675	149	2	this	this	DET
finefocus-675	149	3	study	study	NOUN
finefocus-675	149	4	,	,	PUNCT
finefocus-675	149	5	a	a	DET
finefocus-675	149	6	single	single	ADJ
finefocus-675	149	7	metabolic	metabolic	NOUN
finefocus-675	149	8	inhibiting	inhibit	VERB
finefocus-675	149	9	cancer	cancer	NOUN
finefocus-675	149	10	drug	drug	NOUN
finefocus-675	149	11	known	know	VERB
finefocus-675	149	12	as	as	ADP
finefocus-675	149	13	imatinib	imatinib	NOUN
finefocus-675	149	14	mesylate	mesylate	NOUN
finefocus-675	149	15	was	be	AUX
finefocus-675	149	16	investigated	investigate	VERB
finefocus-675	149	17	.	.	PUNCT
finefocus-675	150	1	imatinib	imatinib	NOUN
finefocus-675	150	2	has	have	AUX
finefocus-675	150	3	shown	show	VERB
finefocus-675	150	4	very	very	ADV
finefocus-675	150	5	promising	promising	ADJ
finefocus-675	150	6	inhibition	inhibition	NOUN
finefocus-675	150	7	of	of	ADP
finefocus-675	150	8	sindbis	sindbis	NOUN
finefocus-675	150	9	virus	virus	NOUN
finefocus-675	150	10	replication	replication	NOUN
finefocus-675	150	11	at	at	ADP
finefocus-675	150	12	different	different	ADJ
finefocus-675	150	13	times	time	NOUN
finefocus-675	150	14	,	,	PUNCT
finefocus-675	150	15	levels	level	NOUN
finefocus-675	150	16	/	/	SYM
finefocus-675	150	17	moi	moi	X
finefocus-675	150	18	’s	’s	PART
finefocus-675	150	19	,	,	PUNCT
finefocus-675	150	20	and	and	CCONJ
finefocus-675	150	21	host	host	NOUN
finefocus-675	150	22	cells	cell	NOUN
finefocus-675	150	23	.	.	PUNCT
finefocus-675	151	1	further	further	ADJ
finefocus-675	151	2	work	work	NOUN
finefocus-675	151	3	will	will	AUX
finefocus-675	151	4	be	be	AUX
finefocus-675	151	5	done	do	VERB
finefocus-675	151	6	148	148	NUM
finefocus-675	151	7	•	•	NUM
finefocus-675	151	8	fine	fine	ADJ
finefocus-675	151	9	focus	focus	NOUN
finefocus-675	151	10	,	,	PUNCT
finefocus-675	151	11	vol	vol	NOUN
finefocus-675	151	12	.	.	NOUN
finefocus-675	151	13	3	3	NUM
finefocus-675	151	14	(	(	PUNCT
finefocus-675	151	15	2	2	NUM
finefocus-675	151	16	)	)	PUNCT
finefocus-675	151	17	1	1	NUM
finefocus-675	151	18	.	.	PUNCT
finefocus-675	151	19	ami	ami	PROPN
finefocus-675	151	20	e	e	PROPN
finefocus-675	151	21	ben	ben	PROPN
finefocus-675	151	22	,	,	PUNCT
finefocus-675	151	23	demetri	demetri	PROPN
finefocus-675	151	24	gd	gd	PROPN
finefocus-675	151	25	.	.	PROPN
finefocus-675	151	26	2016	2016	NUM
finefocus-675	151	27	.	.	PUNCT
finefocus-675	152	1	a	a	DET
finefocus-675	152	2	safety	safety	NOUN
finefocus-675	152	3	evaluation	evaluation	NOUN
finefocus-675	152	4	of	of	ADP
finefocus-675	152	5	imatinib	imatinib	NOUN
finefocus-675	152	6	mesylate	mesylate	VERB
finefocus-675	152	7	in	in	ADP
finefocus-675	152	8	the	the	DET
finefocus-675	152	9	treatment	treatment	NOUN
finefocus-675	152	10	of	of	ADP
finefocus-675	152	11	gastrointestinal	gastrointestinal	ADJ
finefocus-675	152	12	stromal	stromal	ADJ
finefocus-675	152	13	tumor	tumor	NOUN
finefocus-675	152	14	.	.	PUNCT
finefocus-675	153	1	http://dx.doi.org/10.1517/14740338.2016.115	http://dx.doi.org/10.1517/14740338.2016.115	PROPN
finefocus-675	153	2	2258	2258	NUM
finefocus-675	153	3	2	2	X
finefocus-675	153	4	.	.	PUNCT
finefocus-675	154	1	atkins	atkins	PROPN
finefocus-675	154	2	gj	gj	PROPN
finefocus-675	154	3	.	.	PROPN
finefocus-675	154	4	2013	2013	NUM
finefocus-675	154	5	.	.	PUNCT
finefocus-675	155	1	the	the	DET
finefocus-675	155	2	pathogenesis	pathogenesis	NOUN
finefocus-675	155	3	of	of	ADP
finefocus-675	155	4	alphaviruses	alphavirus	NOUN
finefocus-675	155	5	.	.	PUNCT
finefocus-675	156	1	isrn	isrn	PROPN
finefocus-675	156	2	virol	virol	VERB
finefocus-675	156	3	2013:1–22	2013:1–22	NUM
finefocus-675	156	4	.	.	PUNCT
finefocus-675	157	1	3	3	NUM
finefocus-675	157	2	.	.	X
finefocus-675	157	3	boren	boren	PROPN
finefocus-675	157	4	j	j	PROPN
finefocus-675	157	5	,	,	PUNCT
finefocus-675	157	6	cascante	cascante	PROPN
finefocus-675	157	7	m	m	PROPN
finefocus-675	157	8	,	,	PUNCT
finefocus-675	157	9	marin	marin	PROPN
finefocus-675	157	10	s	s	PROPN
finefocus-675	157	11	,	,	PUNCT
finefocus-675	157	12	comín	comín	NOUN
finefocus-675	157	13	-	-	PUNCT
finefocus-675	157	14	anduix	anduix	NOUN
finefocus-675	157	15	b	b	NOUN
finefocus-675	157	16	,	,	PUNCT
finefocus-675	157	17	centelles	centelles	PROPN
finefocus-675	157	18	jj	jj	PROPN
finefocus-675	157	19	,	,	PUNCT
finefocus-675	157	20	et	et	PROPN
finefocus-675	157	21	al	al	PROPN
finefocus-675	157	22	.	.	PROPN
finefocus-675	157	23	2001	2001	NUM
finefocus-675	157	24	.	.	PUNCT
finefocus-675	158	1	gleevec	gleevec	PROPN
finefocus-675	158	2	(	(	PUNCT
finefocus-675	158	3	sti571	sti571	PROPN
finefocus-675	158	4	)	)	PUNCT
finefocus-675	158	5	influences	influence	VERB
finefocus-675	158	6	metabolic	metabolic	NOUN
finefocus-675	158	7	enzyme	enzyme	NOUN
finefocus-675	158	8	activities	activity	NOUN
finefocus-675	158	9	and	and	CCONJ
finefocus-675	158	10	glucose	glucose	NOUN
finefocus-675	158	11	carbon	carbon	NOUN
finefocus-675	158	12	flow	flow	NOUN
finefocus-675	158	13	toward	toward	ADP
finefocus-675	158	14	nucleic	nucleic	ADJ
finefocus-675	158	15	acid	acid	NOUN
finefocus-675	158	16	and	and	CCONJ
finefocus-675	158	17	fatty	fatty	NOUN
finefocus-675	158	18	acid	acid	NOUN
finefocus-675	158	19	synthesis	synthesis	NOUN
finefocus-675	158	20	in	in	ADP
finefocus-675	158	21	myeloid	myeloid	ADJ
finefocus-675	158	22	tumor	tumor	NOUN
finefocus-675	158	23	cells	cell	NOUN
finefocus-675	158	24	.	.	PUNCT
finefocus-675	159	1	j.	j.	PROPN
finefocus-675	159	2	biol	biol	PROPN
finefocus-675	159	3	.	.	PUNCT
finefocus-675	160	1	chem	chem	PROPN
finefocus-675	160	2	276:37747–53	276:37747–53	NUM
finefocus-675	160	3	.	.	PROPN
finefocus-675	161	1	4	4	NUM
finefocus-675	161	2	.	.	X
finefocus-675	161	3	bühler	bühler	NOUN
finefocus-675	161	4	s	s	PROPN
finefocus-675	161	5	,	,	PUNCT
finefocus-675	161	6	bartenschlager	bartenschlager	PROPN
finefocus-675	161	7	r.	r.	PROPN
finefocus-675	161	8	2012	2012	NUM
finefocus-675	161	9	.	.	PUNCT
finefocus-675	162	1	new	new	ADJ
finefocus-675	162	2	targets	target	NOUN
finefocus-675	162	3	for	for	ADP
finefocus-675	162	4	antiviral	antiviral	ADJ
finefocus-675	162	5	therapy	therapy	NOUN
finefocus-675	162	6	of	of	ADP
finefocus-675	162	7	chronic	chronic	ADJ
finefocus-675	162	8	hepatitis	hepatitis	PROPN
finefocus-675	162	9	c.	c.	PROPN
finefocus-675	162	10	liver	liver	PROPN
finefocus-675	162	11	int	int	PROPN
finefocus-675	162	12	32:9–16	32:9–16	NUM
finefocus-675	162	13	.	.	PUNCT
finefocus-675	163	1	5	5	NUM
finefocus-675	163	2	.	.	NUM
finefocus-675	163	3	cristofanilli	cristofanilli	PROPN
finefocus-675	163	4	m	m	PROPN
finefocus-675	163	5	,	,	PUNCT
finefocus-675	163	6	morandi	morandi	PROPN
finefocus-675	163	7	p	p	PROPN
finefocus-675	163	8	,	,	PUNCT
finefocus-675	163	9	krishnamurthy	krishnamurthy	PROPN
finefocus-675	163	10	s	s	PROPN
finefocus-675	163	11	,	,	PUNCT
finefocus-675	163	12	reuben	reuben	PROPN
finefocus-675	163	13	jm	jm	PROPN
finefocus-675	163	14	,	,	PUNCT
finefocus-675	163	15	lee	lee	PROPN
finefocus-675	163	16	bn	bn	PROPN
finefocus-675	163	17	,	,	PUNCT
finefocus-675	163	18	et	et	PROPN
finefocus-675	163	19	al	al	PROPN
finefocus-675	163	20	.	.	PROPN
finefocus-675	163	21	2008	2008	NUM
finefocus-675	163	22	.	.	PUNCT
finefocus-675	164	1	imatinib	imatinib	NOUN
finefocus-675	164	2	mesylate	mesylate	NOUN
finefocus-675	164	3	(	(	PUNCT
finefocus-675	164	4	gleevec	gleevec	PROPN
finefocus-675	164	5	®	®	PROPN
finefocus-675	164	6	)	)	PUNCT
finefocus-675	164	7	in	in	ADP
finefocus-675	164	8	advanced	advanced	ADJ
finefocus-675	164	9	breast	breast	NOUN
finefocus-675	164	10	cancer	cancer	NOUN
finefocus-675	164	11	-	-	PUNCT
finefocus-675	164	12	expressing	express	VERB
finefocus-675	164	13	c	c	NOUN
finefocus-675	164	14	-	-	PUNCT
finefocus-675	164	15	kit	kit	NOUN
finefocus-675	164	16	or	or	CCONJ
finefocus-675	164	17	pdgfr	pdgfr	ADJ
finefocus-675	164	18	-	-	PUNCT
finefocus-675	164	19	β	β	NOUN
finefocus-675	164	20	:	:	PUNCT
finefocus-675	164	21	clinical	clinical	ADJ
finefocus-675	164	22	activity	activity	NOUN
finefocus-675	164	23	and	and	CCONJ
finefocus-675	164	24	biological	biological	ADJ
finefocus-675	164	25	correlations	correlation	NOUN
finefocus-675	164	26	.	.	PUNCT
finefocus-675	165	1	ann	ann	PROPN
finefocus-675	165	2	.	.	PUNCT
finefocus-675	166	1	oncol	oncol	ADJ
finefocus-675	166	2	19:1713–19	19:1713–19	NUM
finefocus-675	166	3	.	.	PUNCT
finefocus-675	167	1	6	6	NUM
finefocus-675	167	2	.	.	X
finefocus-675	167	3	findlay	findlay	PROPN
finefocus-675	167	4	js	js	PROPN
finefocus-675	167	5	,	,	PUNCT
finefocus-675	167	6	ulaeto	ulaeto	VERB
finefocus-675	167	7	d.	d.	PROPN
finefocus-675	167	8	2015	2015	NUM
finefocus-675	167	9	.	.	PUNCT
finefocus-675	168	1	semliki	semliki	PROPN
finefocus-675	168	2	forest	forest	NOUN
finefocus-675	168	3	virus	virus	PROPN
finefocus-675	168	4	and	and	CCONJ
finefocus-675	168	5	sindbis	sindbis	PROPN
finefocus-675	168	6	virus	virus	NOUN
finefocus-675	168	7	,	,	PUNCT
finefocus-675	168	8	but	but	CCONJ
finefocus-675	168	9	not	not	PART
finefocus-675	168	10	vaccinia	vaccinia	NOUN
finefocus-675	168	11	virus	virus	NOUN
finefocus-675	168	12	,	,	PUNCT
finefocus-675	168	13	require	require	VERB
finefocus-675	168	14	glycolysis	glycolysis	NOUN
finefocus-675	168	15	for	for	ADP
finefocus-675	168	16	optimal	optimal	ADJ
finefocus-675	168	17	replication	replication	NOUN
finefocus-675	168	18	.	.	PUNCT
finefocus-675	169	1	j.	j.	PROPN
finefocus-675	169	2	gen	gen	PROPN
finefocus-675	169	3	.	.	PROPN
finefocus-675	169	4	virol	virol	PROPN
finefocus-675	169	5	96:2693–96	96:2693–96	NUM
finefocus-675	169	6	.	.	PUNCT
finefocus-675	170	1	7	7	X
finefocus-675	170	2	.	.	X
finefocus-675	170	3	frantz	frantz	PROPN
finefocus-675	170	4	m	m	PROPN
finefocus-675	170	5	-	-	PUNCT
finefocus-675	170	6	c	c	PROPN
finefocus-675	170	7	,	,	PUNCT
finefocus-675	170	8	wipf	wipf	VERB
finefocus-675	170	9	p.	p.	NOUN
finefocus-675	170	10	2010	2010	NUM
finefocus-675	170	11	.	.	PUNCT
finefocus-675	171	1	mitochondria	mitochondria	PROPN
finefocus-675	171	2	as	as	ADP
finefocus-675	171	3	a	a	DET
finefocus-675	171	4	target	target	NOUN
finefocus-675	171	5	in	in	ADP
finefocus-675	171	6	treatment	treatment	NOUN
finefocus-675	171	7	.	.	PUNCT
finefocus-675	172	1	environ	environ	PROPN
finefocus-675	172	2	.	.	PUNCT
finefocus-675	172	3	mol	mol	PROPN
finefocus-675	172	4	.	.	PUNCT
finefocus-675	173	1	mutagen	mutagen	PROPN
finefocus-675	173	2	51:462–75	51:462–75	PROPN
finefocus-675	173	3	.	.	PUNCT
finefocus-675	174	1	8	8	NUM
finefocus-675	174	2	.	.	PUNCT
finefocus-675	174	3	goodwin	goodwin	PROPN
finefocus-675	174	4	cm	cm	PROPN
finefocus-675	174	5	,	,	PUNCT
finefocus-675	174	6	xu	xu	PROPN
finefocus-675	174	7	s	s	PROPN
finefocus-675	174	8	,	,	PUNCT
finefocus-675	174	9	munger	munger	PROPN
finefocus-675	174	10	j.	j.	PROPN
finefocus-675	174	11	2015	2015	NUM
finefocus-675	174	12	.	.	PUNCT
finefocus-675	175	1	stealing	steal	VERB
finefocus-675	175	2	the	the	DET
finefocus-675	175	3	keys	key	NOUN
finefocus-675	175	4	to	to	ADP
finefocus-675	175	5	the	the	DET
finefocus-675	175	6	kitchen	kitchen	NOUN
finefocus-675	175	7	:	:	PUNCT
finefocus-675	175	8	viral	viral	ADJ
finefocus-675	175	9	manipulation	manipulation	NOUN
finefocus-675	175	10	of	of	ADP
finefocus-675	175	11	the	the	DET
finefocus-675	175	12	host	host	NOUN
finefocus-675	175	13	cell	cell	NOUN
finefocus-675	175	14	metabolic	metabolic	NOUN
finefocus-675	175	15	network	network	NOUN
finefocus-675	175	16	.	.	PUNCT
finefocus-675	176	1	trends	trend	NOUN
finefocus-675	176	2	microbiol	microbiol	PROPN
finefocus-675	176	3	23:789–98	23:789–98	NUM
finefocus-675	176	4	.	.	PUNCT
finefocus-675	177	1	9	9	X
finefocus-675	177	2	.	.	X
finefocus-675	177	3	gullberg	gullberg	PROPN
finefocus-675	177	4	rc	rc	PROPN
finefocus-675	177	5	,	,	PUNCT
finefocus-675	177	6	jordan	jordan	PROPN
finefocus-675	177	7	steel	steel	PROPN
finefocus-675	177	8	j	j	PROPN
finefocus-675	177	9	,	,	PUNCT
finefocus-675	177	10	moon	moon	PROPN
finefocus-675	177	11	sl	sl	PROPN
finefocus-675	177	12	,	,	PUNCT
finefocus-675	177	13	soltani	soltani	PROPN
finefocus-675	177	14	e	e	PROPN
finefocus-675	177	15	,	,	PUNCT
finefocus-675	177	16	geiss	geiss	ADJ
finefocus-675	177	17	bj	bj	NOUN
finefocus-675	177	18	.	.	PUNCT
finefocus-675	177	19	2014	2014	NUM
finefocus-675	177	20	.	.	PUNCT
finefocus-675	178	1	oxidative	oxidative	ADJ
finefocus-675	178	2	stress	stress	NOUN
finefocus-675	178	3	influences	influence	VERB
finefocus-675	178	4	positive	positive	ADJ
finefocus-675	178	5	strand	strand	NOUN
finefocus-675	178	6	rna	rna	NOUN
finefocus-675	178	7	virus	virus	NOUN
finefocus-675	178	8	genome	genome	NOUN
finefocus-675	178	9	synthesis	synthesis	NOUN
finefocus-675	178	10	and	and	CCONJ
finefocus-675	178	11	capping	capping	NOUN
finefocus-675	178	12	.	.	PUNCT
finefocus-675	179	1	virology	virology	NOUN
finefocus-675	179	2	475c:219	475c:219	PROPN
finefocus-675	179	3	–	–	PUNCT
finefocus-675	179	4	29	29	NUM
finefocus-675	179	5	.	.	X
finefocus-675	179	6	10	10	NUM
finefocus-675	179	7	.	.	PUNCT
finefocus-675	180	1	kantarjian	kantarjian	ADJ
finefocus-675	180	2	hm	hm	INTJ
finefocus-675	180	3	,	,	PUNCT
finefocus-675	180	4	talpaz	talpaz	PROPN
finefocus-675	180	5	m	m	PROPN
finefocus-675	180	6	,	,	PUNCT
finefocus-675	180	7	o’brien	o’brien	PROPN
finefocus-675	180	8	s	s	PART
finefocus-675	180	9	,	,	PUNCT
finefocus-675	180	10	jones	jones	PROPN
finefocus-675	180	11	d	d	PROPN
finefocus-675	180	12	,	,	PUNCT
finefocus-675	180	13	giles	giles	PROPN
finefocus-675	180	14	f	f	PROPN
finefocus-675	180	15	,	,	PUNCT
finefocus-675	180	16	et	et	PROPN
finefocus-675	180	17	al	al	PROPN
finefocus-675	180	18	.	.	PROPN
finefocus-675	180	19	2006	2006	NUM
finefocus-675	180	20	.	.	PUNCT
finefocus-675	181	1	survival	survival	NOUN
finefocus-675	181	2	benefit	benefit	VERB
finefocus-675	181	3	with	with	ADP
finefocus-675	181	4	imatinib	imatinib	NOUN
finefocus-675	181	5	mesylate	mesylate	NOUN
finefocus-675	181	6	versus	versus	ADP
finefocus-675	181	7	interferon	interferon	ADJ
finefocus-675	181	8	-	-	PUNCT
finefocus-675	181	9	α	α	NOUN
finefocus-675	181	10	–	–	PUNCT
finefocus-675	181	11	based	base	VERB
finefocus-675	181	12	regimens	regimen	NOUN
finefocus-675	181	13	in	in	ADP
finefocus-675	181	14	newly	newly	ADV
finefocus-675	181	15	diagnosed	diagnose	VERB
finefocus-675	181	16	chronic	chronic	ADJ
finefocus-675	181	17	-	-	PUNCT
finefocus-675	181	18	phase	phase	NOUN
finefocus-675	181	19	chronic	chronic	ADJ
finefocus-675	181	20	myelogenous	myelogenous	ADJ
finefocus-675	181	21	leukemia	leukemia	NOUN
finefocus-675	181	22	.	.	PUNCT
finefocus-675	182	1	blood	blood	NOUN
finefocus-675	182	2	108	108	NUM
finefocus-675	182	3	:	:	PUNCT
finefocus-675	182	4	11	11	NUM
finefocus-675	182	5	.	.	PUNCT
finefocus-675	183	1	luis	luis	PROPN
finefocus-675	183	2	m	m	PROPN
finefocus-675	183	3	,	,	PUNCT
finefocus-675	183	4	de	de	PROPN
finefocus-675	183	5	figueiredo	figueiredo	PROPN
finefocus-675	183	6	g.	g.	PROPN
finefocus-675	183	7	2014	2014	NUM
finefocus-675	183	8	.	.	PUNCT
finefocus-675	184	1	emerging	emerge	VERB
finefocus-675	184	2	alphaviruses	alphavirus	NOUN
finefocus-675	184	3	in	in	ADP
finefocus-675	184	4	the	the	DET
finefocus-675	184	5	americas	america	NOUN
finefocus-675	184	6	:	:	PUNCT
finefocus-675	184	7	chikungunya	chikungunya	ADJ
finefocus-675	184	8	and	and	CCONJ
finefocus-675	184	9	mayaro	mayaro	NOUN
finefocus-675	184	10	.	.	PUNCT
finefocus-675	185	1	rev	rev	PROPN
finefocus-675	185	2	.	.	PROPN
finefocus-675	185	3	soc	soc	PROPN
finefocus-675	185	4	.	.	PUNCT
finefocus-675	186	1	bras	bras	PROPN
finefocus-675	186	2	.	.	PUNCT
finefocus-675	187	1	med	med	PROPN
finefocus-675	187	2	.	.	PUNCT
finefocus-675	188	1	trop	trop	PROPN
finefocus-675	188	2	47:677–83	47:677–83	PROPN
finefocus-675	188	3	.	.	PUNCT
finefocus-675	189	1	12	12	NUM
finefocus-675	189	2	.	.	PUNCT
finefocus-675	190	1	marcelin	marcelin	PROPN
finefocus-675	190	2	jr	jr	PROPN
finefocus-675	190	3	,	,	PUNCT
finefocus-675	190	4	wilson	wilson	PROPN
finefocus-675	190	5	jw	jw	PROPN
finefocus-675	190	6	,	,	PUNCT
finefocus-675	190	7	razonable	razonable	ADJ
finefocus-675	190	8	rr	rr	PROPN
finefocus-675	190	9	,	,	PUNCT
finefocus-675	190	10	mayo	mayo	NOUN
finefocus-675	190	11	clinic	clinic	PROPN
finefocus-675	190	12	hematology	hematology	NOUN
finefocus-675	190	13	/	/	SYM
finefocus-675	190	14	oncology	oncology	NOUN
finefocus-675	190	15	and	and	CCONJ
finefocus-675	190	16	transplant	transplant	NOUN
finefocus-675	190	17	infectious	infectious	ADJ
finefocus-675	190	18	diseases	disease	NOUN
finefocus-675	190	19	services	service	NOUN
finefocus-675	190	20	.	.	PUNCT
finefocus-675	191	1	2014	2014	NUM
finefocus-675	191	2	.	.	PUNCT
finefocus-675	192	1	oral	oral	ADJ
finefocus-675	192	2	ribavirin	ribavirin	NOUN
finefocus-675	192	3	therapy	therapy	NOUN
finefocus-675	192	4	for	for	ADP
finefocus-675	192	5	respiratory	respiratory	ADJ
finefocus-675	192	6	syncytial	syncytial	ADJ
finefocus-675	192	7	virus	virus	NOUN
finefocus-675	192	8	infections	infection	NOUN
finefocus-675	192	9	in	in	ADP
finefocus-675	192	10	moderately	moderately	ADV
finefocus-675	192	11	to	to	PART
finefocus-675	192	12	severely	severely	ADV
finefocus-675	192	13	immunocompromised	immunocompromise	VERB
finefocus-675	192	14	patients	patient	NOUN
finefocus-675	192	15	.	.	PUNCT
finefocus-675	193	1	transpl	transpl	NOUN
finefocus-675	193	2	.	.	PUNCT
finefocus-675	194	1	infect	infect	VERB
finefocus-675	194	2	.	.	PUNCT
finefocus-675	195	1	dis	dis	PROPN
finefocus-675	195	2	16:242	16:242	NUM
finefocus-675	195	3	–	–	PUNCT
finefocus-675	195	4	50	50	NUM
finefocus-675	195	5	.	.	NOUN
finefocus-675	195	6	13	13	NUM
finefocus-675	195	7	.	.	PUNCT
finefocus-675	195	8	markland	markland	PROPN
finefocus-675	195	9	w	w	PROPN
finefocus-675	195	10	,	,	PUNCT
finefocus-675	195	11	mcquaid	mcquaid	PROPN
finefocus-675	195	12	tj	tj	PROPN
finefocus-675	195	13	,	,	PUNCT
finefocus-675	195	14	jain	jain	PROPN
finefocus-675	195	15	j	j	PROPN
finefocus-675	195	16	,	,	PUNCT
finefocus-675	195	17	kwong	kwong	PROPN
finefocus-675	195	18	ad	ad	NOUN
finefocus-675	195	19	.	.	PUNCT
finefocus-675	196	1	2000	2000	NUM
finefocus-675	196	2	.	.	PUNCT
finefocus-675	197	1	broad	broad	ADJ
finefocus-675	197	2	-	-	PUNCT
finefocus-675	197	3	spectrum	spectrum	NOUN
finefocus-675	197	4	antiviral	antiviral	ADJ
finefocus-675	197	5	activity	activity	NOUN
finefocus-675	197	6	of	of	ADP
finefocus-675	197	7	the	the	DET
finefocus-675	197	8	imp	imp	NOUN
finefocus-675	197	9	dehydrogenase	dehydrogenase	NOUN
finefocus-675	197	10	inhibitor	inhibitor	NOUN
finefocus-675	197	11	vx-497	vx-497	PROPN
finefocus-675	197	12	:	:	PUNCT
finefocus-675	197	13	a	a	DET
finefocus-675	197	14	comparison	comparison	NOUN
finefocus-675	197	15	with	with	ADP
finefocus-675	197	16	ribavirin	ribavirin	NOUN
finefocus-675	197	17	and	and	CCONJ
finefocus-675	197	18	demonstration	demonstration	NOUN
finefocus-675	197	19	of	of	ADP
finefocus-675	197	20	antiviral	antiviral	ADJ
finefocus-675	197	21	additivity	additivity	NOUN
finefocus-675	197	22	with	with	ADP
finefocus-675	197	23	alpha	alpha	PROPN
finefocus-675	197	24	interferon	interferon	PROPN
finefocus-675	197	25	.	.	PUNCT
finefocus-675	198	1	antimicrob	antimicrob	PROPN
finefocus-675	198	2	.	.	PUNCT
finefocus-675	199	1	agents	agent	NOUN
finefocus-675	199	2	chemother	chemother	PROPN
finefocus-675	199	3	44:859	44:859	PROPN
finefocus-675	199	4	–	–	PUNCT
finefocus-675	199	5	66	66	NUM
finefocus-675	199	6	.	.	PUNCT
finefocus-675	199	7	14	14	NUM
finefocus-675	199	8	.	.	PUNCT
finefocus-675	200	1	michelakis	michelaki	NOUN
finefocus-675	200	2	ed	ed	PROPN
finefocus-675	200	3	,	,	PUNCT
finefocus-675	200	4	webster	webster	PROPN
finefocus-675	200	5	l	l	PROPN
finefocus-675	200	6	,	,	PUNCT
finefocus-675	200	7	mackey	mackey	PROPN
finefocus-675	200	8	jr	jr	PROPN
finefocus-675	200	9	.	.	PROPN
finefocus-675	200	10	2008	2008	NUM
finefocus-675	200	11	.	.	PUNCT
finefocus-675	201	1	dichloroacetate	dichloroacetate	PROPN
finefocus-675	201	2	(	(	PUNCT
finefocus-675	201	3	dca	dca	PROPN
finefocus-675	201	4	)	)	PUNCT
finefocus-675	201	5	as	as	ADP
finefocus-675	201	6	a	a	DET
finefocus-675	201	7	potential	potential	ADJ
finefocus-675	201	8	metabolic	metabolic	NOUN
finefocus-675	201	9	-	-	PUNCT
finefocus-675	201	10	targeting	target	VERB
finefocus-675	201	11	therapy	therapy	NOUN
finefocus-675	201	12	for	for	ADP
finefocus-675	201	13	cancer	cancer	NOUN
finefocus-675	201	14	.	.	PUNCT
finefocus-675	202	1	br	br	PROPN
finefocus-675	202	2	.	.	PUNCT
finefocus-675	203	1	j.	j.	PROPN
finefocus-675	203	2	cancer	cancer	PROPN
finefocus-675	203	3	99:989–94	99:989–94	PROPN
finefocus-675	203	4	.	.	PUNCT
finefocus-675	204	1	15	15	NUM
finefocus-675	204	2	.	.	PUNCT
finefocus-675	204	3	mota	mota	PROPN
finefocus-675	204	4	mt	mt	PROPN
finefocus-675	204	5	de	de	PROPN
finefocus-675	204	6	o	o	PROPN
finefocus-675	204	7	,	,	PUNCT
finefocus-675	204	8	terzian	terzian	PROPN
finefocus-675	204	9	ac	ac	PROPN
finefocus-675	204	10	,	,	PUNCT
finefocus-675	204	11	silva	silva	PROPN
finefocus-675	204	12	mlcr	mlcr	PROPN
finefocus-675	204	13	,	,	PUNCT
finefocus-675	204	14	estofolete	estofolete	ADJ
finefocus-675	204	15	c	c	NOUN
finefocus-675	204	16	,	,	PUNCT
finefocus-675	204	17	nogueira	nogueira	PROPN
finefocus-675	204	18	ml	ml	NOUN
finefocus-675	204	19	.	.	PROPN
finefocus-675	204	20	2016	2016	NUM
finefocus-675	204	21	.	.	PUNCT
finefocus-675	205	1	mosquito	mosquito	NOUN
finefocus-675	205	2	-	-	PUNCT
finefocus-675	205	3	transmitted	transmit	VERB
finefocus-675	205	4	viruses	virus	NOUN
finefocus-675	205	5	the	the	DET
finefocus-675	205	6	great	great	ADJ
finefocus-675	205	7	brazilian	brazilian	ADJ
finefocus-675	205	8	challenge	challenge	NOUN
finefocus-675	205	9	.	.	PUNCT
finefocus-675	206	1	braz	braz	PROPN
finefocus-675	206	2	.	.	PUNCT
finefocus-675	207	1	j.	j.	PROPN
finefocus-675	207	2	microbiol	microbiol	PROPN
finefocus-675	207	3	47	47	NUM
finefocus-675	207	4	suppl	suppl	ADJ
finefocus-675	207	5	1:38–50	1:38–50	NOUN
finefocus-675	207	6	.	.	PUNCT
finefocus-675	208	1	16	16	NUM
finefocus-675	208	2	.	.	PUNCT
finefocus-675	209	1	olavarria	olavarria	PROPN
finefocus-675	209	2	e	e	NOUN
finefocus-675	209	3	,	,	PUNCT
finefocus-675	209	4	craddock	craddock	PROPN
finefocus-675	209	5	c	c	NOUN
finefocus-675	209	6	,	,	PUNCT
finefocus-675	209	7	dazzi	dazzi	PROPN
finefocus-675	209	8	f	f	PROPN
finefocus-675	209	9	,	,	PUNCT
finefocus-675	209	10	marin	marin	NOUN
finefocus-675	209	11	d	d	NOUN
finefocus-675	209	12	,	,	PUNCT
finefocus-675	209	13	marktel	marktel	NOUN
finefocus-675	209	14	s	s	PROPN
finefocus-675	209	15	,	,	PUNCT
finefocus-675	209	16	et	et	PROPN
finefocus-675	209	17	al	al	PROPN
finefocus-675	209	18	.	.	PROPN
finefocus-675	209	19	2002	2002	NUM
finefocus-675	209	20	.	.	PUNCT
finefocus-675	210	1	imatinib	imatinib	NOUN
finefocus-675	210	2	mesylate	mesylate	NOUN
finefocus-675	210	3	(	(	PUNCT
finefocus-675	210	4	sti571	sti571	PROPN
finefocus-675	210	5	)	)	PUNCT
finefocus-675	210	6	in	in	ADP
finefocus-675	210	7	the	the	DET
finefocus-675	210	8	treatment	treatment	NOUN
finefocus-675	210	9	of	of	ADP
finefocus-675	210	10	relapse	relapse	NOUN
finefocus-675	210	11	of	of	ADP
finefocus-675	210	12	chronic	chronic	ADJ
finefocus-675	210	13	myeloid	myeloid	NOUN
finefocus-675	210	14	leukemia	leukemia	NOUN
finefocus-675	210	15	after	after	ADP
finefocus-675	210	16	allogeneic	allogeneic	ADJ
finefocus-675	210	17	stem	stem	NOUN
finefocus-675	210	18	cell	cell	NOUN
finefocus-675	210	19	transplantation	transplantation	NOUN
finefocus-675	210	20	.	.	PUNCT
finefocus-675	211	1	blood	blood	NOUN
finefocus-675	211	2	99	99	NUM
finefocus-675	211	3	:	:	SYM
finefocus-675	211	4	17	17	NUM
finefocus-675	211	5	.	.	PUNCT
finefocus-675	212	1	oliveira	oliveira	PROPN
finefocus-675	212	2	afc	afc	PROPN
finefocus-675	212	3	da	da	PROPN
finefocus-675	212	4	s	s	PROPN
finefocus-675	212	5	,	,	PUNCT
finefocus-675	212	6	teixeira	teixeira	PROPN
finefocus-675	212	7	rr	rr	PROPN
finefocus-675	212	8	,	,	PUNCT
finefocus-675	212	9	oliveira	oliveira	PROPN
finefocus-675	212	10	as	as	ADP
finefocus-675	212	11	de	de	PROPN
finefocus-675	212	12	,	,	PUNCT
finefocus-675	212	13	souza	souza	PROPN
finefocus-675	212	14	apm	apm	PROPN
finefocus-675	212	15	de	de	PROPN
finefocus-675	212	16	,	,	PUNCT
finefocus-675	212	17	silva	silva	PROPN
finefocus-675	212	18	ml	ml	NOUN
finefocus-675	212	19	da	da	PROPN
finefocus-675	212	20	,	,	PUNCT
finefocus-675	212	21	paula	paula	PROPN
finefocus-675	212	22	so	so	ADV
finefocus-675	212	23	de	de	PROPN
finefocus-675	212	24	.	.	PROPN
finefocus-675	212	25	2017	2017	NUM
finefocus-675	212	26	.	.	PUNCT
finefocus-675	213	1	potential	potential	ADJ
finefocus-675	213	2	antivirals	antiviral	NOUN
finefocus-675	213	3	:	:	PUNCT
finefocus-675	213	4	natural	natural	ADJ
finefocus-675	213	5	products	product	NOUN
finefocus-675	213	6	targeting	target	VERB
finefocus-675	213	7	replication	replication	NOUN
finefocus-675	213	8	enzymes	enzyme	NOUN
finefocus-675	213	9	of	of	ADP
finefocus-675	213	10	dengue	dengue	NOUN
finefocus-675	213	11	and	and	CCONJ
finefocus-675	213	12	chikungunya	chikungunya	NOUN
finefocus-675	213	13	viruses	virus	NOUN
finefocus-675	213	14	.	.	PUNCT
finefocus-675	214	1	molecules	molecule	NOUN
finefocus-675	214	2	22:505	22:505	NUM
finefocus-675	214	3	.	.	PUNCT
finefocus-675	215	1	this	this	DET
finefocus-675	215	2	work	work	NOUN
finefocus-675	215	3	was	be	AUX
finefocus-675	215	4	partially	partially	ADV
finefocus-675	215	5	funded	fund	VERB
finefocus-675	215	6	by	by	ADP
finefocus-675	215	7	a	a	DET
finefocus-675	215	8	seed	seed	NOUN
finefocus-675	215	9	grant	grant	NOUN
finefocus-675	215	10	from	from	ADP
finefocus-675	215	11	colorado	colorado	PROPN
finefocus-675	215	12	state	state	PROPN
finefocus-675	215	13	university	university	NOUN
finefocus-675	215	14	-	-	PUNCT
finefocus-675	215	15	pueblo	pueblo	PROPN
finefocus-675	215	16	awarded	award	VERB
finefocus-675	215	17	to	to	ADP
finefocus-675	215	18	j.	j.	PROPN
finefocus-675	215	19	jordan	jordan	PROPN
finefocus-675	215	20	steel	steel	PROPN
finefocus-675	215	21	and	and	CCONJ
finefocus-675	215	22	csu	csu	PROPN
finefocus-675	215	23	-	-	PUNCT
finefocus-675	215	24	pueblo	pueblo	PROPN
finefocus-675	215	25	’s	’s	PART
finefocus-675	215	26	c	c	NOUN
finefocus-675	215	27	-	-	PUNCT
finefocus-675	215	28	base	base	NOUN
finefocus-675	215	29	(	(	PUNCT
finefocus-675	215	30	communities	community	NOUN
finefocus-675	215	31	to	to	PART
finefocus-675	215	32	build	build	VERB
finefocus-675	215	33	active	active	ADJ
finefocus-675	215	34	stem	stem	NOUN
finefocus-675	215	35	engagement	engagement	NOUN
finefocus-675	215	36	)	)	PUNCT
finefocus-675	215	37	grant	grant	NOUN
finefocus-675	215	38	from	from	ADP
finefocus-675	215	39	the	the	DET
finefocus-675	215	40	us	us	PROPN
finefocus-675	215	41	department	department	PROPN
finefocus-675	215	42	of	of	ADP
finefocus-675	215	43	education	education	PROPN
finefocus-675	215	44	(	(	PUNCT
finefocus-675	215	45	pr	pr	NOUN
finefocus-675	215	46	/	/	SYM
finefocus-675	215	47	award	award	NOUN
finefocus-675	215	48	#	#	NOUN
finefocus-675	215	49	p031c160025	p031c160025	NOUN
finefocus-675	215	50	)	)	PUNCT
finefocus-675	215	51	.	.	PUNCT
finefocus-675	216	1	additional	additional	ADJ
finefocus-675	216	2	financial	financial	ADJ
finefocus-675	216	3	support	support	NOUN
finefocus-675	216	4	was	be	AUX
finefocus-675	216	5	received	receive	VERB
finefocus-675	216	6	from	from	ADP
finefocus-675	216	7	the	the	DET
finefocus-675	216	8	american	american	ADJ
finefocus-675	216	9	society	society	NOUN
finefocus-675	216	10	for	for	ADP
finefocus-675	216	11	microbiology	microbiology	NOUN
finefocus-675	216	12	undergraduate	undergraduate	NOUN
finefocus-675	216	13	research	research	NOUN
finefocus-675	216	14	fellowship	fellowship	NOUN
finefocus-675	216	15	awarded	award	VERB
finefocus-675	216	16	to	to	ADP
finefocus-675	216	17	jessica	jessica	PROPN
finefocus-675	216	18	l.	l.	PROPN
finefocus-675	216	19	costlow	costlow	PROPN
finefocus-675	216	20	.	.	PUNCT
finefocus-675	217	1	we	we	PRON
finefocus-675	217	2	would	would	AUX
finefocus-675	217	3	like	like	VERB
finefocus-675	217	4	to	to	PART
finefocus-675	217	5	thank	thank	VERB
finefocus-675	217	6	dr	dr	PROPN
finefocus-675	217	7	.	.	PROPN
finefocus-675	217	8	jeff	jeff	PROPN
finefocus-675	217	9	smith	smith	PROPN
finefocus-675	217	10	for	for	ADP
finefocus-675	217	11	providing	provide	VERB
finefocus-675	217	12	the	the	DET
finefocus-675	217	13	hek	hek	PROPN
finefocus-675	217	14	cells	cell	NOUN
finefocus-675	217	15	,	,	PUNCT
finefocus-675	217	16	dr	dr	PROPN
finefocus-675	217	17	.	.	PROPN
finefocus-675	217	18	rushika	rushika	PROPN
finefocus-675	217	19	perera	perera	PROPN
finefocus-675	217	20	for	for	ADP
finefocus-675	217	21	providing	provide	VERB
finefocus-675	217	22	the	the	DET
finefocus-675	217	23	huh7	huh7	NOUN
finefocus-675	217	24	and	and	CCONJ
finefocus-675	217	25	bhk	bhk	PROPN
finefocus-675	217	26	cells	cell	NOUN
finefocus-675	217	27	and	and	CCONJ
finefocus-675	217	28	dr	dr	PROPN
finefocus-675	217	29	.	.	PROPN
finefocus-675	217	30	brian	brian	PROPN
finefocus-675	217	31	geiss	geiss	PROPN
finefocus-675	217	32	for	for	ADP
finefocus-675	217	33	providing	provide	VERB
finefocus-675	217	34	the	the	DET
finefocus-675	217	35	virus	virus	NOUN
finefocus-675	217	36	stocks	stock	NOUN
finefocus-675	217	37	used	use	VERB
finefocus-675	217	38	in	in	ADP
finefocus-675	217	39	this	this	DET
finefocus-675	217	40	study	study	NOUN
finefocus-675	217	41	.	.	PUNCT
finefocus-675	218	1	acknowledgements	acknowledgement	NOUN
finefocus-675	218	2	references	reference	NOUN
finefocus-675	218	3	to	to	PART
finefocus-675	218	4	validate	validate	VERB
finefocus-675	218	5	and	and	CCONJ
finefocus-675	218	6	confirm	confirm	VERB
finefocus-675	218	7	these	these	DET
finefocus-675	218	8	findings	finding	NOUN
finefocus-675	218	9	with	with	ADP
finefocus-675	218	10	imatinib	imatinib	NOUN
finefocus-675	218	11	in	in	ADP
finefocus-675	218	12	model	model	NOUN
finefocus-675	218	13	organisms	organism	NOUN
finefocus-675	218	14	and	and	CCONJ
finefocus-675	218	15	in	in	ADP
finefocus-675	218	16	primary	primary	ADJ
finefocus-675	218	17	cells	cell	NOUN
finefocus-675	218	18	.	.	PUNCT
finefocus-675	219	1	additionally	additionally	ADV
finefocus-675	219	2	,	,	PUNCT
finefocus-675	219	3	there	there	PRON
finefocus-675	219	4	are	be	VERB
finefocus-675	219	5	many	many	ADJ
finefocus-675	219	6	other	other	ADJ
finefocus-675	219	7	fda	fda	PROPN
finefocus-675	219	8	-	-	PUNCT
finefocus-675	219	9	approved	approve	VERB
finefocus-675	219	10	cancer	cancer	NOUN
finefocus-675	219	11	drugs	drug	NOUN
finefocus-675	219	12	that	that	PRON
finefocus-675	219	13	specifically	specifically	ADV
finefocus-675	219	14	target	target	VERB
finefocus-675	219	15	and	and	CCONJ
finefocus-675	219	16	slow	slow	ADJ
finefocus-675	219	17	cellular	cellular	ADJ
finefocus-675	219	18	metabolism(7	metabolism(7	NOUN
finefocus-675	219	19	,	,	PUNCT
finefocus-675	219	20	14	14	NUM
finefocus-675	219	21	,	,	PUNCT
finefocus-675	219	22	25	25	NUM
finefocus-675	219	23	,	,	PUNCT
finefocus-675	219	24	27	27	NUM
finefocus-675	219	25	)	)	PUNCT
finefocus-675	219	26	.	.	PUNCT
finefocus-675	220	1	further	further	ADJ
finefocus-675	220	2	work	work	NOUN
finefocus-675	220	3	will	will	AUX
finefocus-675	220	4	be	be	AUX
finefocus-675	220	5	performed	perform	VERB
finefocus-675	220	6	to	to	PART
finefocus-675	220	7	screen	screen	VERB
finefocus-675	220	8	other	other	ADJ
finefocus-675	220	9	metabolic	metabolic	NOUN
finefocus-675	220	10	inhibitor	inhibitor	NOUN
finefocus-675	220	11	compounds	compound	NOUN
finefocus-675	220	12	as	as	ADP
finefocus-675	220	13	effective	effective	ADJ
finefocus-675	220	14	antivirals	antiviral	NOUN
finefocus-675	220	15	.	.	PUNCT
finefocus-675	221	1	by	by	ADP
finefocus-675	221	2	studying	study	VERB
finefocus-675	221	3	clinically	clinically	ADV
finefocus-675	221	4	used	use	VERB
finefocus-675	221	5	and	and	CCONJ
finefocus-675	221	6	already	already	ADV
finefocus-675	221	7	approved	approve	VERB
finefocus-675	221	8	compounds	compound	NOUN
finefocus-675	221	9	,	,	PUNCT
finefocus-675	221	10	it	it	PRON
finefocus-675	221	11	may	may	AUX
finefocus-675	221	12	be	be	AUX
finefocus-675	221	13	possible	possible	ADJ
finefocus-675	221	14	to	to	PART
finefocus-675	221	15	discover	discover	VERB
finefocus-675	221	16	a	a	DET
finefocus-675	221	17	novel	novel	ADJ
finefocus-675	221	18	antiviral	antiviral	ADJ
finefocus-675	221	19	treatment	treatment	NOUN
finefocus-675	221	20	option	option	NOUN
finefocus-675	221	21	that	that	PRON
finefocus-675	221	22	can	can	AUX
finefocus-675	221	23	rapidly	rapidly	ADV
finefocus-675	221	24	be	be	AUX
finefocus-675	221	25	used	use	VERB
finefocus-675	221	26	to	to	PART
finefocus-675	221	27	treat	treat	VERB
finefocus-675	221	28	and	and	CCONJ
finefocus-675	221	29	bring	bring	VERB
finefocus-675	221	30	aid	aid	NOUN
finefocus-675	221	31	to	to	ADP
finefocus-675	221	32	the	the	DET
finefocus-675	221	33	millions	million	NOUN
finefocus-675	221	34	of	of	ADP
finefocus-675	221	35	alphavirus	alphavirus	NOUN
finefocus-675	221	36	infections	infection	NOUN
finefocus-675	221	37	that	that	PRON
finefocus-675	221	38	are	be	AUX
finefocus-675	221	39	occurring	occur	VERB
finefocus-675	221	40	globally	globally	ADV
finefocus-675	221	41	.	.	PUNCT
finefocus-675	222	1	imatinib	imatinib	NOUN
finefocus-675	222	2	mesylate	mesylate	VERB
finefocus-675	222	3	•	•	ADV
finefocus-675	222	4	151	151	NUM
finefocus-675	222	5	150	150	NUM
finefocus-675	222	6	•	•	NUM
finefocus-675	222	7	fine	fine	ADJ
finefocus-675	222	8	focus	focus	NOUN
finefocus-675	222	9	,	,	PUNCT
finefocus-675	222	10	vol	vol	NOUN
finefocus-675	222	11	.	.	NOUN
finefocus-675	222	12	3	3	NUM
finefocus-675	222	13	(	(	PUNCT
finefocus-675	222	14	2	2	NUM
finefocus-675	222	15	)	)	PUNCT
finefocus-675	222	16	18	18	NUM
finefocus-675	222	17	.	.	PUNCT
finefocus-675	223	1	samei	samei	PROPN
finefocus-675	223	2	l	l	PROPN
finefocus-675	223	3	,	,	PUNCT
finefocus-675	223	4	yaling	yale	VERB
finefocus-675	223	5	p	p	NOUN
finefocus-675	223	6	,	,	PUNCT
finefocus-675	223	7	lihua	lihua	PROPN
finefocus-675	223	8	y	y	PROPN
finefocus-675	223	9	,	,	PUNCT
finefocus-675	223	10	yan	yan	PROPN
finefocus-675	224	1	z	z	X
finefocus-675	224	2	,	,	PUNCT
finefocus-675	224	3	shuyan	shuyan	PROPN
finefocus-675	224	4	j.	j.	PROPN
finefocus-675	224	5	2016	2016	NUM
finefocus-675	224	6	.	.	PUNCT
finefocus-675	225	1	effects	effect	NOUN
finefocus-675	225	2	and	and	CCONJ
finefocus-675	225	3	mechanism	mechanism	NOUN
finefocus-675	225	4	of	of	ADP
finefocus-675	225	5	imatinib	imatinib	NOUN
finefocus-675	225	6	in	in	ADP
finefocus-675	225	7	inhibiting	inhibit	VERB
finefocus-675	225	8	colon	colon	NOUN
finefocus-675	225	9	cancer	cancer	NOUN
finefocus-675	225	10	cell	cell	NOUN
finefocus-675	225	11	proliferation	proliferation	NOUN
finefocus-675	225	12	.	.	PUNCT
finefocus-675	226	1	med	med	PROPN
finefocus-675	226	2	.	.	PUNCT
finefocus-675	227	1	sci	sci	PROPN
finefocus-675	227	2	.	.	PUNCT
finefocus-675	227	3	monit	monit	PROPN
finefocus-675	227	4	22:4126–31	22:4126–31	PROPN
finefocus-675	227	5	.	.	PROPN
finefocus-675	228	1	19	19	NUM
finefocus-675	228	2	.	.	X
finefocus-675	228	3	sanchez	sanchez	PROPN
finefocus-675	228	4	el	el	PROPN
finefocus-675	228	5	,	,	PUNCT
finefocus-675	228	6	lagunoff	lagunoff	PROPN
finefocus-675	228	7	m.	m.	PROPN
finefocus-675	228	8	2015	2015	NUM
finefocus-675	228	9	.	.	PUNCT
finefocus-675	229	1	viral	viral	ADJ
finefocus-675	229	2	activation	activation	NOUN
finefocus-675	229	3	of	of	ADP
finefocus-675	229	4	cellular	cellular	ADJ
finefocus-675	229	5	metabolism	metabolism	NOUN
finefocus-675	229	6	.	.	PUNCT
finefocus-675	230	1	virology	virology	NOUN
finefocus-675	230	2	20	20	NUM
finefocus-675	230	3	.	.	PUNCT
finefocus-675	231	1	scheidel	scheidel	PROPN
finefocus-675	231	2	lm	lm	PROPN
finefocus-675	231	3	,	,	PUNCT
finefocus-675	231	4	stollar	stollar	NOUN
finefocus-675	231	5	v.	v.	ADP
finefocus-675	231	6	1991	1991	NUM
finefocus-675	231	7	.	.	PUNCT
finefocus-675	232	1	mutations	mutation	NOUN
finefocus-675	232	2	that	that	PRON
finefocus-675	232	3	confer	confer	VERB
finefocus-675	232	4	resistance	resistance	NOUN
finefocus-675	232	5	to	to	ADP
finefocus-675	232	6	mycophenolic	mycophenolic	ADJ
finefocus-675	232	7	acid	acid	NOUN
finefocus-675	232	8	and	and	CCONJ
finefocus-675	232	9	ribavirin	ribavirin	NOUN
finefocus-675	232	10	on	on	ADP
finefocus-675	232	11	sindbis	sindbis	PROPN
finefocus-675	232	12	virus	virus	NOUN
finefocus-675	232	13	map	map	NOUN
finefocus-675	232	14	to	to	ADP
finefocus-675	232	15	the	the	DET
finefocus-675	232	16	nonstructural	nonstructural	ADJ
finefocus-675	232	17	protein	protein	NOUN
finefocus-675	232	18	nsp1	nsp1	NOUN
finefocus-675	232	19	.	.	PUNCT
finefocus-675	233	1	virology	virology	NOUN
finefocus-675	233	2	181:490–99	181:490–99	NUM
finefocus-675	233	3	.	.	PUNCT
finefocus-675	234	1	21	21	NUM
finefocus-675	234	2	.	.	PUNCT
finefocus-675	234	3	steel	steel	PROPN
finefocus-675	234	4	jj	jj	PROPN
finefocus-675	234	5	,	,	PUNCT
finefocus-675	234	6	henderson	henderson	PROPN
finefocus-675	234	7	br	br	PROPN
finefocus-675	234	8	,	,	PUNCT
finefocus-675	234	9	lama	lama	PROPN
finefocus-675	234	10	sb	sb	PROPN
finefocus-675	234	11	,	,	PUNCT
finefocus-675	234	12	olson	olson	PROPN
finefocus-675	234	13	ke	ke	PROPN
finefocus-675	234	14	,	,	PUNCT
finefocus-675	234	15	geiss	geiss	ADJ
finefocus-675	234	16	bj	bj	NOUN
finefocus-675	234	17	.	.	PUNCT
finefocus-675	234	18	2011	2011	NUM
finefocus-675	234	19	.	.	PUNCT
finefocus-675	235	1	infectious	infectious	ADJ
finefocus-675	235	2	alphavirus	alphavirus	NOUN
finefocus-675	235	3	production	production	NOUN
finefocus-675	235	4	from	from	ADP
finefocus-675	235	5	a	a	DET
finefocus-675	235	6	simple	simple	ADJ
finefocus-675	235	7	plasmid	plasmid	ADJ
finefocus-675	235	8	transfection+	transfection+	NOUN
finefocus-675	235	9	.	.	PUNCT
finefocus-675	236	1	virol	virol	PROPN
finefocus-675	236	2	j.	j.	PROPN
finefocus-675	236	3	8:356	8:356	PROPN
finefocus-675	236	4	.	.	PUNCT
finefocus-675	237	1	22	22	NUM
finefocus-675	237	2	.	.	PUNCT
finefocus-675	238	1	strauss	strauss	PROPN
finefocus-675	238	2	jh	jh	PROPN
finefocus-675	238	3	,	,	PUNCT
finefocus-675	238	4	strauss	strauss	PROPN
finefocus-675	238	5	eg	eg	PROPN
finefocus-675	238	6	.	.	PROPN
finefocus-675	238	7	1994	1994	NUM
finefocus-675	238	8	.	.	PUNCT
finefocus-675	239	1	the	the	DET
finefocus-675	239	2	alphaviruses	alphavirus	NOUN
finefocus-675	239	3	:	:	PUNCT
finefocus-675	239	4	gene	gene	NOUN
finefocus-675	239	5	expression	expression	NOUN
finefocus-675	239	6	,	,	PUNCT
finefocus-675	239	7	replication	replication	NOUN
finefocus-675	239	8	,	,	PUNCT
finefocus-675	239	9	and	and	CCONJ
finefocus-675	239	10	evolution	evolution	NOUN
finefocus-675	239	11	.	.	PUNCT
finefocus-675	240	1	microbiol	microbiol	PROPN
finefocus-675	240	2	.	.	PUNCT
finefocus-675	241	1	rev	rev	PROPN
finefocus-675	241	2	58:491–562	58:491–562	NUM
finefocus-675	241	3	.	.	PUNCT
finefocus-675	242	1	23	23	NUM
finefocus-675	242	2	.	.	PUNCT
finefocus-675	243	1	sun	sun	PROPN
finefocus-675	243	2	c	c	PROPN
finefocus-675	243	3	,	,	PUNCT
finefocus-675	243	4	gardner	gardner	NOUN
finefocus-675	243	5	cl	cl	PROPN
finefocus-675	243	6	,	,	PUNCT
finefocus-675	243	7	watson	watson	PROPN
finefocus-675	243	8	am	am	PROPN
finefocus-675	243	9	,	,	PUNCT
finefocus-675	243	10	ryman	ryman	PROPN
finefocus-675	243	11	kd	kd	PROPN
finefocus-675	243	12	,	,	PUNCT
finefocus-675	243	13	klimstra	klimstra	PROPN
finefocus-675	243	14	wb	wb	PROPN
finefocus-675	243	15	.	.	PROPN
finefocus-675	243	16	2014	2014	NUM
finefocus-675	243	17	.	.	PUNCT
finefocus-675	244	1	stable	stable	ADJ
finefocus-675	244	2	,	,	PUNCT
finefocus-675	244	3	high	high	ADJ
finefocus-675	244	4	-	-	PUNCT
finefocus-675	244	5	level	level	NOUN
finefocus-675	244	6	expression	expression	NOUN
finefocus-675	244	7	of	of	ADP
finefocus-675	244	8	reporter	reporter	NOUN
finefocus-675	244	9	proteins	protein	NOUN
finefocus-675	244	10	from	from	ADP
finefocus-675	244	11	improved	improve	VERB
finefocus-675	244	12	alphavirus	alphavirus	NOUN
finefocus-675	244	13	expression	expression	NOUN
finefocus-675	244	14	vectors	vector	NOUN
finefocus-675	244	15	to	to	PART
finefocus-675	244	16	track	track	VERB
finefocus-675	244	17	replication	replication	NOUN
finefocus-675	244	18	and	and	CCONJ
finefocus-675	244	19	dissemination	dissemination	NOUN
finefocus-675	244	20	during	during	ADP
finefocus-675	244	21	encephalitic	encephalitic	ADJ
finefocus-675	244	22	and	and	CCONJ
finefocus-675	244	23	arthritogenic	arthritogenic	ADJ
finefocus-675	244	24	disease	disease	NOUN
finefocus-675	244	25	.	.	PUNCT
finefocus-675	245	1	j.	j.	PROPN
finefocus-675	245	2	virol	virol	PROPN
finefocus-675	245	3	88:2035–46	88:2035–46	NUM
finefocus-675	245	4	.	.	PUNCT
finefocus-675	246	1	24	24	NUM
finefocus-675	246	2	.	.	PUNCT
finefocus-675	247	1	te	te	PROPN
finefocus-675	247	2	hs	hs	PROPN
finefocus-675	247	3	,	,	PUNCT
finefocus-675	247	4	randall	randall	PROPN
finefocus-675	247	5	g	g	PROPN
finefocus-675	247	6	,	,	PUNCT
finefocus-675	247	7	jensen	jensen	PROPN
finefocus-675	247	8	dm	dm	PROPN
finefocus-675	247	9	.	.	PROPN
finefocus-675	247	10	2007	2007	NUM
finefocus-675	247	11	.	.	PUNCT
finefocus-675	248	1	mechanism	mechanism	NOUN
finefocus-675	248	2	of	of	ADP
finefocus-675	248	3	action	action	NOUN
finefocus-675	248	4	of	of	ADP
finefocus-675	248	5	ribavirin	ribavirin	NOUN
finefocus-675	248	6	in	in	ADP
finefocus-675	248	7	the	the	DET
finefocus-675	248	8	treatment	treatment	NOUN
finefocus-675	248	9	of	of	ADP
finefocus-675	248	10	chronic	chronic	ADJ
finefocus-675	248	11	hepatitis	hepatitis	PROPN
finefocus-675	248	12	c.	c.	PROPN
finefocus-675	248	13	gastroenterol	gastroenterol	PROPN
finefocus-675	248	14	.	.	PUNCT
finefocus-675	249	1	hepatol	hepatol	ADJ
finefocus-675	249	2	.	.	PUNCT
finefocus-675	250	1	(	(	PUNCT
finefocus-675	250	2	n.	n.	NOUN
finefocus-675	250	3	y	y	PROPN
finefocus-675	250	4	)	)	PUNCT
finefocus-675	250	5	3:218–25	3:218–25	NUM
finefocus-675	250	6	.	.	PUNCT
finefocus-675	251	1	25	25	NUM
finefocus-675	251	2	.	.	PUNCT
finefocus-675	252	1	toogood	toogood	PROPN
finefocus-675	252	2	pl	pl	PROPN
finefocus-675	252	3	.	.	PROPN
finefocus-675	252	4	2008	2008	NUM
finefocus-675	252	5	.	.	PUNCT
finefocus-675	253	1	mitochondrial	mitochondrial	ADJ
finefocus-675	253	2	drugs	drug	NOUN
finefocus-675	253	3	.	.	PUNCT
finefocus-675	254	1	curr	curr	PROPN
finefocus-675	254	2	.	.	PUNCT
finefocus-675	255	1	opin	opin	NOUN
finefocus-675	255	2	.	.	PUNCT
finefocus-675	256	1	chem	chem	NOUN
finefocus-675	256	2	.	.	PUNCT
finefocus-675	257	1	biol	biol	PROPN
finefocus-675	257	2	12:457–63	12:457–63	NUM
finefocus-675	257	3	.	.	PUNCT
finefocus-675	258	1	26	26	NUM
finefocus-675	258	2	.	.	PUNCT
finefocus-675	258	3	wahid	wahid	PROPN
finefocus-675	258	4	b	b	PROPN
finefocus-675	258	5	,	,	PUNCT
finefocus-675	258	6	ali	ali	PROPN
finefocus-675	258	7	a	a	PROPN
finefocus-675	258	8	,	,	PUNCT
finefocus-675	258	9	rafique	rafique	PROPN
finefocus-675	258	10	s	s	PROPN
finefocus-675	258	11	,	,	PUNCT
finefocus-675	258	12	idrees	idree	NOUN
finefocus-675	258	13	m.	m.	NOUN
finefocus-675	258	14	2017	2017	NUM
finefocus-675	258	15	.	.	PUNCT
finefocus-675	259	1	global	global	ADJ
finefocus-675	259	2	expansion	expansion	NOUN
finefocus-675	259	3	of	of	ADP
finefocus-675	259	4	chikungunya	chikungunya	NOUN
finefocus-675	259	5	virus	virus	NOUN
finefocus-675	259	6	:	:	PUNCT
finefocus-675	259	7	mapping	map	VERB
finefocus-675	259	8	the	the	DET
finefocus-675	259	9	64	64	NUM
finefocus-675	259	10	-	-	PUNCT
finefocus-675	259	11	year	year	NOUN
finefocus-675	259	12	history	history	NOUN
finefocus-675	259	13	.	.	PUNCT
finefocus-675	260	1	int	int	NOUN
finefocus-675	260	2	.	.	PUNCT
finefocus-675	261	1	j.	j.	PROPN
finefocus-675	261	2	infect	infect	PROPN
finefocus-675	261	3	.	.	PUNCT
finefocus-675	262	1	dis	dis	PROPN
finefocus-675	262	2	.	.	PUNCT
finefocus-675	263	1	27	27	NUM
finefocus-675	263	2	.	.	PUNCT
finefocus-675	264	1	wang	wang	PROPN
finefocus-675	264	2	f	f	PROPN
finefocus-675	264	3	,	,	PUNCT
finefocus-675	264	4	ogasawara	ogasawara	PROPN
finefocus-675	264	5	ma	ma	PROPN
finefocus-675	264	6	,	,	PUNCT
finefocus-675	264	7	huang	huang	PROPN
finefocus-675	264	8	p.	p.	PROPN
finefocus-675	264	9	2010	2010	NUM
finefocus-675	264	10	.	.	PUNCT
finefocus-675	265	1	small	small	ADJ
finefocus-675	265	2	mitochondria	mitochondria	NOUN
finefocus-675	265	3	-	-	PUNCT
finefocus-675	265	4	targeting	target	VERB
finefocus-675	265	5	molecules	molecule	NOUN
finefocus-675	265	6	as	as	ADP
finefocus-675	265	7	anti	anti	ADJ
finefocus-675	265	8	-	-	ADJ
finefocus-675	265	9	cancer	cancer	ADJ
finefocus-675	265	10	agents	agent	NOUN
finefocus-675	265	11	.	.	PUNCT
finefocus-675	266	1	mol	mol	PROPN
finefocus-675	266	2	.	.	PUNCT
finefocus-675	266	3	aspects	aspect	NOUN
finefocus-675	266	4	med	med	ADJ
finefocus-675	266	5	31:75–92	31:75–92	NUM
finefocus-675	266	6	.	.	PUNCT
finefocus-675	267	1	28	28	NUM
finefocus-675	267	2	.	.	PUNCT
finefocus-675	268	1	wiley	wiley	PROPN
finefocus-675	268	2	mr	mr	PROPN
finefocus-675	268	3	,	,	PUNCT
finefocus-675	268	4	roberts	roberts	PROPN
finefocus-675	268	5	lo	lo	PROPN
finefocus-675	268	6	,	,	PUNCT
finefocus-675	268	7	adelman	adelman	PROPN
finefocus-675	268	8	zn	zn	PROPN
finefocus-675	268	9	,	,	PUNCT
finefocus-675	268	10	myles	myles	PROPN
finefocus-675	268	11	km	km	PROPN
finefocus-675	268	12	,	,	PUNCT
finefocus-675	268	13	blair	blair	PROPN
finefocus-675	268	14	c.	c.	PROPN
finefocus-675	268	15	2010	2010	NUM
finefocus-675	268	16	.	.	PUNCT
finefocus-675	269	1	double	double	ADJ
finefocus-675	269	2	subgenomic	subgenomic	ADJ
finefocus-675	269	3	alphaviruses	alphavirus	NOUN
finefocus-675	269	4	expressing	express	VERB
finefocus-675	269	5	multiple	multiple	ADJ
finefocus-675	269	6	fluorescent	fluorescent	ADJ
finefocus-675	269	7	proteins	protein	NOUN
finefocus-675	269	8	using	use	VERB
finefocus-675	269	9	a	a	DET
finefocus-675	269	10	rhopalosiphum	rhopalosiphum	ADJ
finefocus-675	269	11	padi	padi	PROPN
finefocus-675	269	12	virus	virus	NOUN
finefocus-675	269	13	internal	internal	ADJ
finefocus-675	269	14	ribosome	ribosome	PROPN
finefocus-675	269	15	entry	entry	NOUN
finefocus-675	269	16	site	site	NOUN
finefocus-675	269	17	element	element	NOUN
finefocus-675	269	18	.	.	PUNCT
finefocus-675	270	1	plos	plos	PROPN
finefocus-675	270	2	one	one	NUM
finefocus-675	270	3	5	5	NUM
finefocus-675	270	4	:	:	PUNCT
finefocus-675	270	5	e13924	e13924	NOUN
finefocus-675	270	6	.	.	NOUN
finefocus-675	270	7	29	29	NUM
finefocus-675	270	8	.	.	PUNCT
finefocus-675	271	1	young	young	PROPN
finefocus-675	271	2	jd	jd	PROPN
finefocus-675	271	3	.	.	PROPN
finefocus-675	271	4	2013	2013	NUM
finefocus-675	271	5	.	.	PUNCT
finefocus-675	272	1	metabolic	metabolic	PROPN
finefocus-675	272	2	flux	flux	PROPN
finefocus-675	272	3	rewiring	rewire	VERB
finefocus-675	272	4	in	in	ADP
finefocus-675	272	5	mammalian	mammalian	ADJ
finefocus-675	272	6	cell	cell	NOUN
finefocus-675	272	7	cultures	culture	NOUN
finefocus-675	272	8	.	.	PUNCT
finefocus-675	273	1	curr	curr	PROPN
finefocus-675	273	2	.	.	PUNCT
finefocus-675	274	1	opin	opin	NOUN
finefocus-675	274	2	.	.	PUNCT
finefocus-675	275	1	biotechnol	biotechnol	PROPN
finefocus-675	275	2	24:1108–15	24:1108–15	NUM
finefocus-675	275	3	.	.	PUNCT
finefocus-675	275	4	30	30	NUM
finefocus-675	275	5	.	.	PUNCT
finefocus-675	276	1	zacks	zacks	PROPN
finefocus-675	276	2	m	m	VERB
finefocus-675	276	3	a.	a.	NOUN
finefocus-675	276	4	,	,	PUNCT
finefocus-675	276	5	paessler	paessler	NOUN
finefocus-675	276	6	s.	s.	PROPN
finefocus-675	276	7	2010	2010	NUM
finefocus-675	276	8	.	.	PUNCT
finefocus-675	277	1	encephalitic	encephalitic	ADJ
finefocus-675	277	2	alphaviruses	alphavirus	NOUN
finefocus-675	277	3	.	.	PUNCT
finefocus-675	278	1	vet	vet	NOUN
finefocus-675	278	2	.	.	PUNCT
finefocus-675	278	3	microbiol	microbiol	PROPN
finefocus-675	279	1	140:281–86	140:281–86	NUM
finefocus-675	279	2	.	.	PUNCT
finefocus-675	280	1	imatinib	imatinib	NOUN
finefocus-675	280	2	mesylate	mesylate	VERB
finefocus-675	280	3	•	•	ADV
finefocus-675	280	4	153152	153152	NUM